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ABSTRACT OF DISSERTATION 
 
 
 
 
NOVEL MECHANISM LEADING TO MISMATCH REPAIR DEFICIENCY AND 
MUTATOR PHENOTYPE 
 
DNA mismatch repair (MMR) is a critical genome-maintenance system. It ensures 
genome stability by correcting mismatches generated during DNA replication, 
suppressing homologous recombination, and inducing apoptosis in response to severe 
DNA damage. As a result, defects in MMR lead to genome-wide mutations and 
susceptibility to both hereditary and sporadic cancer syndromes. The hallmark of cancer 
cells defective in MMR is their ability to display frequent instability in simple repetitive 
DNA sequences, a phenomenon called microsatellite instability (MSI). However, only 
~70% of the MSI-positive tumors have identifiable MMR gene mutations, indicating that 
additional factor(s) are responsible for the MSI phenotype in the remaining 30% MSI-
tumors. 
 
We demonstrate here that phosphorylation of proliferating cell nuclear antigen 
(PCNA), an MMR component required for the initiation and resynthesis steps of the 
repair reactions, blocks in vitro MMR. We found that nuclear extracts derived from 
colorectal cell lines containing high levels of phosphorylated PCNA are not only 
defective in MMR, but also inhibitory to MMR activity in HeLa extracts. To determine if 
PCNA phosphorylation inhibits MMR, several PCNA isoforms that mimic 
phosphorylated or non-phosphorylated PCNA were examined for their effects on MMR 
activity. We show that all phosphorylated PCNA mimics block MMR at the initiation 
step but MMR was not affected by the non-phosphorylated mimetic PCNA. In vitro gap-
filling experiments reveal that the phosphorylated PCNA induces a mutational frequency 
several fold higher than non-phosphorylated PCNA. Since PCNA has been shown to 
interact with MMR initiation factors MutS and MutL, we examined the interactions of 
phosphorylated PCNA with these two initiation factors. Interestingly, PCNA 
phosphorylation reduces the PCNA-MutS interaction, but not the PCNA-MutL 
interaction. Since PCNA is proposed to transfer MutS to the mismatch site, the simplest 
explanation of the result is that PCNA phosphorylation inhibits MMR by blocking 
 
 
MutS-mismatch binding activity. Taken together, our results reveal that PCNA 
phosphorylation induces genetic instability by inhibiting MMR at the initiation step and 
by promoting DNA polymerase-catalyzed mis-incorporations. This study provides a 
novel mechanism by which posttranslational modifications inhibit MMR, leading to 
genome instability and tumorigenesis.    
 
A second part of the study is to determine MMR function of several MutL mutants 
associated with relapse leukemia patients. One of the mutants contains a phenylalanine99 
to leucine substitution in the MLH1 subunit of MutL. We show that this mutation 
inhibits MMR by blocking both the ATPase activity and the endonuclease activity 
associated with MutLα, supporting the importance of the MutLα ATPase and the 
endonuclease activities in MMR. 
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CHAPTER ONE: DNA REPAIR AND CANCER 
 
INTRODUCTION 
The activities of gene products can be regulated at several different levels, including 
regulation of their production at the transcriptional and translational levels and by post-
translational modifications, cellular targeting, and stability once they are produced. 
Deregulation by the cell of any of these regulatory steps can produce an imbalance in cell 
homeostasis. Genetic (i.e. mutations) and epigenetic (i.e. promoter methylation) factors 
are known to deregulate some gene products having influence over cancer development 
and progression (1-4). These genetic and epigenetic factors are caused or influenced by 
exogenous and endogenous agents. In the 1970s, Bruce Ames’ laboratory reported that 
chemicals which induce tumors in laboratory animals may act by producing damage to 
the DNA and therefore, should be categorized based on their mutagenic properties (5). 
Later on, new evidence supported the hypothesis that cancer cells may contain changes in 
certain genes (6). The development of new techniques opened the doors to explore this 
hypothesis, resulting in the discovery of tumor suppressor genes and oncogenes, and the 
multistep tumorigenesis model. In this model, a normal cell transforms into a cancer cell 
after a series of genetic mutations take place in different genes (7). The exact number of 
mutations that have to occur for a normal cell to be transformed is still not clear, but is 
known that a series of oncogenes need to be activated, while tumor suppressor genes 
have to be inactivated (6,8). These mutations in key genes can be transmitted to offspring 
or may arise from somatic alterations. One of the pioneer studies that showed this 
behavior was performed by Alfred Knudson in the early 1970’s (9). In this study, 
Knudson compared the onset of sporadic and familial retinoblastoma and concluded that 
while sporadic retinoblastoma seems to arise from two independent successive somatic 
mutations, familial retinoblastoma resulted from a mutation inherited from one of the 
parents (found in all germ-line cells) followed by a single somatic mutation (6). This 
finding brought better understanding about the basis of other familial cancers and also 
provides an explanation for the observation that people who inherit a defective allele can 
display early onset of disease.   
 
It is believed that the characteristics of different cancers such as progression, 
invasion, and prognosis are related to the different combination of defects in oncogenes 
and tumor suppressor genes. Normally, tissues are selective in the combination of 
mutations that are formed so that only a subset of mutations is observed in a specific type 
of cancer (1)(10). Therefore, it is not surprising that the same inherited mutation can lead 
into the development of different cancer types in the same family (11,12). To better 
understand the role of tumor suppressor genes and oncogenes in cancer development, 
progression and invasion, it is important to understand their role in normal cell function. 
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Oncogenes 
Proto-oncogenes are normal genes involved in cell differentiation and proliferation 
that when mutated or over-expressed become oncogenes, resulting in the formation of 
cancerous cells (13). Because of the important role of these genes in determining cell 
fate, it is not surprising that deregulation of proto-oncogene signaling cascades can lead 
to aberrant cell function and proliferation. An example of an oncogenic mutation can be 
observed frequently in the genes of the tyrosine kinase family. In some tumors, this 
family of tyrosine kinases has been observed to undergo gene amplification, 
overexpression, and mutations that result in their constitutive activation (14). The gain of 
function of these gene products result in the activation of different signaling cascades that 
influence the cell proliferation and/or cell survival in different human cancers. Although 
hereditary mutations in oncogenes have been identified they are very rare. The vast 
majority of the alterations observed in these genes arise from somatic events such as 
chromosomal translocations (15). An example of this can be observed in chronic myeloid 
leukemia (CML). In this type of disease chromosomal translocations produce the fusion 
of the Abl1 gene that contains a tyrosine kinase domain and the BCR gene. The product 
of this fusion, BCR-ABL results in a constitutive tyrosine kinase activity that produces 
the deregulation of cell division, inhibits DNA repair and subsequently cause genome 
instability (16).  
 
Tumor Suppressor Genes 
Tumor suppressor genes are commonly involved in the control of the cell cycle, the 
repair of DNA damage, and in the induction of apoptosis  (17). The loss of activity of 
these genes may cause the cell to undergo cell division even in the presence of DNA 
damage and result in uncontrolled cell proliferation. Mutations and epigenetic 
modifications (promoter hypermethylation) have been observed in tumor suppressor 
genes. But unlike oncogenes, alterations in tumor suppressor genes are observed in the 
vast majority of inherited cancers. It has been shown that promoter hypermethylation and 
loss of one wild-type allele results in the reduction of the gene expression and activity 
(haploinsufficiency) (17). However, tumor suppressor genes mostly require a 
homozygous recessive genotype to result in a complete loss of function (9,18,19). One of 
the most studied tumor suppressor genes is p53. This tumor suppressor gene plays an 
important role in the regulation of the cell cycle and the induction of apoptosis. 
Therefore, it is not surprising that haploinsufficiency and mutations in both p53 alleles 
have been identified in several human cancers (17). Moreover, because of its role in 
apoptosis the status of p53 in a cancer cell can determine the response of the cell to 
cancer drugs.   
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DNA REPAIR PATHWAYS  
DNA is the most important macromolecule in the cell, as it contains all the genetic 
information needed for appropriate cell functions. However, different factors can 
influence the normal DNA environment. It is known that mutagenic compounds, ionizing 
radiation, and oxidative stress among other factors can cause alterations in the DNA. This 
long polymer can also undergo spontaneous events such as hydrolysis of the 
phosphodiester backbone and deamination of cytosine. In addition, normal DNA 
metabolic activities like replication and recombination can also result in DNA lesions 
such as base pair mismatches and the wrongful incorporation of oxidized nucleotides 
such as 8-oxo-guanine. In spite of the variety of possible mutations that can occur, 
somatic gene mutation is a rare event, occurring with a frequency of 10
-6
 per cell 
generation (6). This indicates that cells have mechanisms of defense against the 
accumulation of DNA damage, thereby maintaining genomic stability and guarantying 
the transmission of the appropriate genetic information from one cell to another. These 
defense mechanisms are known to be DNA repair pathways and have been defined as the 
cellular responses associated with the restoration of the proper base-pair sequence and 
DNA structure (20). In the past decades, the major DNA repair pathways have been 
studied from simple systems such as bacteria to more complex organisms including 
human cells. The major DNA repair pathways include base excision repair (BER), 
nucleotide excision repair (NER), mismatch repair (MMR), homologous recombination 
(HR), and non-homologous end-joining (NHEJ) (Table 1.1). In addition to these 
pathways, cells have evolved another system to survive lesions that result in replication 
fork blockage. This last mechanism is known as translesion synthesis (TLS) and, 
although it is part of the DNA repair pathways, it can result in lesion bypass or damage 
tolerance.   
 
The different DNA repair pathways are composed of a series of biochemical events 
that work in coordination with the cell cycle checkpoint regulators to allow time for the 
DNA repair machineries to remove the damage, preventing the damage from becoming 
permanent in the cell. The first three repair pathways mentioned above, BER, NER, and 
MMR, all work in a similar fashion. First, the DNA damage is detected, followed by 
removal of the damage, and finally the restoration of the normal DNA sequence and 
genomic homeostasis (Figure 1.1). Although the mode of action is similar, the proteins 
recruited by a particular pathway differ from one system to another. In addition, the final 
decision of which DNA repair pathway is used depends on the type of DNA lesion and 
sometimes on the cell cycle phase (20). One example is the recruitment of the HR and 
NHEJ pathways that are recruited to repair double-strand breaks (DSBs). The HR system 
is recruited when the damage is encountered during S-phase (21). When DSBs are 
formed during mitosis, the NHEJ pathway will be used to repair this type of lesion. While 
HR uses homologous sequences to repair the DSBs, the NHEJ is an error-prone repair 
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pathway that functions by the fusion of the blunt-ended double strands and it may result 
in the insertion and deletion of DNA sequences. Another error-prone pathway that is 
recruited during the S-phase is the TLS system that, as mention above, will bypass 
replication fork blockage during DNA replication. In contrast to TLS, HR, and NHEJ, the 
activation of the other three pathways, BER, NER, and MMR, are more dependent on the 
type of lesion formed in the DNA although can also be recruited during a cell cycle 
phase. 
 
 
 
Base Excision Repair      
Base excision repair (BER) is the major pathway for the repair of a broad spectrum of 
modified and inappropriate bases including apurinic/apyrimidic (AP) sites, deaminated, 
oxidized and alkylated bases (22). The BER pathway contains a number of DNA 
glycosylases that can sense the DNA damage and trigger the initiation of the repair. The 
specific DNA glycosylase that is recruited will depend of the type of DNA lesion. 
Although different glycosylases are recruited the mode of repair is basically the same. 
The glycosylase recognizes the DNA lesion and cleave the N-glycosyl bond releasing the 
base from the sugar moiety resulting in the formation of an AP site. Two types of 
glycosylases have been identified that work in the BER, the monofunctional and 
bifunctional glycosylases. The monofunctional DNA glycosylase works by simply 
generating the AP sites, and require the function of a separate AP endonuclease to 
generate the single-strand break in the phosphodiester backbone of the AP site needed for 
repair. On the other hand, the bifunctional DNA glycosylases contain both the 
glycosylase and the AP lyase activity, which means that they can generate the single-
strand break at the AP site without the assistance of an additional lyase. After the single-
strand break is generated, the missing base is replaced by the activity of a DNA 
polymerase, followed by DNA ligase activity resealing the strand break. 
DNA Repair Pathway Function
Base Excision Repair  (BER) Repair of damaged bases or single strand breaks
Nucleotide Excision (NER) Repair a variety of helix-distorting DNA lesions
Mismatch Repair (MMR) Repair of mismatches and insertion/deletion loops
Homologous Recombination (HR) Repair  of double-strand DNA breaks
Non-homologous End Joining (NHEJ) Repair  of double-strand DNA breaks
Translesional Synthesis (TLS) Bypass of DNA adducts at stolen replication forks 
during DNA replication 
Table 1.1. The six major  DNA Repair pathways*
*Modified from D'ANDREAA.D., (2008) DNA REPAIR PATHWAYS AND HUMAN CANCER. IN THE MOLECULAR
BASIS OF CANCER (ELSEVIER, S. ED.), SAUNDERS ELSEVIER PHILADELPHIA, PA. PP 39-55.
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Figure 1.1 Summary of the Major Steps of Excision Repair Pathways 
Different protein-protein interactions are involved in the biological events that result in i). 
Sensing the DNA lesions caused by exogenous and endogenous factors, ii). Damage 
removal carried out by the specific endonucleases and/or exonucleases, and iii). 
Restoration of normal base-pair to maintain the genomic stability in cells. 
  
 
Although we simplify the biochemical events that occur in the BER pathway (Figure 
1.1), studies have shown that this mechanism can be divided into two different 
subpathways, the short-patch and the long-patch repair pathways (23). These two 
pathways differ in the repair patch and the proteins involved. Short-patch repair involves 
the incorporation of a single nucleotide, which is carried out by the activity of 
polymerase  In the case of long-patch repair, DNA polymerases or  with the aid of 
the processivity factor PCNA, displaces a number of nucleotides on the strand being 
repaired during the replacement of the damaged nucleotide. This displacement synthesis 
results in the generation of a flap of single stranded DNA that must be removed before 
repair is completed. In order to do this, after the re-synthesis step the flap endonuclease, 
Fen-1, is recruited to remove the 5’ flap generated during this process. It is not clear how 
the cell decides which of these two pathways to take, although it is believed that the type 
of DNA lesion, the recruited DNA glycosylase, the different termini created during the 
removal of the AP site, and the different protein interactions involved in the repair 
process all influence the decision to choose one patch pathway over the other (22-24).  
 
Because BER is an important pathway for repairing much of the endogenous and 
Damage 
Recognition BER NER MMR
Excision
DNA Re-synthesis
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some of the exogenous damage it is not surprising that genetic mutations and lost or 
reduced activity of proteins involved in BER have been found in some tumors. For 
example, single nucleotide polymorphisms (SNPs) have been identified in some of the 
DNA glycosylase genes such as MYH and OGG1 that are linked to different 
malignancies (22,25). The SNPs found in the MYH gene can cause an inherited 
malignancy known as MYH-associated polyposis (MAP) that predisposes carriers to 
colorectal tumors (26). Although alterations and defects in BER have been reported, the 
incidence of these changes has been found to be less frequent when compared with 
defects found in the NER and MMR pathways. 
 
Nucleotide Excision Repair  
Bulky adducts formed by exogenous compounds that directly interact with DNA are 
recognized and repaired by the NER pathway. These helix-distorting DNA lesions, 
including those formed by ultraviolet light (UV), recruit the proteins of this system to the 
damaged DNA sites. In contrast to other excision repair pathways, the NER system, after 
sensing the DNA damage, produces dual incisions on each side of the DNA lesion. 
Normally, the first incision occurs close to the DNA lesion, while the second incision 
occurs about 20 nucleotides away from the damage. After the incisions occur, this section 
of DNA containing the damaged nucleotide(s) is removed by the activity of the NER 
helicase, generating a gap. This gap is then filled by a DNA polymerase, followed by 
ligation of the DNA by a DNA ligase.  
 
The NER pathway can also be divided into two subpathways, the transcription-
coupled repair (TCR) and the global genomic repair (GGR) pathways (27). These two 
pathways differ from each other in the initial steps in which the lesion is detected by 
different sensor proteins that are recruited to the DNA. The TCR machinery is recruited 
to the transcribed DNA strand of active genes to repair transcription blocking lesions 
(28). The GGR pathway is independent of transcription and is constantly screening the 
genome for the identification of distorting lesions in the DNA helix. The recognition of 
the bulky adducts in the GGR pathway is sensed by the xeroderma pigmentosum 
complementation group C (XPC) protein, while in the TCR pathway the XPC activity is 
replaced by the RNA polymerase, which senses the DNA damage when it stalls during 
transcription.  
 
As mention before, NER plays an important role in the repair of lesions caused by UV 
light. Somatic alterations in some of the NER components are associated with skin 
cancer. Defects in this mechanism are also associated with inherited disorders, such as 
the xeroderma pigmentosum (XP) syndrome. This recessive autosomal disease produces 
cutaneous hypersensitivity to UV exposure and also high predisposition to the early onset 
of skin cancer (28). 
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Mismatch Repair 
 
The importance of the mismatch repair (MMR) system in maintaining genome 
stability has been well illustrated in vitro and in vivo. Studies in bacteria showed that 
defects in the MMR pathway result in high levels of spontaneous mutations (29). This 
mutator phenotype can also be observed in human deficient in the MMR pathways in 
which the predisposition to cancer is greatly increased. The maintenance of genome 
stability by the MMR pathway has been attributed to its capacity for repairing nucleotide 
mismatches, small insertions and deletions generated during DNA replication and 
recombination, and to its ability to inhibit DNA recombination between divergent DNA 
sequences and trigger apoptosis (programmed cell death) in cells with heavily damaged 
DNA. MMR-dependent apoptosis plays an important role in determining the way that 
cells respond to certain cancer treatments. Many forms of chemotherapy work by 
producing severe DNA damage in tumor cells, which consequently leads to the activation 
of the apoptotic pathway, resulting in tumor cell death. In tumor cells defective in MMR, 
chemotherapy may fail to trigger MMR-dependent apoptosis, leading to drug resistance.  
 
Genomic DNA contains hundred and thousands of simple repetitive DNA elements 
known as microsatellites (30). One of the hallmarks of MMR-deficiency in cells is the 
instability of these microsatellite sequences, also known as microsatellite instability 
(MSI). MSI had been reported in both sporadic and inherited cancers such as hereditary 
nonpolyposis colorectal cancer (HNPCC). Therefore, screening for MSI can give us an 
idea of the MMR status in cells. Different biochemical and molecular approaches have 
been implemented to show that MSI is caused by MMR-deficiency. Extracts derived 
from MSI tumor cells have found to be defective in MMR, and the defect can be 
complemented by purified MMR proteins (31,32). In addition, stable transfection with a 
good gene for the deficient protein into MMR-deficient cell lines also results in the 
recovery of MMR activity in those cells (33-35). Microsatellite sequences can be found 
distributed throughout the genome including in a number of tumor suppressor genes such 
as Bcl-2 associated X factor (BAX) and Transforming Growth Factor Receptor Type II 
(TGFβRII). Therefore, under the condition of MMR deficiency, these tumor suppressor 
genes can be inactivated as a result of MSI, contributing to cancer development, 
progression, and invasion (Figure 1.2).  
 
Mismatch Repair in Escherichia coli  
In late 1980’s, Paul Modrich’s laboratory reported the reconstitution of the E. coli MMR 
pathway (37). Using purified proteins this group showed that the MutS homodimer 
complex recognizes base-base mismatches (Figure 1.3). In addition, MutS possesses an 
intrinsic ATPase activity that is required for the protein’s normal function and the 
recruitment of MutL to the DNA. Once recruited to the DNA, MutL increases the 
substrate binding affinity of MutS and recruits, binds and activates the MutH 
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endonuclease, which cleaves the newly synthesized DNA strand, generating a nick either 
5’ or 3’ to the mismatch (Figure 1.3). In the bacterial system, discrimination of the newly 
synthesized DNA and the template strands by the MMR pathway is dependent on the 
methylation state of the DNA. The bacterial genomic DNA is normally found methylated 
at the N6 position of the adenine residue in GATC sequences. When the DNA undergoes 
replication the newly synthesized strand is initially unmethylated. This hemimethylated 
state of the GATC sequences is recognized by MutH, which binds to the methylated 
strand (parental strand) and produces an incision in the unmethylated strand (daughter 
strand). For this reason, MutH is referred to as the strand discriminator protein in this 
system.    
 
 
 
 
 
Figure 1.2 MMR defects influences HNPCC development, progression, and invasion 
Tumorigenesis is a multistep process where can be found tumors at different stage (from 
adenoma to carcinomas). Adenoma arise from a single pocket of epithelial stem cells 
(yellow circle), when one or a  small  number  of  cells  within  this  pocket  initiate  the 
process  of  neoplasia  by  clonal  expansion (red circles) (36). In HNPCC, this process 
can be initite by defects in the MMR pathways resulting in further genetic alterations in 
tumor promoting (pink square) and tumor suppressor factor (blue square). Microsatellite 
sequences are found in tumor suppressor genes such as BAX and TGFβRII (blue square). 
MMR defects will cause instability in these sequences resulting in inactivation of these 
tumor suppressor genes and cancer initiation and/or progression.  
Epidermal Growth Factor
Normal Epithelium Early Adenoma Late Adenoma Carcinoma Metastasis
MMR-
defects
APC
β- catenin
KRAS TP53
BAX
TGFβR II
Tumor Promoting Factor Tumor Suppresor Factor
Modified from Rajagopalan H., Nowak M.A., Vogelstein B., and Lengauer C. (2003) The significance of 
unstable chromosomes in colorectal cancer. Nature Reviews Cancer, 3, 695-701.
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  Like MutS, MutL also possesses an ATPase activity. Mutations in MutL or the 
absence of this protein in bacterial cells causes an increase in the mutator phenotype. The 
importance of MutL in the MMR pathway can be attributable to the number of different 
proteins that are recruited by and bind to this protein. In addition to increasing MutS 
binding and recruiting and activating MutH, the MutL homodimeric complex is also 
responsible for the recruitment of the helicase II to the DNA. The activity of the helicase 
in MMR is to unwind the double stranded DNA from the nick created by MutH towards 
the mismatch, separating the parental and the newly synthesized strands. Subsequently, 
the exposed parental single strand is occupied by the single-strand binding (SSB) protein 
that prevents the parental strand from being attacked by any nuclease (Figure 1.3). On the 
other hand, the nicked strand is exposed and is degraded by one of several exonuclease 
activities used by the MMR system. The E. coli MMR pathway utilizes four different 
exonucleases; two of them are 5’→3’ exonucleases while the other two possess 3’→5’ 
exonuclease activity. The exonuclease recruited will depend on the nick location relative 
to the mismatch and the directionality required to remove the mismatch. After removal of 
the section of the DNA containing the mismatch, the gap generated is refilled by the 
DNA polymerase holoenzyme III, followed by DNA ligase-catalyzed nick ligation. The 
repair of the mismatched DNA by the MMR pathway restores DNA homeostasis in the 
cell. 
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Figure 1.3 Schematic representation of the E. coli MMR pathway 
 The E.coli MMR is a bidirectional process that target the new synthesized strand based 
in the DNA hemimethylation state of the GATC sequences. The mismatch removal is 
initiated after the recruitment of MutS and MutL into the DNA, which further recruit 
MutH endonuclase activity that incises the newly synthesized strand either 3’ or 5’ to the 
mismatch. This nick created by MutH serves as an entry site for Helicase II that unwinds 
the DNA towards the mismatch. The exposed parental strand is further protected by the 
SSB protein to prevent its degradation, while the newly synthesized strand is degraded by 
the exonucleases. The gap generated is refilled by the polymerase holoenzyme III and the 
processivity factor, β- clamp. (Figure draw using Microsoft PowerPoint)  
3’ 5’
3’ 5’
3’ 5’
3’ 5’
3’ 5’
3’ 5’
CH3 CH3
CH3 CH3
CH3
3’ 5’
CH3 CH3 CH3
3’ 5’
3’ 5’
CH3 CH3 CH3 CH3
CH3 CH3
Polymerase 
Holoenzyme III
MutS
MutL
SSB
Exonucleases
MutH
β-clamp
5’3’
CH3CH3
Helicase II
 
 
 
11 
Mismatch Repair in Human Cells  
The human MMR pathway functions in a fashion similar to the E. coli mechanism. It 
also targets the newly synthesized strand in a nick-dependent and bidirectional manner. 
The MMR pathway, although highly conserved through evolution, shows a higher level 
of complexity in higher eukaryotes. This complexity can be seen in the increased number 
of components that are homologous to the components of the E. coli system (Table 1.2). 
For example, in E. coli the MutS and MutL are homodimers, whereas the human 
homologs are heterodimeric complexes and there are two MutS (MutSα and MutSβ) and 
three MutL (MutLα, MutLβ, MutL) homologs. In the human system, MutSα recognizes 
base-base mismatches (Figure 1.4) and small insertion/deletions (IDs) (1 to 2 bases) 
while MutSβ recognizes larger IDs (2 or more bases). Both MutS-homologs contain the 
intrinsic ATPase domain that is essential for the proteins function. When one of the 
MutS-homologs encounters and binds its respective DNA lesion, like in the E. coli 
system, it also induces the recruitment of the MutL-homolog to the DNA. Three different 
MutL heterodimers, MutLα, MutL and MutL have been identified in the human 
system. But only MutLα is shown to play an essential role in the MMR pathway. Acting 
as an endonuclease, MutLα is required for 3’ nick-directed MMR (38) (Figure 1.4). In 
contrast to the E. coli pathway, where at least 4 exonucleases were identified, only one 
exonuclease,  exonuclease I (EXOI), has been shown to be involved in human MMR 
(39,40). EXOI possesses a 5’→3’ directionality that is essential when the nick is 5’ to the 
mismatch. However, knockdown of EXOI in cells does not confer a high mutator 
phenotype as does the knockdown of MutSα or MutLα, indicating that other nucleases 
may also be involved (41). In addition, the bidirectional activity of the human MMR 
reaction also indicates that a nuclease with 3’→5’ directionality may also be recruited 
into the pathway (40). However, recent evidence implies that rather than a 3’→5’ 
exonuclease being recruited when the nick is located 3’ to the mismatch, the MutLα 
endonuclease can be activated in a way to perform incisions to create a nick 5’ to the 
mismatch, where EXOI is loaded to initiate the mismatch-provoked excision. Activation 
of the MutLα endonuclease requires RFC and PCNA (42). After removal of the 
mismatch, the gap generated by the removal is refilled and the newly synthesized DNA is 
ligated in. These last steps are performed by DNA polymerase δ/ε, PCNA, and DNA 
Ligase I in a concert manner.  
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Human MMR Proteins Function
hMutS-homologs
MutSα (hMSH2-hMSH6)
MutSβ (hMSH2-hMSH3)
DNA mismatch and damage recognition
Mispaired and 1-2 IDs
2-16 ID loops
hMutL-homologs
MutLα (hMLH1-hPMS2)
Molecular matchmaker; mediate the
termination of mismatch-provoked excision
upon mismatch removal
Endonuclease Activity
hMutH-homolog (Unknown) Strand discrimination 
UvrD (Unknown) Unwind the DNA Helix
hEXOI Mismatch-provoked excision 
RPA Protects DNA for degradation; stimulates
excision at the presence of the mismatch and
facilitates excision termination upon mismatch
removal; facilitates DNA synthesis when
phosphorylated
HMGB1 Facilitates mismatch-provoked excision
PCNA Participates in DNA initiation and DNA 
symthesis
RFC Facilitates PCNA loading and orientation
Polymerse δ DNA synthesis
DNA Ligase I Nick ligation
Table 1.2. The MMR effectors protein*
*Modified from Li G. M. (2008) Mechanism and functions of DNA Mismatch Repair. 
Cell Research, 18, 85-98
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Figure 1.4 Schematic representation of the hMMR pathway 
The human MMR pathways function in a similar fashion than the E.coli MMR. It is a 
bidirectional mechanism that also target to repair the newly synthesized strand. Different 
from E. coli the endonuclease involved in generated the nick on the daughter strand still 
unknown (question mark). Left panel, Represents the different molecular processes 
involve in the repair of 3’nicked substrates, where the presence of PCNA and MutSα are 
required for the activation of MutLα endonuclease activity. When activated, MutLα 
performes several incisions (red arrows) that may serve as new entry sites for ExoI. Right 
panel, Represents the repair of 5’nicked substrates but opposite to the 3’- repair, the 
presence of PCNA is not that required. (Figure draw using Microsoft PowerPoint) 
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HUMAN MALIGNANCIES  
Defects in the MMR pathway caused by germline mutations, sporadic mutations or 
loss of heterozygocity have been linked to a number of different malignancies (43). 
Among these the most common is Hereditary Nonpolyposis Colorectal Cancer (HNPCC). 
More than 90% of HNPCC cases show MSI and ~70% exhibit genetic modifications in at 
least one component of the MMR pathway (44).   
 
Hereditary Nonpolyposis Colorectal Cancer 
Although the vast majority of colorectal cancers (CRCs) are caused by sporadic 
events, about 10% of the cases are caused by inherited mutations or hereditary bias. 
According to the National Cancer Institute, about 1% of the population is at risk of 
colorectal cancer due to genetic predisposition. HNPCC, also known as Lynch Syndrome, 
is an autosomal dominant disorder and the most common hereditary colon cancer. 
Patients with Lynch Syndrome contain germ-line defects in one of the genes involved in 
the MMR pathway, mainly in MSH2 and MLH1, and more rarely in MSH6, MSH3, and 
PMS2.  This disorder is characterized by the early onset of adenomatous polyps (~44 
years old) and advanced carcinogenesis (Figure 1.2). Individuals with the disorder also 
show an increase in cancer risk in other parts of the gastrointestinal tract, the 
endometrium, and the ovary (45). To define a family with HNPCC, the Amsterdam 
criteria are normally used (46). Based on these criteria, the family should have at least 
three relatives with CRC, two successive generations with CRC, and one of the CRC 
cases should be diagnosed before 50 years of age. However, some patients that meet the 
Amsterdam criteria do not have identifiable defective MMR genes (47,48). These cases 
are categorized as Familial Colorectal Cancer type X and occur with less frequency than 
HNPCC. Therefore, to identify patients with CRC that meet the Amsterdam criteria as 
being HNPCC cases MSI analysis and immunohistochemistry (IHC) staining are used. 
These two techniques will determine the MMR status in these patients without the 
necessity to sequence the MMR genes.  
 
Acute Myeloid Leukemia 
Acute myeloid leukemia or AML is the most common leukemia among adults, with 
higher incidence in men older than 60 years old and rarer in women or people younger 
than 40 years old. It is a malignancy that develops quickly inside the bone marrow, 
specifically at the soft (spongy) tissue that helps in the differentiation of the different 
blood cells. It affects the myeloid white cells that normally will develop into the different 
mature blood cells (red blood cells, white blood cells, and platelets)(49). Normally 
somatic mutations give rise to this type of malignancy, but up to now it is not clear 
exactly what can cause these DNA mutations, because defects in specific cell signaling 
pathways have not been identified. However, it is known that exposure to cigarette 
smoke, radiation, chemotherapy, and genetic disorders such as Down syndrome increase 
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the risk of developing AML. AML patients can be divided into two karyotypes; normal 
and abnormal (50). Patients with a normal karyotype show point mutations, duplications 
or deletions in some tumor suppressor genes. Patients with an abnormal karyotype show 
more genomic aberrations such as chromosomal translocations (51,52). Somatic 
mutations in some of the MMR genes have been identified in AML patients at the time of 
diagnosis and also after leukemia relapse, indicating that MMR-deficiency may play a 
role in the formation and progression of AML (50,53). However, the loss of MMR genes 
can be observed more often in AML patients with a normal karyotype and more often in 
relapsed patients than in newly diagnosed patients (50). Interestingly, after disease 
relapse those patients contain a more aggressive cancer phenotype and poorer prognosis. 
A hematopoietic stem cell transplant is usually the most effective treatment for these 
patients. 
 
In this study we explore the mechanism of how somatic mutations or post-
translational modifications in some of MMR components that have been identified to 
occur in AML or CRC patients disrupt the MMR activity. The results of this study may 
help to identify new therapeutic targets for the early diagnostic or a better treatment of 
malignancies caused by MMR defects. 
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CHAPTER TWO:  MATERALS AND METHODS 
 
CHEMICAL AND REAGENTS 
Amersham: ECL Detection Reagent 
Perkin Elmer: [γ-
32
P]-ATP, [α-
32
P]-ATP 
FisherBiotech: 1- Butanol, Iso-propanol, KH2PO4 (Potassium Phosphate Monobasic), 
K2HPO4 (Potassium Phosphate Dibasic), SDS (Sodium Dodecyl Dulfate), Potassium 
Acetate, Sodium Bisulfate, Tween-20, P.E.G.-8000, NaOH (Sodium Hydroxide), KOH 
(Potassium Hydroxide) 
New England Biolab: Restriction enzymes 
Santa Cruz: MSH2, PCNA, EGFR, and Tubulin antibodies 
BD Pharmigen: MLH1 and PMS2 antibodies 
Bethyl: MSH6 antibody 
Roche: ATP (Adenosine Triphosphate), dNTPs (deoxy Nucleotides triphosphate), DTT 
(Dithiothreitol), NP-40 (Nonidet P-40), Superdex G25 column, Protein G-agarose beads, 
Fugene HD transfection reagent 
USB: Ammonium Sulfate, Ammonium Persulfate, Agarose, CsCl (Cesium Chloride), 
Exonuclease V (Exo V), EDTA, Ethidium Bromide, Glycine, HEPES, Urea, T4-PNK, 
Tris, Phenol, etc. 
Invitrogen: Insulin  
 
BUFFER PREPARATIONS 
All solutions and cell culture media were prepared in double-distilled water (ddH2O). 
Solutions were sterilized either by autoclaving at 121 ºC for 30 min or by passing a 0.22 
μM filter. Stock solutions were adjusted to the desired pH at the time of preparation or 
after dilution to the working concentration.  
 
AGAROSE GEL ELECTROPHORESIS 
Agarose gel was run in 1x TAE (Tris/Acetate/EDTA) buffer containing 40 mM Tris-
Acetate (pH 8.5) and 2 mM EDTA (54). DNA samples were mixed with 0.1 volume (vol) 
of 10x agarose gel loading buffer containing 40% (w/v) sucrose, 0.05% (w/v) 
bromophenol blue, 0.05% (w/v) xylene cyanol, 20 mM EDTA, and 0.2% SDS. Gel was 
stained in 0.5 μg/ml ethidium bromide (EtBr) solution for 10-15 min and rinsed for 20-40 
min in ddH2O. DNA products were visualized on an ultraviolet (UV) transilluminator and 
gel images were captured using a Kodak Image Gel Logic 112 system.  
 
SDS- POLYACRYLAMIDE GEL ELECTROPHORESIS (SDS-PAGE)  
Slab gels containing an 8 to 15% acrylamide separating gel in 0.375 M Tris-HCl (pH 
8.8) and 0.1% SDS and 4% acrylamide stacking gel in 0.0125 M Tris-HCl (pH 6.8) and 
0.1% SDS were prepared from an 30% acrylamide stock solution (acrylamide: bis-
 
 
 
17 
acrylamide = 37.5:1) (55). Protein samples were mixed with 0.2 vol of 6 x protein 
loading buffer containing 0.125 M Tris-HCl (pH 6.8), 2% SDS, 20% glycerol, 0.2% 
bromophenol blue, followed by heating at 90 ºC for 5 min and loaded on the gel. SDS-
PAGE was performed at 150 V in a running buffer containing 2.5 mM Tris, 0.2 M 
glycine, and 0.1% SDS .  
 
UREA-PAGE (Denaturing PAGE)  
Denaturing gels were preparing at the desired concentration of acrylamide with 8 M 
Urea and 1x TBE buffer containing 89 mM Tris-HCl, 89 mM boric acid, and 2 mM 
EDTA (54). Gels were pre-run at 16 watts for 30 min or 1 hr. Samples were prepared by 
adding 0.5 vol of the 2 x SSCP loading buffer (95% formamide, 0.05% bromophnol blue, 
0.05% xylene cyanol, and 20 mM EDTA), followed by heating at 95 ºC for 5 min and 
then cool down on ice for 2 min. 
  
5’-OLIGONUCLEOTIDE LABELING  
All DNA oligonucleotides were synthesized by Integrated DNA Technologies (IDT 
Inc.). DNA oligonucleotides were radiolabelled with [γ-
32
P]-ATP (3000 Ci/mmol, and T4 
polynucleotide kinase (PNK) (USB) in T4 PNK buffer that contained 70 mM Tris-HCl 
(pH 7.6), 10 mM MgCl2, and 5 mM Dithiothreitol at 37 ºC for 1 hr. Labeling reactions 
were stopped by heating in at 60 ºC for 10 min following USB protocol. Labeled 
oligonucleotides were further purified through Superdex G25 column.   
 
PREPARATION OF E.coli COMPETENT CELLS  
All of E. coli bacterial strains (XL-I Blue, DH5α, BL21, and D10Bac) were obtained 
from Stratagene and cultured in Luria-Bertani (LB) or in 2xYT medium. 2 ml of 
overnight bacterial culture were diluted in 200 ml of LB or 2 x YT media. Cells were 
grown at 37 ºC x 220 rpm in an orbital shaker until the optical density at 600 nM (OD600) 
reached 0.3 to 0.4. Cultured cells were harvested by centrifugation at 2,000 x g for 15 
min at 4 ºC. The cell pellet was suspended in 2 ml of 2 x YT containing 20% (w/v) 
polyethylene glycol (PEG) 3350, and 10% (v/v) DMSO (56). Aliquots of 50-150 µl were 
stored at -80 ºC until use.  
 
TRANSFORMATION OF COMPETENT CELLS 
Frozen aliquots of competent cells were thawed on ice. DNA (usually 100 to 500 ng) 
was mixed with the competent cells and incubated on ice for 30 min. The DNA-cell 
mixture was heated at 42 ºC for 30 sec, followed by incubation on ice for 2 min (57). 
Then, 0.7 ml of LB or 2xYT media was added to the cells and cells were incubated for 
1hr at 37 ºC with constant shaking. Transformed cells were placed on LB plates, which 
contain selective antibiotics and the plates were incubated overnight at 37 ºC.      
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MAMMALIAN AND INSECT CELLS CULTURE 
A number of mammalian cell lines were used during this study. HeLa-S3, HCT15, 
and DLD-1 cells were grown in Roswell Park Memorial Institute (RPMI) 1640 with 10% 
fetal bovine serum (FBS) and 4 mM L-glutamine. HCT116 and HCT116+ chromosome 3 
were grown in McCoy’s 5A with 10% FBS.  LoVo cells were grown in Dulbecco’s 
Modified Eagle Medium (DMEM) and 10% FBS.  Lim2405 was grown in RPMI 1640 
containing 5% FBS, 4 mM L-glutamine, 25U/L insulin, 10
–5
 M α-thioglycerol, and 1 
μg/ml hydrocortisone. All cultures were grown at 37 ºC in a humidified atmosphere of 
95% air and 5% CO2.  
 
High-5 (H5) insect cells were purchased from Invitrogen. The cells were cultured in 
monolayers at 25 ºC in TNM-FH medium (USBiological) with 10% heat inactivated 
FBS. Cells were dislodged by sloughing or tapping the flask using moderate force.  
 
TRANSFECTION OF EUKARYOTIC CELLS 
Transfections were performed using the Fugene HD transfection reagent. The mixture 
of DNA and Fugene HD reagent at 3:1 ratio (3 μl Fugene: 1 μg DNA) were added to the 
97 μl of growth media. The mixtures were incubated at room temperature for 30 min to 
allow complex formation and then added in to the 60 to 80% confluence cell cultures in 
6-well plates. Transfection was performe based on Fugene HD protocol.  
 
PREPARATION OF CELL NUCLEAR EXTRACT 
Preparation of nuclear extract was performed on ice or at 4 ºC as described previously 
(58). All of solutions contained 1 x protease inhibitor cocktail (0.1% PMSF, 1 µg/ml 
leupeptin, 1 µg/ml pepstain A). The cultured cells were harvested by centrifugation at 
3,000 x g for 8 min using an H-6000A rotor. The supernatant was discarded and the cell 
pellet was resuspended  in wash buffer that contained 20 mM Hepes-KOH (pH 7.5), 5 
mM KCl, 0.5 mM MgCl2, 0.2 M Sucrose, 0.5 mM DTT, followed by centrifugation at 
3,300 x g for 5 min. Cells were resuspended in hypotonic buffer (2.78 ml/g of cells) that 
contained 20 mM Hepes-KOH (pH 7.5), 5 mM KCl, 0.5 mM MgCl2, 0.5 mM DTT and 
incubated on ice for 10 min. Swollen cells were broken using a dounce homogenizer on 
ice to obtain intact nuclei (about 10 to 15 strokes using the B pestle). Cell nuclei were 
then collected by centrifugation at 2,000 x g using the Beckman Coulter JA-20 rotor. The 
cell nuclei pellet was resuspended in extraction buffer (1.39 ml/ g cells) that contained 20 
mM Hepes-KOH (pH 7.5), 5 mM KCl, 0.5 mM MgCl2, 10% (w/v) sucrose, 0.5 mM 
DTT, followed by addition of 0.031 volumes of 5 M NaCl. Nuclear proteins were 
extracted by incubation of the resuspended nuclei on a rotating rack for 60 min in 4 ºC. 
After centrifugation in a JA-20 rotor at 14,500 x g for 20 min, the nuclear debris was 
discarded and the supernatant was collected.  Nuclear proteins were precipitated by 
adding ammonium sulfate (0.42 g/ml) to the supernatant and the mixture was slowly 
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stirred for 20 min on ice. Precipitated proteins were pelleted by centrifugation in a JA-20 
rotor at 15,800 x g for 20 min. The supernatant was completely removed and the protein 
pellet was resuspended in dialysis buffer (~90µl) that contained 20 mM Hepes-KOH (pH 
7.6), 50 mM KCl, 2 mM DTT, 0.1 mM EDTA. The slurry was transferred into a dialysis 
bag and the mixture was dialyzed until conductivity of the sample reached 50 μS/cm (10 
μl sample/ 4 ml ddH2O). Dialyzed extract was clarified by centrifugation at 16,000 x g 
for 15 min at 4 ºC. Aliquots of 30 to 50 µl were quickly frozen by submersion in liquid 
nitrogen and stored at -80 ºC until use. 
 
PCNA AND p21C OVEREXPRESSION AND PURIFICATION  
Human PCNA and GST-p21
(CIP1/WAF)
 C-terminal DNA constructs for bacterial 
overexpression were generously provided by Dr. Jerald Hurwitz (Memorial Sloan-
Kettering Cancer Center, New York, NY) and Dr. Anindya Dutta (U. of Virginia, 
Charlottesville, VA), respectively. These proteins were overexpressed in BL21 DE3 E. 
coli cells, and purified to homogeneity as described previously (59-61).  Briefly, freshly 
transformed BL21 with PCNA or GST-p21c were grown overnight in 10 ml of LB 
containing 0.1 mg/ml ampicillin at 37 °C. The overnight culture was diluted 1:100 in 1 L 
LB media and grown until the OD600 reached 0.4. Then, 1 mM of Isopropyl-1-thio-β-D-
galactopyranoside (IPTG) was added to the flask, and the culture was incubated for an 
additional 3 hr. The cells were collected, lysed and the proteins were purified at 4 ºC to 
homogeneity by passing different chromatography columns. GST-p21c was purified by 
using anion exchange (Q-sepharose (GE Healthcare) and glutathione sepharose (GST-
sepharose (GE Healthcare) columns (62). For PCNA purification, cells were lysed in 40 
ml of Buffer A that contained 25 mM Tris (pH 7.4), 1 mM EDTA, 0.1% (v/v) NP-40, 10 
mM NaHSO3, 5 mM DTT, 10% (v/v) glycerol, 1x proteinase inhibitor cocktail and 
sonicated 5 times at 20% power (30 sec/1 min interval) (Misonix XL-2000). The salt 
concentration was adjusted to 0.1 M NaCl and the solution was centrifuged at 68, 452 x g 
for 1 hr. The collected supernatant was adjusted to 0.2 M NaCl and applied to a 30 ml 
bed volume of Q-sepharose beads that equilibrated with Buffer A with 0.2 M NaCl. The 
PCNA peak was eluted around 0.4 M NaCl , collected and dialyzed for 3 hrs in HAP 
Buffer A containing 25 mM KPO4 (pH 7.0) , 0.1% (v/v) NP-40, 10 mM NaHSO3, 5 mM 
DTT, 10% (v/v) glycerol, 1x proteinase inhibitor cocktail. Dialyzed protein was applied 
to a 5 ml S-sepharose column (GE Healthcare) and the flow-through was collected loaded 
on a 20 mL of bed volume hydroxyapatite (HAP) resin. The PCNA peak was collected 
and dialyzed against PS Buffer A containing 25 mM Tris (pH 7.4), 1.2 M NaCl, 1 mM 
EDTA, 0.1% (v/v) NP-40, 10 mM NaHSO3, 5 mM DTT, 1x proteinase inhibitor cocktail. 
The dialyzed PCNA was loaded to a Phenyl-sepharose column. The flow-through 
containing the PCNA was collected and dialyzed overnight against dialysis buffer that 
contained 25 mM Tris (pH 7.4), 1 mM EDTA, 0.1% (v/v) NP-40, 10 mM NaHSO3, 5 
mM DTT, 10% (v/v) glycerol, 25 mM NaCl, 20% (w/v) sucrose, 1x proteinase inhibitor 
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cocktail. Aliquots of 10 to 25 µl were frozen by submersion in liquid nitrogen and stored 
in -80 ºC until use. 
 
PURIFICATION OF MutSα, MutSβ, AND MutLα  
All three protein complexes were expressed using the Bac-to-Bac expression system 
from Invitrogen. MSH2, MSH6his, MSH3his, MLH1, and PMS2his DNA constructs were 
used to transform D10Bac E. coli cells and the positive colonies were screened by PCR. 
The positive bacmids containing MSH2, MSH6his, MSH3his, MLH1, or PMS2his were 
transfected into H5 insect cells to get P1 Baculovirus stock. Further amplification of the 
different Baculoviruses was performed in 175 cm
2
 culture flasks.  
 
Insect cells grown at 60 to 80% confluence in (6-8) 150 cm
2
 dishes were inoculated 
with MSH2 and MSH6 (MutSα) viruses, MSH2 and MSH3 (MutSβ) viruses, or MLH1 
and PMS2 (MutLα) virus for 48 hrs. Cells were collected by centrifugation at 1,200 x g 
for 5 min. Pellet cells were washed once with phosphate buffered saline (PBS) and 
centrifuged at 1,200 x g for 5 min. Cells were resuspended in Buffer A (5 ml/g) 
containing 25 mM Hepes (pH 8.0), 2 mM DTT, 300 mM NaCl, 25 mM Imidazole, 10% 
(v/v) glycerol, and 1x protease inhibitor cocktail, broken by using a Dounce homogenizer 
(10 to 12 strokes using pestle B), and then sonicated for 5 times at 20% power (30 sec/1 
min interval). Cell debris was removed by centrifugation at 20,000 x g using the 
Beckman Coulter JA-20 rotor for 1 hr at 4 ºC. The supernatant was collected and applied 
to a 5 ml Nickel column (GE Healthcare) pre-equilibrated with Buffer A, followed by an 
8 column volume (CV) wash with the same buffer. MutSα, MutSβ, and MutLα were 
eluted using a gradient of 0.025 to 0.5 M Imidazole. The protein peak was collected; the 
salt concentration of the solution was adjusted to 150 mM NaCl by using Buffer C that 
contained 25 mM Hepes (pH 8.0), 1 mM EDTA, 2 mM DTT, 10% (v/v) glycerol, and 1x 
protease inhibitor cocktail and loaded to onto second column. 
 
MutSα and MutSβ from the first column were loaded on a 5 ml Heparin column (GE 
Healthcare) pre-equilibrated with 15% Buffer D. The proteins were eluted with a 15 to 
75% Buffer D gradient. The collected protein fractions were combined and diluted to the 
equivalent 150 mM KCl conductivity. MutSα was further applied onto a 1ml Mono Q 
column and eluted with a 15 to 50% Buffer D gradient. While, MutSβ from the second 
column was loaded onto a 1 ml Mono S (GE Healthcare) column and eluted with 15 to 
50% Buffer D gradient. The protein peak was detected by the coomassie blue staining of 
SDS-PAGE and MutSα or MutSβ fractions were combined for storage.  
 
MutLα from the first column was applied onto a 1 ml Mono Q column (GE 
Healthcare) pre-equilibrated with 15 % Buffer D (Buffer C+ 1 M NaCl). The MutLα was 
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eluted with a 10 to 60% Buffer D gradient and the protein peak was detected by the 
coomassie blue staining of SDS-PAGE. The MutLα fractions were combined for storage.  
 
All three proteins were stored in the presence of 1 mg/ml bovine serum albumin 
(BSA) and 10% sucrose. Aliquots of 10 to 25 µl were frozen by submersion in liquid 
nitrogen and stored in -80 ºC until use.   
 
PREPARATION OF DNA SUBSTRATE  
Bacteriophage stock preparation 
The f1MR1 and f1MR3 phage were generously provided by Dr. Paul Modrich (Duke 
University, Durham, NC). The M13Mp18-UKY1 and M13Mp18-UKY2 phage were 
derived from M13mp18 (New England Biolab) as described previously (63). 10-100 ng 
of phage DNA was added to 150 µl XL-1 Blue competent cells (Strategene) and the 
mixture was incubated on ice for 30 min. The mixtures were heated at 42 ºC for 2 min, 
followed by incubation on ice for 2 min. 0.7 ml of 2 xYT was added to the transformed 
cells and the solutions were incubated with 250 rpm shaking at 37 ºC for 1 hr. 30 µl of 
the culture was mixed with 3 ml of 2 x YT soft agar (top agar) containing 200 µl of fresh 
overnight (O/N) cultured XL-1 Blue cells and then plated on LB plates. Plates were 
incubated overnight at 37 ºC. Individual plaque was inoculated in 3 ml of 2 x YT 
containing 60 µl of O/N XL-1 Blue cells and the culture was incubated with 250 rpm 
shaking at 37 ºC for 6 hrs. The cells were spanned down at 12, 000 x g for 10 min at 4 °C 
and the supernatant was collect (phage stock).  For large scale of phage stock, 150 µl of 
phage stock were added into 50 ml of 2 x YT medium containing 1 ml of O/N XL-1 Blue 
cells. The culture was grown for at 37 ºC in a shaking incubator for 6 to 8 hrs and the 
supernatant was collected by centrifugation. 
 
ssDNA and dsDNA preparation  
30 ml of O/N cultured XL-1 Blue cells were inoculated into 3 L of 2 x YT medium 
pre-warmed to 37 ºC. The cell culture was shaken at 220 rpm at 37 ºC until the OD595 
reached 0.3. Then, the culture was inoculated with 25 ml of phage stock and the culture 
was continuously shaken at 37 ºC x 220 rpm for 6 to 7 hours. The culture was then 
chilled using ice-water slurry for 20 min and the cells were harvested by centrifugation at 
4,500 x g for 10 min. The supernatant was kept for ssDNA preparation. The cell pellet 
was suspended in 60 ml of ice-cold solution I that contained 25 mM Tris-HCl (pH 8.0), 
10 mM EDTA, 0.9% (w/v) sucrose and 5 mg/ml lysozyme and incubated at RT for 10 
min, followed by 10 min incubation on ice. 120 ml of freshly prepared solution II that 
contained 0.2 N NaOH and 1% SDS was added by stirring gently with a rubber 
policeman attached to the end of 5 ml plastic pipette to lyse the cells. The solution was 
then incubated on ice for 10 min. 90 ml of freshly prepared solution III that contained 3 
M potassium acetate and 2 M acetic acid was added to the lysed cell solution while 
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stirring gently with the rubber policeman. The solution was then incubated on ice for 10 
min and clarified by centrifugation at 13,000 x g at 4 ºC for 30 min.   
 
The supernatant was filtered through 4 layers of cheesecloth and its volume was 
measured. 0.6 volume of isopropanol was added and the mixture was incubated at RT for 
30 min to precipitate the DNA. DNA was collected by centrifugation at 16,000 x g at 4 
ºC for 30 min with no brake after the spin was completed. The supernatant was discarded 
and the pellet was washed in 50 to 100 ml of 70% (v/v) ice-cold ethanol, followed by 
another centrifugation as described above. The supernatant was decanted and the DNA 
pellet was allowed to dry for 15 to 30 min. The DNA was suspended in 20 ml TE 
solution and the weight of the solution was measured. Then, 1.05g CsCl /g solution and 
50 µl EtBr (10 mg/ml stock)/g solution were added to the TE suspended DNA. Isolation 
of the DNA was performed by equilibrium centrifugation at 45,000 x g at 25 ºC for 18 
hrs using a Beckman NVT65 rotor. All steps that involved DNA were performed with the 
over head light off. The band of supercoiled DNA was located near to the middle of the 
tube and was removed from the tube using a syringe with an 18 gauge needle. EtBr was 
removed from the DNA by repeated extraction (4 to 6 times) using 1 vol of water-
saturated n-butanol and gently mixing by inversion until no pink color was detected in the 
upper phase. The aqueous solution that contains the DNA was dialyzed against TE 
buffer. The DNA concentration was measure by UV absorption at 260 and 280 nm. 
 
Phage particles from the culture supernatant were precipitated by adding 36 g NaCl 
and 50 g PEG-8000 per L of supernatant. The solution was stirred at RT for 1 hr, 
followed by centrifugation at 5,500 x g at 4 ºC for 30 min. The pellet was suspended in 
23 ml TE buffer, incubated for 1 hr at 37 ºC with shaking at 150 rpm, and then 
centrifuged for 10 min at 14,500 x g at 4 ºC. The pellet was discarded and the supernatant 
volume was determined. Phage particles were concentrated by CsCl (0.4342g CsCl/g 
phage solution) equilibrium centrifugation using the same conditions for dsDNA 
isolation. The band of phage particles was removed from the centrifuge tube by using a 
syringe with an 18 gauge needle, and dialyzed against 500 mLTE buffer (10 mM Tris, pH 
7.6 and 1 mM EDTA). The buffer was changed at least three times with a minimum of 6 
hours in between changes. Single-stranded DNA (ssDNA) from phage particles was 
isolated by extraction with warm phenol (2-3 times) and ethylether (2 times). The 
centrifugation steps for all extractions were at 12,000 x g and 25 ºC for 5 min. After the 
last ether extraction, the trace of ether remaining in the solutions was evaporated by 
incubation at 37 ºC for 10 to 30 min. The solution was then dialyzed as described for 
dsDNA isolation. The DNA concentration was measure by UV absorption at 260 and 280 
nm.  
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Preparation of circular mismatch heteroduplex substrates  
The different nicked DNA mismatch heteroduplexes were constructed by annealing 
linear dsDNA with circular ssDNA containing one base difference among the 
complementary sequences (63). The end product contained a base-base mismatch and a 
nick either 3’ or 5’ to the mismatch. The 5’-nicked mismatch substrates were constructed 
by using dsDNA and ssDNA purified from f1MR1 and f1MR3. The 3’-nicked mismatch 
substrate was constructed by using dsDNA and ssDNA purified from M13mp18-AT and 
M13mp18-GC.  DNA and the correct restriction enzymes used to linearize the circular 
DNA are listed in Table 2.1.  
 
Substrate ssDNA dsDNA Enzyme cutting dsDNA
5’ G/T nick f1MR1 f1MR3 Sau96I
3’ G/T nick M13Mp18-AT M13Mp18-GC PstI
3’ GT gap M13Mp18-AT M13Mp18-GC SalI + PstI
171 nt gap f1MR3 f1MR3 SspI + NheI
283 nt gap M13Mp18-GC M13Mp18-GC PstI + Bsu36I
Table 2.1 DNA used in the preparation of mismatch substrate 
 
 
A 5-fold excess of circular ssDNA (relative to dsDNA) was mixed with the linear 
dsDNA (Figure 2.1 A & B). The dsDNA was denatured in 30 ml of a solution containing 
50 mM Tris-HCl (pH 7.6), 100 mM NaCl, 1 mM EDTA, and 0.3 N NaOH at RT for 5 
min. The mixture was then neutralized by adding 3 ml of 2.9 N acetic acid, followed by 
adjusting the salt concentration and pH to 100 mM KCl (1.35 mL) and pH 7.4 (3.7 ml of 
1 M Na-Pi). The C (complementary) strand of linear dsDNA was annealed to the V 
(virus) strand of circular ssDNA by incubating the solution for 30 min at 65 ºC, gradually 
cooling the solution down in water bath to 37 ºC over 5 hrs, and then incubating for an 
additional 30 min at 37 ºC. The solution was then stored on ice.  The solution contained 
nicked circular heteroduplex (end product), circular ssDNA, re-annealed linear dsDNA 
homoduplex, and linear ssDNA from the displaced V strand (Figure 2.1C). The 
efficiency of annealing was determined by analysis of pre- and post- annealing solutions 
(100 ng) using 0.7% agarose gel electrophoresis. In the gel, linear dsDNA and ssDNA 
migrate at different positions and faster than nicked DNA. For that reason, the 
appearance of a third band that migrates slower in the post-annealing solution indicates 
that the nicked heteroduplex substrate was produced.  
 
The nicked circular DNA was separated from the other species (linear dsDNA and 
ssDNA) through different chromatography steps. 8 g of Hydroxyapatite resin was pre-
equilibrated three times in 30 mM Na-Pi (pH 6.9) by gently swirling in 20-30 ml of 
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buffer. The resin was incubated for 15 min at RT after each equilibration step to decant 
the supernatant and the fine particles that did not settle down. A column with a diameter 
of 2.5 cm was poured and washed with 2 CV of 30 mM Na-Pi (pH 6.9, 3 times) at a flow 
rate of 1-1.3 volume/hour. The annealed substrate was loaded onto the column slowly. 
The resin bed was washed with 6 CV of 30 mM Na-Pi (pH6.9), 160 mM Na-Pi (pH6.9), 
and 420 mM Na-Pi (pH6.9). For each step 1.0 ml fractions were collected by using a 
fraction collector from Pharmacia. The ssDNA was eluted from the column by 160 mM 
Na-Pi (pH6.9), while dsDNA was eluted by 420 mM Na-Pi (pH6.9) (Figure 2.1D). 3 μl 
from each fraction was mixed with 7 μl EtBr (1μg/ml) on a plastic wrap to visualize the 
peak of DNA by using an UV transilluminator (Fisher Sicentific). Fractions that 
contained DNA had greatly increased in fluorescence compared to the fractions that just 
contained buffer. Fractions from the 420 mM Na-Pi (pH6.9) elution were separated 
through a 0.7 % agarose gel to visualize the efficiency of the separation between ssDNA 
and dsDNA. Those fractions that contained the highest concentration of dsDNA were 
combined and concentrated 3-4 fold by n-butanol extraction and then dialyzed against 
500 mL TE (pH 7.6) buffer at 4 ºC. The buffer was changed 3 times with minimum 6 hrs 
between changes.   
 
Linear homoduplex dsDNA was removed from the solution by E. coli Exonuclease V 
enzyme digestion (ExoV) (USB) (Figure 2.1E).  The dialyzed DNA solution was brought 
to 66.7 mM glycine (pH 9.4), 5 mM MgCl2, 8.3 mM β-mercaptoethanol (β-ME), and 0.5 
mM adenosine triphospate (ATP). Exo V was added to 0.2 U/μg total DNA and the 
solution was incubated for 60 min at 37 ºC. An agarose gel electrophoresis was 
performed to analyze the pre- and post- ExoV samples for the disappearance of the fast 
migrating linear dsDNA. Sometimes traces of the linear dsDNA could be observed in 
which case the DNA solution was incubated at 37 ºC until the linear dsDNA was 
undetectable. The reaction solution was then extracted once with phenol and concentrated 
to 0.5 ml using n-butanol extraction. Free nucleotides produced during the ExoV 
digestion were removed from the preparation using Sephacryl S300 resin column 
chromatography (Pharmacia) (Figure 2.1F). The resin was poured in a long (45 cm) and 
narrow (1.2 cm) glass column and beads were equilibrated with 3 CV of TES solution 
(TE with 0.3 mM NaCl). The concentrated ExoV digested reaction was loaded to the top 
of the resin bed and allowed to enter to the resin. The flow rate was maintained at 10-15 
ml/hr through all the S300 purification. Once the DNA entered to the column, 1.0 ml 
fractions were collected using the fraction collector. The substrate would typically be 
present around the 12
th
 fraction. The purity of the substrate in each fraction was checked 
using 1% agarose gel electrophoresis and appropriate fractions were combined and 
concentrated 8-fold using n-butanol. The substrate was dialyzed against TE (pH 7.6) and 
the concentration was measured by UV absorbance at 260 nm. A diagram of the different 
substrates is shown in Figure 2.2.   
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Figure 2.1 Schematic diagram of substrate preparation and purification 
A. Circular DNA (black) was linearized with Sau96I (5’ nicked substrate) or PstI (3’ 
nicked substrate) (V= viral strand; C= complementary strand). B. Linearized dsDNA was 
denatured and annealed with excess of circular ssDNA (orange) from the respective 
phage. C. After annealing, 4 different DNA species are present in the solution (nicked 
circular heteroduplex, circular ssDNA, and linear dsDNA and ssDNA). D. dsDNA is 
separated from ssDNA through Hydroxyapatite column. E. linear dsDNA was digested 
by E. coli Exo V into short fragments (1-5 nt). F. Exo V digestion products were 
separated by size exclusion through by S300 column, resulting in the purification of the 
desired nicked heteroduplex substrate.  
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Figure 2.2 Schematic representations of the nicked heteroduplexes substrates 
Left: 5’ nick G/T substrate used for in vitro MMR assay. Right: 3’ nick G/T substrate 
used also for in vitro MMR assay. Middle: 3’ nick G/T substrate used for in vitro 
Excision assay and Southern Blot.      
   
DNA MMR ASSAY USING CIRCULAR MISMATCH HETERODUPLEX  
The MMR assay was performed as described previously (58) in a 20 μl reaction 
containing 30 fmol of DNA heteroduplex, 110 mM KCl, 75 μg of nuclear extract, 
purified proteins (if required), 10 mM Tris-HCl (pH 7.6), 5 mM MgCl2, 1.5 mM ATP, 1 
mM Glutathione, 50 μg/ml BSA, and 0.1 mM dNTPs. Reactions were incubated at 37 ºC 
for 15 min, followed by addition of 30 μl of proteinase K (PK) solution (2.5 mM Tris-
HCl (pH 7.5), 5 mM CaCl2, 12.5% (v/v) glycerol, 6.7% SDS, 25 mM EDTA, and 5mg/ml 
proteinase K). Reactions with PK solution were incubated at 37 ºC for 20 min. DNA 
samples were recovered by phenol extraction (2 times) and ethanol precipitation (1/10 
NaOAC and 2.5 vol of 100% ethanol). DNA was pelleted by centrifugation at 14,000 x g 
and 4 ºC for 15 min, and washed with 70% EtOH followed by another centrifugation at 
14,000 x g for 5 min at RT. DNA samples were dried through speed vacuum 
centrifugation and then suspended in 10 μl ddH2O. The DNA was then incubated in the 
presence of the restriction enzymes, Hind III and BseRI to score repair activity with the 
3’ nick GT substrate (Figure 2.2, right) and HindIII and ClaI to score for repair activity 
with the 5’ nick GT substrates (Figure 2.2, left). The products were analyzed by 1% 
agarose gel electrophoresis. Three different bands can be observed, linear dsDNA 
heteroduplex (7.1 kb or 6.4 kb) and the desired products (two bands at 3.1 kb and 3.3 kb 
for 5’ substrate and 3.0 kb and 4.1 kb for 3’ substrate) that correspond to the repair 
products.  
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EXCISION ASSAY AND SOUTHERN BLOT 
The MMR excision assay was performed as described previously (58) in a 20 μl 
reaction containing 30 fmol of DNA heteroduplex, 110 mM KCl, 75 μg of nuclear 
extract, purified proteins (if required), 10 mM Tris-HCl (pH 7.6), 5 mM MgCl2, 1.5 mM 
ATP, 1 mM Glutathione, and 50 μg/ml BSA. Reactions were incubated at 37 ºC for 15 
min, followed by addition of 30 μl of PK solution.  The mixtures were incubated at 37 ºC 
for 20 min. DNA samples were recovered by phenol extraction (2 times) and ethanol 
precipitation (1/10 NaOAC and 2.5 vol of 100% ethanol). DNA was pelleted by 
centrifugation at 14,000 x g and 4 ºC for 15 min, and washed with 70% EtOH followed 
by another centrifugation at 14,000 x g for 5 min at RT. DNA samples were dried 
through speed vacuum centrifugation and then suspended in 10 μl ddH2O. The DNA was 
then incubated in the presence of the restriction enzymes, PstI and BglI to score for 
excision activity in the 3’ nick GT substrate (Figure 2.2, middle).  
 
DNA excision intermediates were visualized using the Southern Blot technique, 
performed essentially as described previously (64). MMR excision reactions were carried 
out as described above. After restriction enzyme digestion, the DNA samples were 
denatured and separated by 6% UREA-PAGE pre–run at 16 watts for 30 min. Samples 
were resolved at 8 watts for 1 ½ hrs. DNA products were then transferred onto a nylon 
membrane (GE healthcare) in 0.5x TBE buffer using the Hofer electrotransfer apparatus 
for 1 hr in a cold room. After the electrotransfer, the membrane was air-dried and DNA 
was crosslinked to the membrane by a 7 min exposure to UV transilluminator (membrane 
was placed on the transilluminator with the DNA facing down). The membrane was 
hybridized with a 5’-labeled oligonucleotide (V6370, close to BglI site) (Table 2.2) probe 
in buffer containing 50 mM Tris-HCl (pH 7.5), 1 M NaCl, 2% SDS, 1 mM EDTA, 0.5% 
polyvinylpyrrolidone, and 0.2% heparin for at least 3 hr at 42 ºC. Reaction products were 
visualized by autoradiography (see Figure 3.15).  
 
IN VITRO DNA SYNTHESIS ASSAY AND MUTAGENESIS ASSAY 
DNA synthesis reactions were performed in 20 µl reaction mixture, containing 75-
100 µg nuclear extract, purified proteins (if required), 100 ng gapped substrate (171 or 
283 nt gap), 10 mM Tris-HCl (pH 7.6), 5 mM MgCl2, 1.5 mM ATP, 1 mM Glutathione, 
50 μg/ml BSA, 110 mM KCl, and 0.1 mM dNTPs. Reactions were incubated at 37 ºC for 
the indicated times. DNA was recovered by PK digestion, phenol extraction (2 times), 
and ethanol precipitation as described before. Recovered DNA was digested with HindIII 
and BseRI restriction enzymes for 2-3 hours at 37 ºC. Products were analyzed by 1% 
agarose gel. The appearance of the 3.0 kb and 4.3 kb bands indicated synthesis products, 
while the 7.3 kb band indicated the presence of the gap substrate. The mutagenesis assay 
was performed essentially as described previously (65). Reactions were carried out as 
described above.  0.5-0.2 ng of DNA was transformed into 150 µl E. coli XL-1 Blue 
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cells.  30 µl of the transformed cell culture was added into 3 ml of 2 x YT soft agar 
containing 200 µl of fresh O/N cultured XL-1 Blue cells, 6.6 µl/ml IPTG, and 17.3 µl/ml 
of 5-bromo-4-chloro-3-indolyl-βD-galactosidase (X-gal) and then plated on a LB plate. 
Plates were incubated overnight at 37 ºC and mutant plaques were determined by white 
and blue screening. The mutation frequency was calculated by adding the number of 
white/light blue plaques and dividing by the total number of plaques present (see Figure 
3.19).    
 
SITE DIRECTED MUTAGENESIS 
To construct PCNA and MutLα mutants, site-directed mutagenesis was performed 
using pT7-PCNA and pFastBacDUAL-MLH1/PMS2 vectors, respectively. The 
procedure for this technique was adapted from the protocol of the QuickChange Site-
Directed mutagenesis kit from Stratagene. The oligonucleotide pairs used to generate the 
specific mutations in the PCNA and MLH1 cDNAs are listed in Table 2.2. PCR reactions 
were performed in an Eppendorf thermal cycler (Bio-Rad) in a final volume of 50 µl 
containing 50-200 ng DNA (pT7-PCNA or pFastBacDUAL-MutLα), 1 U Phusion 
polymerase (Finnzymes), 0.2 mM dNTPs, and 0.2 µM of each oligonucleotide pair. After 
the PCR was completed, reactions were mixed with 1 µl DpnI restriction enzyme (10 
U/µl) and incubated at 37 ºC for 1 hr to digest the parental supercoiled dsDNA. 7 µl of 
the pre- and post DpnI reactions were analyzed by 1% agarose electrophoresis. The 
desired product (nicked circular dsDNA) can be observed at the right molecular weight, 
while the supercoiled DNA (template) migrates in the gel faster than the PCR product. 5 
µl of the DpnI digested products were transformed into 50 µl of E.coli DH5α competent 
cells. 50 µl of the transformed cells were plated onto LB plates containing 100 µg/ml 
ampicillin and incubated O/N at 37 ºC. Ampicillin resistant clones were selected and 
amplified for plasmid extraction using the miniprep DNA extraction kit (Omega-Bio 
Tek). Mutant DNAs were selected after sequences were verified by Eton Bioscience. 
 
UV CROSSLINKING  
The UV crosslinking experiments were performed as essentially described by Mazur 
et al. with minor modifications (66). 10 Ci/mmol γ-
32
P-ATP and 800 Ci/mmol α-
32
P-ATP 
were purchased from PerkinElmer. Reactions were performed in 10 µl reaction 
containing 50 mM Tris-HCl (pH 7.6), 5 mM dithiolthreitol (DTT), 0.2 mg/ml BSA, 10% 
(v/v) glycerol, 10% (w/v) sucrose, with or without MgCl2, 1 µg purified protein (MutLα), 
and γ or α-
32
P-ATP. Reactions were incubated on ice for 30 min, followed by 5 min of 
UV crosslinking (UVP Crosslinkers). Products were fractionated by 8% SDS-PAGE, the 
gel dried by vacuum (BioRad gel dryer), and products visualized using a PhosphorImager 
(Molecular Dynamics).  
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Oligonucleotides Sequence Application
V6370 5’-atagcgaagaggcccgcac-3’ Southern Blot
MLH1A120V 1: 5’-gttactattacaacgaaaacagttgatggaaagtgtgcatacaga-3’
2: 5’-tctgtatgcacactttccatcaactgttttcgttgtaatagtaac-3’
Site-directed mutagenesis
MLH1V716M 1: 5’-caaactcctggaagtggactatggaacacattgtc-3’
2: 5’-gacaatgtgttccatagtccacttccaggagtttg-3’
Site-directed mutagenesis
MLH1 L509F 1: 5’-ggatcattaacctcactagtgttttgagtttccaggaagaaatta-3’
2: 5’-taatttcttcctggaaactcaaaacactagtgaggttaatgatcc-3’
Site-directed mutagenesis
MLH1 F99L 1: 5'-tatttctacctatggcttacgaggtgaggctttgg-3‘
2: 5'-ccaaagcctcacctcgtaagccataggtagaaata-3'
Site-directed mutagenesis
MLH1 W712R 1: 5'-ctccattccaaactccaggaagtggactgtgga-3‘
2: 5'-tccacagtccacttcctggagtttggaatggag-3'
Site-directed mutagenesis
MLH1 F571L 1: 5'-agatactcatttatgattttgccaatcttggtgttctcaggttatc-3‘
2: 5'-gataacctgagaacaccaagattggcaaaatcataaatgagtatct-3'
Site-directed mutagenesis
PCNA Y211D 1: 5'-caactaacttttgcactgagggacctgaacttctttacaaaag-3‘
2: 5'-cttttgtaaagaagttcaggtccctcagtgcaaaagttagttg-3'
Site-directed mutagenesis
PCNA Y211F 1: 5'-caactaacttttgcactgaggttcctgaacttctttacaaaag-3‘
2: 5'-cttttgtaaagaagttcaggaacctcagtgcaaaagttagttg-3'
Site-directed mutagenesis
PCNA Y211E 1: 5'-caactaacttttgcactgagggagctgaacttctttacaaaagcc-3‘
2: 5'-ggcttttgtaaagaagttcagctccctcagtgcaaaagttagttg-3'
Site-directed mutagenesis
Table 2.2 Oligonucleotides used for Site-directed Mutagenesis and Southern Blot
 
 
ATPASES ANALYSES 
Reactions for measuring the ATPase activity of MutLα were carried out in a 25 µl 
reaction containing 20 mM Tris-HCl (pH 8.0), 120 mM NaCl, 5 mM MgCl2, 1 mM DTT, 
1.0 µg MutLα, and γ-
32
P-ATP (66,67). The reaction was incubated at 37 ºC and 
terminated at the indicated times by adding 0.5 vol of the 2x SSCP loading buffer (95% 
(v/v) formamide, 0.05% (v/v) bromophnol blue, 0.05% (v/v) xylene cyanol, and 20 mM 
EDTA). Reactions were analyzed using a 20% urea PAGE and products visualized using 
a PhosphoImager. 
  
MLH1 MUTATION DETECTION IN LIM2405 CELLS 
Detection of MLH1 gene mutation in the Lim2405 was performed using PCR-based 
single-strand conformation polymorphism (SSCP). These procedures were performed 
essentially as described previously (68). Each of MLH1 exon was amplified by PCR.  
PCR reactions were carried out in a 10 μl reaction containing 1  μg of  DNA,  5  pmoles  
of  each primer,  0.5  U Phusion polymerase (Finnzymes)/reaction,  0.2 mM of dNTPs , 
10  mM  Tris-HCl  (pH  8.0),  50  mM  KC1, 1.5  mM  MgC12, and  0.5  μCi  of  α-[
32
P]-
dCTP  (3000  Ci/mmole, Perkin Elmer). The amplified products were mixed with 0.5 vol 
of the 2x SSCP loading buffer (95% formamide, 0.05% bromophnol blue, 0.05% xylene 
cyanol, and 20 mM EDTA) and heated at 95 ºC for 5 min, followed by incubation in a 
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ice-water slurry for 5 min. Products were resolved in a 0.5x MDE gel (Sigma) poured 
into standard sequencing gel plates using 0.4-mm spacers and a sharkstooth comb. 
Denatured DNA samples were loaded and electrophoresis in 0.6x TBE was performed at 
RT for 12-15 hrs. After electrophoresis, the gel was transferred onto a sheet of Whatmann 
3MM paper and vacuum-dried. Samples exhibiting altered migration were visualized by 
autoradiography. 
 
WESTERN BLOT TECHNIQUE  
50 µg of whole lysates or nuclear extract was fractionated by SDS-PAGE as 
described above.  Proteins were then transferred onto a nitrocellulose membrane by an 
electrotransfer for 1 hour (BioRad electrotransfer) at 400 mA in transfer buffer (3.03 g 
Tris, 14.4 g glycine/L, and 200 ml/L methanol) (55,69,70). The nitrocellulose membrane 
was blocked for nonspecific binding in 5% (NFDM) dissolved in TBS-T buffer 
containing 10 mM Tris-HCl (pH 7.5), 0.8% NaCl, and 0.1 % (v/v) Tween 20 for 1 hr at 
RT. The membrane was then incubated O/N with the primary antibody in 5% NFDM. 
Unbound antibody was washed out with a 5 min wash using TBS-T buffer (repeated 3 
times). Then, the membrane was incubated with the secondary antibody conjugated with 
horseradish peroxidase (Sigma) at RT for 1-3 hrs. The membrane was washed with TBS-
T buffer for 5 min at RT (3 times), followed by protein detection through 
chemiluminescence using the ECL detection reagents (Roche) and autoradiography. 
 
FAR-WESTERN BLOT 
Purified PCNAs or MutLα variants were spotted onto a nitrocellulose membrane. 
Dots were allowed to dry at 4 ºC for 10 min, followed by overnight incubation with the 
respective purified interacting protein (MutSα, MutSβ, MutLα, or ExoI) (600 ng to 1000 
ng). After washing the membrane 3 times with TBS-T buffer, immunoblotting with 
primary and secondary antibodies was performed (71). Bound antibodies were detected 
using ECL detection reagents and the interaction was visualized by autoradiography. 
 
IN VITRO KINASE ASSAY 
The recombinant GST-EGFR kinase domain was purchased from Millipore and Cell 
signaling. 25 µl reactions containing 5 µg PCNA, 50-100 ng GST-EGFR kinase, 60 mM 
Hepes (pH 7.5), 5 mM MgCl2, 5 Mm MnCl2, 3 µM Na3VO4, 1.25 mM DTT, and 200 µM 
ATP were incubated at RT for 30 min (72). The reactions were terminated by adding 0.2 
vol of 6x protein loading buffer that contained 125 mM Tris-HCl (pH 6.8), 2% SDS, 20% 
glycerol, 0.2% bromophenol blue, followed by heating at 90 ºC for 5 min. Reactions were 
fractionated by 12% SDS-PAGE and the proteins were transferred to membranes for 
western blot analysis. PCNA phosphorylation was detected by immunoblotting the 
membrane with the phosphotyrosine antibody  
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IMMUNOPRECIPITATION ASSAY and BIOTINYLATED DNA PULL DOWN 
Whole lysate or nuclear extract (1 mg total protein) was incubated with 15 µl protein 
G- agarose beads (Roche) for 1 hr at 4 ºC on a LabQuake shaker. Clarified proteins were 
recovered by centrifugation at 100 x g and 4 ºC for 3 min, followed by overnight 
incubation with 3-5 µg antibodies against PCNA (Santa Cruz) and PCNA Y211-p 
(Bethyl and/or generated in our lab) (73). The mixture was then incubated with 15 µl 
prewashed protein G-agarose for 1 hr at 4 ºC on the LabQuake shaker. Pulled down 
protein was recovered by centrifugation (100 x g for 3 min), washed with LS Buffer (PBS 
(pH 7.5), 10% (v/v) glycerol, 0.1% (v/v) NP-40 and 1x proteinase inhibitor cocktail) for 
10 min on the LabQuake shaker.  
 
Purified recombinant proteins were incubated overnight at 4 ºC in the biotinylation 
binding buffer (18 mM Hepes-KOH, pH 7.9, 40 mM KCl, 2 mM MgCl2, 10 mM DTT, 
and 1 x proteinase inhibitor) (74). Next day, 80 pmoles of biotinylated G/T mismatch 
DNA were added with 20 μl of streptavadin beads and incubated for 1 hour at room 
temperature. 
 
Pull down and immunoprecipitated complexes were resuspended  in 10 µl of 6x 
protein loading buffer containing 125 mM Tris-HCl (pH 6.8), 2% SDS, 20% glycerol, 
0.2% bromophenol blue, followed by heating at 90 ºC for 5 min. Products were resolved 
by 12% SDS-PAGE. Proteins were then transferred onto a nitrocellulose membrane and 
immunoblotted as described above. 
 
IMMUNOHISTOCHEMISTRY  
Ninteen colorectal cancer tissues samples with their respective normal tissues were 
used for immunihistochemistry as described previously (75). Dr. Dana Naspier performed 
the immunohistochemistry stainings and Dr. Eun- Young Lee provides us the tissue 
staining pictures, the intensity and the percentage scores used to calculate the 
immunoreactivity scores. 
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CHAPTER THREE: PCNA PHOSPHORYLATION INHIBITS THE MMR 
PATHWAY AT A STEP PRIOR TO MISMATCH-PROVOKED EXCISION/ 
INCISION  
 
INTRODUCTION 
Proliferating Cell Nuclear Antigen (PCNA) is a homotrimeric protein that interacts 
with numerous other proteins in the cell. PCNA is well known to be involved in DNA 
replication as the processivity factor for polymerases δ and ε (76,77). Moreover, its 
presence at the replication fork allows the dynamic exchange of polymerase α (primer 
extension) for polymerase δ in a way to ensure the initiation and the elongation of the 
Okazaki fragments (78). The significance of PCNA function in cells can be observed 
through its evolutionary conservation among species. Although the yeast and human 
PCNAs only share 35% identical amino acids in their sequences, their three dimensional 
structures are highly superimposable (79,80). The eukaryotic PCNA is composed of three 
identical monomers, which interact with each other by a head-to-tail arrangement 
forming a pseudo-six-fold symmetric ring. Each monomer contains two globular domains 
linked by a flexible loop known as the interdomain connecting loop (IDCL) (Figure 3.1). 
The outside part of the ring structure is composed of β-sheets which are mostly 
negatively charged, while the inner side contains a layer of α-helixes rich in basic 
residues (Figure 3.2)(81). This arrangement allows the homotrimer to encircle, be in 
close proximity to, and freely slide along the DNA in both directions. In addition, PCNA 
has two distinguishable sides; the front and the back (Figure 3.1). The vast majority of 
PCNA interactions are believed to be carried out on the front side of the homotrimeric 
structure. For example, when PCNA is loaded on the DNA by the clamp loader 
replication factor C (RFC), it is loaded with its front side facing towards the 3’ end of the 
elongating DNA. This orientation allows PCNA to interact with the DNA polymerase, 
which also binds to the front side of PCNA and in that way it can orient the polymerase 
to the growing end (82). In addition, this orientation allows PCNA to discriminate among 
the parental and daughter DNA strands.  
 
Not only do different PCNA homologs share similar sequences and the same 
structure, but also the same function. The retention of its function among species can be 
observed in studies in which the mammalian PCNA was replaced by the yeast or the 
Drosophila homologs in in vitro DNA replication assays. In these assays, the two 
homologs were able to support DNA replication in the mammalian system (83,84). 
PCNA’s role in DNA replication is not the only function that this DNA clamp possesses. 
It is also involved in a number of different cellular functions such as cell cycle regulation, 
sister-chromatid cohesion, chromatin remodeling, and DNA repair (81). The vast 
majority of these interactions occur through PCNA-specific binding motifs contained in 
interacting proteins. Among these the PIP-box (PCNA-interaction protein box) has been 
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observed most often in the interacting proteins and it is the most studied. This motif is 
characterized by the consensus sequence, QXX(M/L/I)XX(F/Y)(F/Y) that sometimes can 
be flanked by a KAX sequence (82). The proteins containing this PIP-box bind to a 
hydrophobic groove in PCNA buried under the IDCL (Figure 3.3) (82).  
 
 
 
 
Figure 3.1 human PCNA structure 
The PCNA homotrimeric structure is composed of three monomeric subunits.  Each 
monomer possesses two globular domains connected together by the interdomain 
connecting loop (IDCL). The monomers interact with each other through a head-to-tail 
arrangement creating the pseudo-six-fold symmetrical ring. PCNA’s front side can be 
distinguished from its back side through the IDCLs that face to the front side. The figure 
was prepared using the file 1VYM from the RCSB Protein Bank and PyMol Software.  
 
 
Back sideFront side
Interdomain 
Connecting Loop
Globular 
Domain
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Figure 3.2 PCNA electrostatic surface  
PCNA possesses a net negative surface charge. However, the inner surface is positively 
charged due the presence of many lysine and arginine residues. The inner ring diameter is 
estimated to be 34Å, while the external diameter is around 80Å and its thickness around 
30Å (81). The figure was prepared using the file 1VYM from the RCSB Protein Bank 
and PyMol Software. 
 
 
 
Figure 3.3 PCNA interaction domain 
PCNA can interact with numerous proteins involved in many cellular processes. Many of 
these proteins contain a PIP-box sequence that is known to interact with a groove 
(orange) underneath the interdomain connecting loop. The figure was prepared using the 
file 1VYM from the RCSB Protein Bank and PyMol Software 
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Later analysis of peptide sequences from other proteins that bind to PCNA revealed 
the presence of a second PCNA-specific binding motif that was catalogued as the KA-
box (85). This box is characterized by the consensus sequence 
KA(A/L/I)(A/L/Q)XX(L/V) and is believed to function as a canonical site to 
preferentially bind some specific proteins among all the PCNA interacting proteins. This 
hypothesis is based on the observation that some of the PCNA interacting partners such 
as polymerase δ and MSH6 contain both motifs, the PIP and the KA-box. As observed in 
Table III, PCNA undergoes interactions with proteins containing the PIP-box and/or the 
KA-box. Although it is believed that the three monomers that compose the homotrimeric 
ring and the presence of both PCNA-binding motifs can influence the selection of PCNA 
interacting partners, double homotrimer forms of PCNA have been also observed in 
mammals (27,86). This interaction is carried out by Arg5 and Lys110 and organized 
through a back to back interaction providing two front sides facing outwards, therefore, 
producing a higher surface area for protein-protein interactions. 
 
Cellular processes Proteins
DNA Replication DNA polymerase δ, DNA polymerase ε, RFC, 
RPA, DNA topoisomerase 1 and 2A, Flap 
Endonuclease (Fen1), DNA Ligase I, Cdt1
Cell Cycle Control and Survival p21(CIP/WAF1), p27(Kip2), Cyclin D1, CDC25C, 
MCL1, p15 (PAF), ING1b, CDK2, Gadd45, 
MyD118, CR6, p53, MDM2
DNA Repair MSH3, MSH6, MLH1, EXOI, UNG2, MPG, 
NTHL1, hMYH, APE I and II, DNA 
polymerase β, XRCC1, XPG, PARP-1, WRN, 
BLM, RecQ5
DNA Damage Avoidance DNA polymerases η, ι, κ, λ, and ζ, REV1, 
RAD18, SHPRH, HLTF, RNF8
Sister-Chromatid Cohesion ESCO1 and 2
Chromatin Assembly and 
Maintenance 
WSTF, DMT1, HDAC1, p300
PIP Box: Qxx(M/L/I)xx(F/Y)(F/Y)
KA Box: KA(A/L/I)(A/LQ)xx(L/V)
PIP and KA box
Table 3.1 PCNA interacting partners*
*Modified from Stoimenov, I. and Helleday, T. (2009). PCNA on the crossroad of 
cancer. Biochem Soc Trans, 37(Pt 3): 605-613
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Besides the PCNA-specific binding motifs and the double homotrimer structure, it is 
known that PCNA can undergo a number of post-translational modifications that affect 
its function. Although the vast majority of PCNA in cells is observed in the unmodified 
form, a small portion of the protein is modified to increase its specificity for some 
proteins. Some of the PCNA post-translational modifications reported are ubiquitylation, 
sumoylation, and phosphorylation among others (81). The most documented modification 
has been the PCNA ubiquitylation. It has been reported that PCNA can undergo two 
different ubiquitylation events; mono-ubiquitylation and poly-ubiquitylation. Both of 
these events occur at the conserved lysine 164 (Lys164) and are distinguished by the 
attachment of a single ubiquitin moiety or a chain of interlinked ubiquitins (82,87). In 
addition, each of these events is carried out by a different set of modification proteins that 
results in different protein-protein interactions. For example, monoubiquitylation of 
PCNA has been reported to switch the polymerase δ/ε at stalled replication forks for a 
translesion polymerase to reestablish DNA replication, while polyubiquitylation is 
required for the error-free or bypass repair (81,82).  In addition to ubiquitylation, another 
PCNA modification that also occurs at Lys164 and in less extent at Lys127 is 
SUMOylation (88). This modification consists of the attachment of the small ubiquitin-
related modifier (SUMO) to this residue. Eventhough, PCNA sumoylation has not been 
well characterized in mammals is known that can recruit the helicase Srs2 resulting in the 
inhibition of homologous recombination (89) (90).  
 
There has been some controversy about whether or not PCNA is phosphorylated in 
vivo. A recent study using tandem mass spectrometry showed that PCNA is 
phosphorylated at Tyrosine 211 (Tyr211) in human and mouse cells (72). Furthermore, it 
was observed that this modification occurs in around 6% of the chromatin-bound PCNA 
and results in PCNA stabilization. It was hypothesized that this post-translational 
modification helps to retain PCNA activity on the chromatin. PCNA has been used as a 
cancer cell marker because its expression levels are associated with proliferation and/or 
neoplastic transformation (72,82).  Consistently, increased PCNA Tyr 211 
phosphorylation coincides with pronounced cell proliferation, and is correlated with poor 
survival and prognosis of cancer patients. Using a series of kinase inhibitors and an in 
vitro kinase assay, Wang et. al (72) showed that the nuclear translocation of the 
epidermal growth factor receptor (EGFR) was responsible for the PCNA phosphorylation 
at Tyr211.  
 
In MMR, PCNA function is required at two different steps, prior to and after the 
mismatch-provoked excision (91,92). As a polymerase processivity factor it is recruited 
at the repair synthesis step to tether the polymerase on the DNA to re-fill the gap 
generated during mismatch provoked excision. Moreover, PCNA interaction with MSH6, 
MSH3, and MLH1 suggested a role of this protein in the steps preceding the DNA repair 
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synthesis. Different studies showed that PCNA enhances MutSα and MutSβ substrate 
binding affinity, indicating a role for PCNA in recruiting the MMR initiation factors to 
the DNA lesion (93,94). However, it seems that during MMR initiation the PCNA 
activity is required differently depending on the nick location. PCNA is indispensable for 
initiating excision when the nick is located 3’ to the lesion, while it is not absolutely 
required for at least some 5’ nick-directed repair to occur (92). Recent studies imply that 
PCNA’s role in MMR initiation of the 3’ nick substrates is to activate the latent MutLα 
endonuclease that introduces single strand breaks near the lesion, subsequently 
generating new entry sites for EXOI nuclease (38). 
  
In colorectal cancers (CRCs), mismatch repair deficiency has been identified to be the 
main cause of hereditary nonpolyposis colorectal cancer (HNPCC). However, based on 
the multistep tumorigenesis model, many oncogenes are activated while many tumor 
suppressor genes are inactivated. In addition, increased expression of EGFR is closely 
associated with CRC development. Interestingly, a recent study revealed that colorectal 
cell lines exhibiting microsatellite instability (MSI) often have a high-level of EGFR 
expression (95), suggesting a role for EGFR in modulating cancer development, 
progression, and metastasis. 
 
RATIONALE 
Colorectal cancer patients with MSI and high levels of epidermal growth factor 
receptor (EGFR) expression show low response to cancer treatment and poor prognosis. 
However, the reason, if any, for the correlation between these two tumor promoting 
factors has not yet been determined. EGFR has been shown in vitro and in vivo to 
phosphorylate PCNA at Tyr211 (72). This modification increases the stability of PCNA 
bound to chromatin, promoting cell proliferation. It is known that PCNA plays an 
important role in the MMR pathway and alterations of PCNA function by 
phosphorylation may lead to a mutator phenotype. Therefore, studying the effect of 
PCNA phosphorylation at Tyr211 on MMR may provide a better understanding of the 
pathway behind the clinical outcome in cancer patients with MSI and high EGFR 
expression. Using different biochemical and molecular approaches we demonstrate here 
that phosphoryation of PCNA at Tyr211 affects the interaction between PCNA, MutSα 
and MutSβ, inhibits MMR initiation, and promotes misincorporations during the DNA 
gap-filling processing.    
 
RESULTS 
 
EGFR kinase phosphorylates PCNA at Tyr211 in vitro 
EGFR can normally be found in the plasma membrane of cells where it is activated in 
a ligand-dependent manner by either epidermal growth factor (EGF) or transforming 
 
 
 
38 
growth factor α (TGFα). Binding of either growth factor to the receptor, results in 
activation of a signaling cascade, and translocation of EGFR to the nucleus, leading to 
activation of DNA replication and cell proliferation (96). Recently, Wang et al. reported 
that nuclear EGFR (nEGFR) interacts with and stabilizes PCNA by phosphorylating its 
Tyr211, residue. This modification occurs by direct interaction between the proteins rather 
than through the activation of the MAPKK pathway by EGFR.  
 
To corroborate these previous findings, recombinant PCNA was incubated in the 
presence of GST-EGFR kinase domain (Figure 3.4A). The reactions were performed in 
the presence of 100 μM ATP at room temperature. The kinase and the substrate 
incubation were performed at different time points to determine the best time where the 
highest level of PCNA phosphorylation can be observed. In this in vitro kinase assay, 
activation of EGFR kinase domain through tyrosine phosphorylation can be observed as 
early as 5 min (top lane 1) and although some levels of PCNA phosphorylation can also 
be observed at this time point, it is not until 20 min that significant levels of tyrosine 
phosphorylation can be observed on PCNA (bottom lane 1 vs lane 3). The highest level of 
PCNA phosphorylation was observed after 30 min of incubation with no significant 
change after 60 min of interaction (bottom lane 4 vs lane 5). This result indeed confirms 
the previous study that EGFR kinase activity phosphorylates PCNA at a tyrosine residue. 
To determine if the phosphorylation is specifically at the Tyr211 residue, Tyr211 (Y) was 
substituted with phenylalanine (F) or glutamic acid (E), and the resulting PCNA variants 
were incubated with EGFR for phosphorylation. As expected, the wild type PCNA can be 
phosphorylated after 30 min of incubation (Figure 3.4B lane 1), but little phosphorylation 
was detected in PCNA with Y211F or Y211E substitution, suggesting that Y211 is the 
phosphorylation target for EGFR.   
 
The colorectal cancer cell lines, Lim2405 and DLD-1 contain high levels of EGFR  
High levels of EGFR have been linked to tumor development, progression, and 
metastasis in different cancer types including colorectal cancer. Because a direct 
correlation exists between EGFR and the PCNA phosphorylation levels, we screened 
severa; human colon cancer cell lines for elevated expression of EGFR (Figure 3.5). The 
levels of EGFR in the different MSI colorectal cancer cell lines were compared with the 
microsatellite stable (MSS) HeLa cell line. The EGFR expression in the cell lines were 
normalized based on the EGFR levels in HeLa cells. During this screening, we confirmed 
that three MSI colorectal cell lines, Lim2405 (Lim), LoVo, and DLD-1, show high 
expression levels of EGFR, with Lim and DLD-1 containing the highest EGFR 
expression (Figure 3.5).  
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Figure 3.4 EGFR kinase phosphorylated PCNA at Tyr211  
In vitro kinase assay were performed by incubating the indicated PCNA isoforms (5μg) 
and EGFR kinase (180 ng). Products were resolved on a 12% SDS-PAGE and visualized 
by immunoblotting using an antibody specific for phosphorylated tyrosine. 
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Figure 3.5 EGFR expressions in MSI colon cancer cell lines 
Whole-cell lysate (150µg) were run on an 8%-SDS-PAGE. EGFR expression and β-actin 
were detected by immunoblotting. Products were observed by autoradiography and 
quantified by using Kodak Image software.        
 
 
High EGFR and PCNA Tyr211 phosphorylation levels in colorectal cancers  
Colorectal cancer (CRC) is the second leading cause of death among adult cancers 
(National Cancer Institute). However, when CRC is restricted to the colon wall (Stage I 
& II) it is curable by surgical excision (97). Otherwise, if cancerous cells are found in the 
lymph nodes (Stage III), the cancer requires a more aggressive treatment that includes 
surgery and adjuvant chemotherapy. If the disease has undergone metastasis (Stage IV), 
chemotherapy treatment can increase the patient’s life span but normally the disease is 
incurable (98). High EGFR expression has been observed in MSI colorectal cancer cell 
lines and tissues (95,99). Moreover, EGFR overexpression was observed to be 
significantly associated with TNM (tumor node metastasis) stage III (99). To determine 
EGFR expression and PCNA Tyr211 phosphorylation in CRC tumor tissues, 19 tumor 
cores with their respective normal tissue controls were examined by 
immunohistochemistry (IHC) (Figure 3.7 left panel). Before performing the tissue IHC, 
HeLa and Lim cell lines were stained for EGFR and PCNA phosphorylation as a positive 
control (Figure 3.6). As observed in Figure 3.6, Lim cells exhibit greater EGFR staining 
intensity and a higher percentage of positive cells than HeLa. This result corroborates the 
findings from the western blot and immunoprecipitation assays (Figures 3.5 and 3.7 
A/B). Once it was established that the antibodies used for IHC could show the expression 
of these proteins in the cells, staining of the tumor tissues was performed. Representative 
patient samples for each protein staining are shown in Figure 3.7 right panel. Each 
sample was assigned an immunoreactivity score. These scores were calculated based on 
the semiquantitative seven-tier system (75). In this system, the percentage of positive 
cells and intensity of staining are added to give a final immunoreactivity score from 0 to 
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6. In normal tissue, the immunoreactivity score for EGFR and PCNA Tyr211 
phosphorylation was 3 for each protein. Different expression levels for each protein were 
observed in the CRC tissue samples (Figure 3.7 left panel). If we take a closer look to the 
data analysis in Figure 3.7, it can be observed that 69% of CRC samples contain EGFR 
immunoreactivity above the normal levels detected in the control samples. And, 53% of 
the samples contain higher levels of PCNA Tyr211 phosphorylation. Unfortunately 
different from the cell lines, a direct correlation among EGFR and PCNA 
phosphorylation expression was not observed in the colorectal cancer tissue samples. 
However, previous study indicated that was only the expression of nEGFR that correlates 
with the increase levels of PCNA Tyr211
 
phosphorylation (72). Neverthless, any staining 
of nEGFR was observed in our study. Different factors can contribute to the lack of 
nEGFR expression observed in the CRC samples. One possibility can be that the 
antibody used can recognize better the membrane EGFR than the nuclear EGFR. In 
addition, can also exist the possibility that other tyrosine kinase rather than EGFR can 
phosphorylate PCNA in cells. But based in previous findings, different antibodies can be 
used to have a better idea whether it can be observe a direct correlation between EGFR 
and PCNA phosphorylation.  
 
    
 
 
Figure 3.6 Higher PCNA phosphorylation expression can be observed in Lim2405 
Representative illustrations from the Immunohistochemistry staining in HeLa and Lim 
cell lines. Left panel shows EGFR expression (brown staining) in both cell lines while the 
right panel illustrated PCNA Y211p (purple staining). Pictures were provided by Dr. 
Eun- Young Lee. 
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Figure 3.7 EGFR and PCNA Tyr211 expression in CRC tissue 
Left panel. Show representative illustrations from the immunohistochemistry staining of 
EGFR (top) and PCNA Y211-p (bottom) in CRC tissue. Right panel illustrated the data 
analysis for all the samples obtained by adding the intensity and percentage score for 
each sample. Pictures, intensity scores, and percentage scores were provided by Dr. Eun- 
Young Lee. 
 
Elevated expression and activation of EGFR are associated with higher levels of 
PCNA phosphorylation 
To determine whether the high level of EGFR expression in Lim cells is associated 
with a higher level of PCNA phosphorylation, two different co-immunoprecipitation 
assays were performed (Figure 3.8 A & B). In Figure 3.8A, PCNA was 
immunoprecipitated and the tyrosine phosphorylation was detected. A direct correlation 
can be observed between EGFR expression and PCNA phosphorylation in Lim, where 
high levels of EGFR correlate with higher levels of PCNA phosphorylation (Figure 
3.8A). Moreover, when the co-immuniprecipitation was performed using a PCNA Tyr211-
phosphorylation-specific antibody and the products were immunoblotted by a regular 
PCNA antibody, the same outcome can be observed. These results show that PCNA 
Y211 phosphorylation is higher in the MSI Lim cells, when compared with the levels 
detected in HeLa. PCNA Y211 phosphorylation was also similarly detected in DLD-1 
cells (data not shown). A more direct correlation between EGFR activation and PCNA 
phosphorylation was observed in DLD-1 cells, when the cell line was treated with 20 
ng/μl of EGF (EGFR ligand) for 24 hours. As shown in Fig. 3.8C, in comparison with 
untreated cells, the EGF treatment resulted in a higher level of PCNA phosphorylation. 
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These results support the hypothesis that cells overexpressing EGFR or with a 
constitutive activation of this receptor will contain higher levels of PCNA Y211 
posphorylation than normal cells. 
 
 
 
 
 
 
 
Figure 3.8 High levels of PCNA phosphorylation at Tyr211 in Lim2405 and DLD-1 
Immunoprecipitation assays where were performed in the indicated whole cell lysates 
using an antibody against PCNA (A) or Y211-phosphorylated PCNA (B and C), as 
indicated. Products were visualized by autoradiography and quantified by the Kodak 
Image software. 
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Lim2405 cell line lacks MutLα expression 
Lim2405 is a colon cancer cell line that exhibits MSI (100). The majority of the colon 
cancer cell lines with MSI (~90%) have mutations in the MSH2 or MLH1 genes (44). To 
investigate the levels of protein expression of MutSα (MSH2-MSH6) and MutLα 
(MLH1-PMS2) in Lim2405, a western blot was performed using Lim2405 and HeLa 
whole cell lysates. It was found that Lim2405 cells express MSH2 and MSH6 but do not 
express detectable levels of MLH1 or PMS2 (MutLα) (Figure 3.9A). It is known that the 
stability of PMS2 can be affected in the absence of MLH1. In other words, when MLH1 
is absent PMS2 is not stable and undergoes degradation, resulting in the lack of both 
polypeptides. Therefore, it is possible that Lim may contain an alteration in only MLH1 
and not PMS2. For this reason, we analyzed individual MLH1 exons of Lim2405 for 
alterations using a single-strand conformation polymorphism assay (SSCP) (Figure 
3.9B). Different primers targeting all 19 exons of MLH1 were used to amplify Lim2405 
and HeLa genomic DNA.  By comparing the results from Lim2405 (L: lane 2) and HeLa 
(H: lane 1) some variations in the sequences of exons 11 and 12-1 of Lim can be 
observed, suggesting that Lim2450 cells carry genetic alterations in MLH1 (Figure 3.9B).    
 
 
 
Figure 3.9 Lim2405 contains genetic alterations in MLH1  
A). MutSα (MSH2-MSH6) and MutLα (MLH1-PMS2) expression in Lim. B). SSCP 
analysis of MLH1 exons. Different exons of MLH1 were amplified by PCR in the 
presence of [α-
32
P]-dCTP and resolved in a 5% nondenaturing SSCP polyacrylamide gel. 
The PCR products are observed by the [α-
32
P]-dCTP incorporation and phosphoimaging. 
Exon 13 represents the amplified exons with non detectable alterations between HeLa 
and Lim2405 genomic DNA, while exons 11 and 12-1 exhibit polymorphisms (red stars).  
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PCNA Tyr211 phosphorylation in Lim and DLD-1 affects in vitro MMR activity 
To explore the effect of PCNA phosphorylation on MMR, we examined the MMR 
activity of nuclear extracts derived from Lim2405 cells using a well-established in vitro 
MMR assay (31,39,92). Traditionally, in this assay the DNA substrate used is a circular 
heteroduplex containing a G/T mismatch and a strand break 3’ to the mismatch (Figure 
2.2 and 3.10A). The mismatch is located in the recognition sequence of a restriction 
endonuclease (HindIII), resulting in resistance of cleavage at the mismatch. Incubation of 
the substrate with a MMR-proficient nuclear extract such as HeLa extract results in the 
removal of the mispaired base in the nicked strand (the “G” strand). The resynthesis 
machinery uses the continuous strand (the “T” strand) as a template to refill the gap 
generated during the mismatch removal and incorporates the correct base (i.e “A”) 
regenerating the HindIII restriction site, thereby rendering the repaired products sensitive 
to HindIII cleavage (Figure 3.10A) (Material and Methods). Moreover, if the substrate is 
incubated in the presence of an MMR-deficient nuclear extract, the mismatch is not 
removed and the DNA substrate remains resistant to HindIII cleavage. Nevertheless, 
previous studies have shown that MMR deficiency in cells derived from HNPCC and 
sporadic tumors with MSI can be corrected by the addition of purified MutSα or MutLα 
(31,32). For example, incubation of MutLα and the nuclear extract derived from the 
HCT116 colorectal cell line, which is deficient in MLH1, restores the MMR activity at a 
level comparable to that of MMR-proficient HeLa cells (Figure 3.10B, lane 8 vs 6). 
Interestingly, incubation of MutLα and Lim nuclear extract slightly restores the MMR 
activity, but the repaired products are significantly reduced when compared to HeLa 
(lane 1) or the complemented HCT116 (lane 8) (Figure 3.10B).    
 
As observed in Figure 3.5, the only detectable difference between HCT116 and 
Lim2405 cell lines apart from the deficiency in MLH1 is the EGFR expression and 
subsequently the levels of PCNA Tyr211 phosphorylation. Therefore, it can be proposed 
that the lack of full recovery of MMR activity might be because the Lim2405 cells 
contain increased levels of phosphorylated PCNA. When PCNA wild type (WT) was 
added along with MutLα to the Lim nuclear extract, additional MMR activity was 
recovered above what was seen with MutLα alone (Figure 3.10B, lane 5 vs 3). But this 
repair activity stimulation is not obvious when PCNA WT is added along with MutLα to 
the HCT116 reaction (Figure 3.10B, lane 10). This result strongly suggests that Tyr211 
phosphorylation is responsible for inhibiting MMR in Lim. 
 
MMR activity was also assayed in DLD-1 cells, which express high levels of EGFR 
and PCNA Tyr211 phosphorylation (Figure 3.5 and 3.8C). DLD-1’s MMR activity was 
the same as observed with Lim nuclear extract (Figure 3.10C). These results suggest that 
PCNA phosphorylation inhibits MMR activity which could lead to MMR deficiency in 
cancer patients with tumors that over express EGFR.    
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 To further determine if the inhibitory effect was a characteristic of the high levels of 
PCNA phosphorylation in Lim2405 cells, increasing concentrations of Lim2405 nuclear 
extract were incubated in the presence of 75 μg HeLa nuclear extract (Figure 3.11B). 
When HeLa and Lim2405 nuclear extracts are incubated at a 1:1.3 ratio, HeLa’s MMR 
activity is significantly inhibited by the presence of Lim2405 extract. This inhibition is 
not due to high concencentration of protein in the reaction as a 1.3:1 ratio of HeLa: 
Lim2405 ratio did not block MMR activity in HeLa (Figure 3.11B). To corroborate that 
this inhibitory effect was related to the levels of PCNA phosphorylation in Lim2405 and 
not due to the lack of MutLα, the same experiment was repeated in the presence of 
increasing concentrations of HCT116 (Figure 3.11C). Under these conditions no 
significant change was observed in HeLa MMR activity in the presence of HCTT116 
extract. These results support the previous findings where PCNA Tyr211 phosphorylation 
present in Lim2405 inhibits the MMR activity. These results indicate that PCNA 
phosphorylation levels inhibit MMR.     
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Figure 3.10 Purified PCNA restores MMR activity to Lim2405 and DLD-1 nuclear 
extracts  
A). Principles of in vitro MMR assay. The mismatch located at the HindIII restriction site 
is used to score for the MMR activity in different cell lines. When the substrate 
undergoes into the MMR pathway, the mismpair is removed and the right base is 
incorporate, regenerating the HindIII endonuclease site, and two bands with different 
molecular weights can be observe. Nuclear extracts derived from Lim2405, HCT116 (B), 
and DLD-1(C) were supplemented with 350 ng of MutLα (B) or MutSα (C) in the 
presence of 100 ng of 3’G/T heteroduplex. Lim2405 and DLD-1 cell lines (B & C: lane 
5) fully recovered the in vitro MMR activity in the presence of MutLα (B) or MutSα  (C) 
and PCNA, while HCT116 fully recovered the MMR activity in the presence of MutLα 
alone (B: lane 3).  
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Figure 3.11 Lim2405 nuclear extract inhibits in vitro MMR activity in HeLa nuclear 
extract 
Nuclear extracts derived from Lim, HCT116, and HeLa were incubated with the presence 
of 100 ng of 3’G/T heteroduplex. Lim nuclear extract (75μg) was incubated in the 
presence of increasing concentration of HeLa nuclear extract (0 to100 μg) (A). HeLa 
nuclear extract (75μg) was incubated in the presence of increasing concentration of 
Lim2405 (0 to100 μg) (B). HeLa nuclear extract (50 μg) was incubated in the presence of 
increasing concentration of HCT116 (0 to 75 μg) (C). Products were resolved in a 1% 
agarose gel and visualized by ethidium bromide staining.  
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Tyr211 phosphorylation mimetic PCNAs inhibit in vitro MMR activity 
The data obtained from Lim2405 and DLD-1 nuclear extracts indicate that the PCNA 
phosphorylation at Tyr211 inhibits the MMR pathway. To obtain more direct evidence to 
support this, two mimetic PCNAs Y211D and Y211E, were created by site-direct 
mutagenesis (Figure 3.12). In addition, Tyr211 was also changed to phenylalanine (F), 
which mimics unphosphorylated PCNA. These PCNA isoforms cannot undergo 
phosphorylation by the EGFR kinase activity as observed in Figure 3.4B. Incubation of 
these mimetic PCNAs with an MMR proficient nuclear extract such as HeLa will provide 
a clearer picture of the role of PCNA phosphorylation in the MMR pathway. These 
phosphorylation mimicking PCNA isoforms were tested for their ability to restore MMR 
to HeLa extracts whose endogenous PCNA was inhivited by addition of purified p21c, a 
PCNA inhibitor. As shown in Figure 3.13, a concentration of 0.7 μM of p21c was enough 
to completely inhibit PCNA and MMR activity in HeLa cells. In the presence of 
increasing concentrations of wild type (WT) PCNA and the unphosphorylated mimic 
PCNA (YF), the in vitro MMR activity was recovered (Figure 3.14A). On the other hand, 
in the presence of both phosphorylation mimic PCNAs (Y211D and Y211E) the repair 
activity is significantly inhibited when compared with HeLa, WT PCNA, and PCNA 
Y211F. Moreover, when the phosphorylation mimic Y211D and Y211E are added to 
normal HeLa nuclear extract, inhibition of the in vitro MMR activity also was observed 
(Figure 3.14B) These results provide clear evidence that high levels of PCNA 
phosphorylation will inhibit the MMR activity, explaining why Lim2405 extract inhibit 
the MMR in HeLa extract.  
 
 
 
 
Figure 3.12  Purification of phosphorylation mimetic PCNAs  
1 μl of each purified PCNA protein were analyzed in a 15% SDS-PAGE and observed by 
coomassie blue staining.  
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Figure 3.13 C-terminal of p21
(CIP1/WAF1)
 inhibits endogenous PCNA  
HeLa nuclear extract (75 μg) was incubated with increasing concentration of p21c (0.7 to 
3 μM) on ice for 15 min and the pre-incubated nuclear extract was incubated in the 
presence of 100 ng of 3’G/T heteroduplex at 37ºC for 15 min. Repair products were 
digested with HindIII and BseRI. Products were resolved in a 1% agarose gel and 
visualized by ethidium bromide staining.  
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Figure 3.14 Tyr211 phosphorylation mimetic PCNAs inhibit in vitro MMR activity  
A). HeLa nuclear extract (75μg) was pre-incubated with 0.7μM of p21c, followed by 
incubation in the presence of 100 ng of 3’G/T heteroduplex and the WT or mimetic 
PCNAs (0.7, 3, and 7 μM) at 37 ºC for 15 min. B). HeLa nuclear extract was incubated in 
the presence of PCNA WT, Y211D, or Y211E (3µM). Repair products were digested 
with HindIII and BseRI. Products were resolved in a 1% agarose gel and visualized by 
ethidium bromide staining.  
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PCNA Tyr211 phosphorylation inhibits MMR initiation 
The PCNA homotrimer is a well known processivity factor for polymerases δ and ε 
during DNA synthesis (82,101). However, in the MMR pathway PCNA plays an 
important role prior to the DNA resynthesis step. PCNA interaction with MSH6 and 
MSH3 increases the DNA binding specificity of MutSα and MutSβ, respectively, 
resulting in the recruitment of other MMR downstream effectors (91,93,94). Furthermore, 
when MutLα is recruited to the DNA lesion, the interaction among PCNA, MutSα or 
MutSβ, and MutLα results in the activation of the latent MutLα endonuclease (38). This 
last interaction may play a more important role with 3’nicked-MMR substrates where 
MutLα endonuclease performs incisions that subsequently lead to the mismatch removal 
and further gap filling. To first explore the role of PCNA Tyr211 phosphorylation on the 
initiation step of MMR, the 3’G/T heteroduplex substrate was incubated in the absence of 
dNTPs and in the presence of p21c-inhibited HeLa nuclear extract and individual PCNA 
isoforms. Under normal conditions, PCNA is be able to initiate the mismatch-provoked 
excision resulting in different sized fragments that can be observed by probing the DNA 
with an oligomer (V6370) that binds to a sequence 5’ to the mismatch (Figure 3.15). 
Initiation of excision can be observed by the appearance of the small ssDNA fragments 
below the mismatch site (Figure 3.16A & B). PCNA inhibition in HeLa nuclear extract 
results in the lack of MMR initiation. Moreover, incubation of the p21-added nuclear 
extract with WT PCNA and PCNA Y211F results in recovery of the mismatch-provoked 
excision, i.e. production of the small intermediates (Figure 3.16A). However, incubation 
with the phosphorylation mimicking PCNA Y211D produced little excision 
intermediates.  Therefore, this result indicates that PCNA Tyr211 phosphorylation inhibits 
MMR initiation by blocking the initiation reaction.  
 
To corroborate this result, Lim2405 nuclear extract was incubated under the same 
conditions in the presence of MutLα, and PCNA WT or PCNA Y211D (Figure 3.16B). 
As observed in the in vitro MMR assay (Figure 3.10B), MutLα can slightly recover the 
MMR activity in the excision assay. These results are not surprising because while 
nonphosphorylated PCNA is still present in Lim2405 cells, the levels of PCNA 
phosphorylation are high enough to prevent the full recovery of the mismatch-provoked 
excision by MutLα. On the other hand, the MMR initiation is fully recovered in the 
presence of MutLα and PCNA WT supporting the previous finding that PCNA 
phosphorylation inhibits the initiation of the MMR reaction.  
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Figure 3.15  Schematic representation of MMR excision products and Southern Blot 
detection 
The absence of dNTPs in the reaction will terminate the MMR pathway at mismatch 
removal. If the 3’G/T substrate undergo into mismatch-provoked excision, the 
hybridization of the products with the 
32
P- labeled oligonucleotide (red square) would 
show intermediates smaller in size than the mismatch size marker (MM: NsiI/BglI).  
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Figure 3.16  Phosphorylation of PCNA Tyr211 inhibits MMR initiation 
A). p21c-added HeLa and B). Lim2405 nuclear extracts were incubated in the presence 
of 100 ng of 3’G/T heteroduplex and the mimetic PCNAs A. 0.7-3 μM or B. 3 μM at 37 
ºC for 15 min. Products were resolved in 6% UREA-PAGE and visualized by oligomeric 
probing (V6370). Unmodified (WT) and unphosphorylated mimic PCNA (Y211F) were 
able to restore the MMR initiation, while the phosphorylation mimetic PCNA Y211D 
significantly inhibit the initiation step in the in vitro MMR excision assay. (MM: 
mismatch site)  
 
PCNA phosphorylation at Tyr211 disrupts PCNA interaction with MutSα and 
MutSβ 
During MMR initiation, PCNA phosphorylation levels in Lim and the mimetic PCNA 
Y211D fail to support mismatch-provoked excision. At this step in the MMR signaling 
cascade, a series of coordinated protein interactions needs to take place in order to 
support MMR initiation and the subsequent mismatch removal. Based on a number of 
studies, it has been proposed that PCNA promotes the stability of MutSα or MutSβ and 
their affinity for their respective substrates. This interaction will recruit MutLα to the 
DNA where its endonuclease activity is activated in a PCNA and MutS-homolog 
dependent manner. Therefore, a coordinated interaction among PCNA, MutS, and MutLα 
is required for proper MMR initiation.  
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To determine which interaction among these proteins is disrupted as a result of PCNA 
phosphorylation, different concentrations of PCNA WT, Y211D, and Y211F were added 
on a nitrocellulose membrane (Figure 3.17). Then MutSα, MutSβ, or MutLα was 
incubated overnight with the membrane to allow enough time for the proteins to interact 
with the different PCNAs. Interaction among the proteins was detected using antibodies 
targeting MSH6, MSH3, or MLH1. The Y211F mutation does not appear to alter PCNA 
interaction with MutSα, MutSβ or MutLα.  However, the interaction of PCNA Y211D 
with MutSα and MutSβ is significantly decreased when compared with the WT and 
Y211F PCNAs. On the other hand, the interaction between MutLα and the Y211D PCNA 
appears to be unchanged compared to Y211F suggesting that the interaction with MutLα 
is unaffected by Tyr211 phosphorylation. These results suggest that PCNA 
phosphorylation affects MMR initiation through disruption of the PCNA-MutS 
interaction. However, whether the disruption of this interaction prevents the stable 
binding of the MutS protein to the DNA or inhibits either the recruitment of MutLα 
endonuclease activity to the DNA or its activation needs further study. Nevertheless, 
these results indicate that phosphorylation of PCNA acts as a functional regulatory 
modification where phosphorylated PCNA may preferentially interact with the 
replication machinery instead of the DNA repair proteins.  
 
 
 
 
 
 
Figure 3.17 PCNA phosphorylation disrupt its interaction with MutSα and MutSβ  
Interactions among these proteins were visualized by Far- western Blot. Purified PCNA 
WT, phosphorylation mimic (Y211D), and unphosphorylation mimic (Y211F) PCNAs 
(1-0.25μg) were spotted on the nitrocellulose membrane and incubated in the presence of 
1μg of MutSα, MutSβ, and MutLα. Interactions among these proteins were visualized by 
immunoblotting and autoradiography.  
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PCNA Tyr211 phosphorylation delays DNA synthesis initiation but does not disrupt 
the overall MMR resynthesis  
Although disruption of MMR initiation was observed in the presence of PCNA Tyr211 
phosphorylation, it was also important to study the behavior of this modification during 
DNA synthesis. This will provide better insides not only of the mechanistic activity of 
PCNA phosphorylation in the MMR pathway, but also show that the different PCNA 
isoforms created by site-directed mutagenesis conserve their functional structure.  
 
To determine whether PCNA phosphorylation also disrupts the gap filling process 
during the MMR pathways, a 171- nt gap-containing homoduplex was incubated in the 
presence of HeLa-p21c extract (pretreated with p21c) and the PCNA isoforms (Figure 
3.18A). The reactions were performed at 37 ºC for 15 min. Products were digested with 
HindIII and BseRI. Therefore, two bands would be generated if DNA synthesis occurs 
and fills in the gap (Marker), while if the gap is not filled in a linear product at the top of 
the 1% agarose gel (Gap HD) would be observed. When the resynthesis in HeLa extract 
is compared with HeLa extract pretreated with p21c there is essentially complete 
inhibition of gap filling.  When the different mimetic PCNAs are added to p21c 
containing extracts, gap filling is restored although the amount of resynthesis is less when 
Y211D or Y211E are added compared to wild type PCNA or Y211F (Figure 3.18A). 
Although, PCNA Y211D seems a little bit slower than the other purified PCNAs. 
However, to compare the gap filling resynthesis activity of the different PCNAs to what 
is happening in HeLa or Lim cells, the gap-filling reaction was carried out at a time 
course in the presence of 75 µg of nuclear extracts (Figure 3.18B). It was observed that 
the DNA synthesis activity in Lim2405 nuclear extract shows a lower resynthesis 
initiation, similar to the activity observed in the presence of PCNA Y211D (Data not 
shown). The gap filling activity in HeLa can reach maximum resynthesis in around 3 min 
of incubation, while it takes Lim 10 min of incubation to get to similar levels of 
resynthesis. In addition when the different resynthesis rate (n=2) are plot using one-phase 
exponential association analysis was observed that Hela contains a half life of 0.3488 
(R
2
=0.995), while Lim2405 half life was 0.9615 (R
2
=0.970). This suggests that PCNA 
phosphorylation levels in Lim cells delays the gap filling process, but Lim2405 cells are 
still capable of performing the DNA synthesis step in the MMR pathway. Some possible 
explanantions to the delay observed during gap filling in the presence of Lim2405 
nuclear extract and PCNA Y211D can be attributing to either the switch of replicative 
polymerase for low processivity polymerase (translational polymerases) or to a decrease 
in the interaction between polymerase δ and PCNA phosphorylation. 
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Figure 3.18 Effect of PCNA phosphorylation on DNA gap filling  
A). Pre-incubated HeLa (p21c inhibition) was incubated in the presence of 100 ng 171 nt 
gap substrate and the WT and modified PCNAs (0.7 and 3 μM) B). 100 ng of the 171 nt 
gap substrate was incubated for different lengths of time in the presence of HeLa and Lim 
(75 µg) nuclear extracts. Products were resolved in 1% agarose gel and visualized by 
ethidium bromide. Gap-filling kinetic graph obtained by using GraphPad prism and the 
non-linear one-phase exponential association analysis.  
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 PCNA Tyr211 phosphorylation promotes error-prone DNA synthesis 
DNA synthesis is a coordinated event that requires the presence of the homotrimeric 
PCNA to switch the polymerase α primase to polymerase δ or ε, which subsequently 
results in DNA elongation (102). If polymerase δ or ε encounters a bulky lesion during 
DNA synthesis that leads to blockage of replication, PCNA ubiquitylation may occur 
(82). This post-translational modification will induce the polymerase switching where the 
polymerase δ or ε is replaced by a translational polymerase (103). This polymerase 
switching normally delays the DNA synthesis process but it will provide a mechanism to 
bypass the lesion (104). During the in vitro gap filling assay, delays in DNA synthesis in 
the presence of phosphorylation mimic PCNA Y211D and Lim2405 nuclear extract were 
observed. To explore whether or not the delay observed may be due to misincorporation 
of nucleotides during DNA synthesis, a mutagenesis assay was performed. In this assay, a 
circular M13Mp18 homoduplex substrate that contains a single-strand gap located in the 
β-galactosidase gene (LacZ α’) (Figure 3.19) (105). Therefore, if a wrong nucleotide is 
incorporated during the in vitro DNA synthesis, the β-galactosidase gene will be mutated, 
creating a mutant protein that may fail to cleave X-gal after transformation into E.coli, 
which allows for a blue and white plaques selection (Figure 3.20). These plaques can then 
be counted and the number of clear and light blue plaques divided by the total of plaques 
to calculate the mutation frequency (Table 3.2).  
 
For each reaction more than 2000 plaques were quantified. HeLa cells showed a low 
muatation frequency, while Lim extract produced around an 8-fold increase in the 
frequency of mutations observed during the in vitro DNA resynthesis (Table 3.2). 
Furthermore, the Lim mutation frequency was significantly decreased when the nuclear 
extract was incubated in the presence of PCNA WT or the unphosphorylated mimic 
PCNA Y211F. In the presence of Y211F the mutation frequency decreased by 6 fold, 
while in the presence of PCNA WT the mutation frequency was 4-fold lower than the one 
observed in Lim. The difference between the mutation frequencies observed among these 
two proteins may be because PCNA WT contains an intact Tyr211 residue that can still be 
modified by the nEGFR during the 60 min that the reaction was incubated. On the other 
hand, PCNA Y211F cannot be modified at this residue due to the tyrosine substitution to 
phenylalanine. However, whether other modifications or protein interactions can 
influence the DNA synthesis in Lim is unknown. Neverthless, these preliminary results 
strongly suggest that PCNA phosphorylation promotes error-prone DNA synthesis, likely 
by inducing misincorporations. But to corroborate these findings additional replicate 
should be performed for be able to calculate the significance among the different 
reactions.  
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Figure 3.19 Schematic representation of the 283nt gap substrate and the 
determination of the mutant plaques 
A gap substrate containing the gap located at the β-galactosidase gene (blue) was used to 
perform the in vitro gap-filling assay (α’ complementation). If the gap is filled under high 
fidelity conditions a functional β-galactosidase (WT) protein will be obtained resulting in 
the formation of blue plaques. In the other hand, if misincorporations occur during the 
DNA re-synthesis, a non-functional β-galactosidase protein will be expressed leading in 
the formation of white or light blue plaques 
 
 
Figure 3.20 Representative gel and plates from the in vitro DNA synthesis 
mutagenesis assay 
Left panel, Represent the in vitro DNA synthesis performed in the presence of  100 ng 
283 gap homoduplex, HeLa, Lim, and Lim with PCNA WT or PCNA Y211F. Middle 
panel is a representative picture of the mutagenesis plate. Right panel, Shows the white 
(bottom) and light blue (top) plaques (arrows) obtained in the mutagenesis assay.    
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Table 3.2 Quantification of the mutagenesis frequency in HeLa and Lim 
Reactions White Blue Total Mutagenesis 
Frequency (%)
HeLa 16 2197 2213 0.72
Lim 150 2536 2686 5.60
Lim + PCNA WT 84 3024 3111 2.70
Lim + PCNA Y211F 41 2648 2689 1.52
 
 
DISCUSSION 
PCNA is a fundamental protein involved in a variety of cellular mechanisms 
including DNA replication and repair. The structure of PCNA facilitates its interaction 
with numerous other proteins involved in these mechanisms. It is reported that the 
different protein interactions that PCNA undergoes are influenced by post-translational 
modifications of PCNA. Evidence for PCNA phoshorylation have been found by 
different laboratories but other studies claimed that the phosphorylation does not occur in 
vivo. Whether or not this modification occurred in vivo has been surrounded by some 
controversy in the past years. In a recent study, by the use of electrospray ionization mass 
spectrometry (MS/MS), PCNA phosphorylation was shown to occur in human and mouse 
cell lines. Moreover, by using antibodies and some inhibitors, the phosphorylation of 
PCNA was determined to be carried out by the EGFR. This receptor when activated in 
the cell membrane initiates a signal cascade that targets activation and transcription of 
different proteins, but it has been found that EGFR can also undergo translocation into 
the nucleus. The kinase activity of EGFR in the nucleus can phosphorylate PCNA at 
Tyr211, resulting in the increased stability of PCNA binding to chromatin. As previously 
reported (72), we were able to observe PCNA phosphorylation in vitro after 30 min of 
incubation with the recombinant GST-EGFR kinase domain. Moreover, we were able to 
demonstrate by using unmodified and modified Tyr211 PCNAs that EGFR activity 
specifically targets the Tyr211 of PCNA and not any other tyrosine. The specificity 
between EGFR and PCNA interaction was also observed in the MSI CRC cell lines, 
Lim2405 and DLD-1. These two cell lines showed the highest EGFR expression among 
the different MSI CRC cell lines screened during this study. Detection of PCNA 
phosphorylation at Tyr211 in these cells revealed higher levels of this modification when 
compared with a cell line containing lower levels of EGFR expression. When CRC 
tissues were screen for expression of EGFR and PCNA Tyr211 phosphorylation was 
observed that more than 60% show higher expression of EGFR, while more than 50% 
contain high levels of PCNA phosphorylation. A direct correlation among the EGFR and 
PCNA phosphorylation expression was not observed in the tissue samples (Figure 3.7). 
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However, it have been observe that instead of the total EGFR amount are the levels of 
nEGFR that directly correlates with the levels of PCNA phosphorylation. For that reason, 
the failure to detect a correlation among EGFR and PCNA phosphorylation may due to 
the failure to detect nEGFR in the tissue staining. Moreover, it cannot be rule out the 
possibility that not only EGFR can phosphorylate PCNA at Tyr211 and that other tyrosine 
kinase capable of doing the same activity may exist in colorectal cancer as well as the 
downregulation of the phosphatase in charge of maintain the balance of PCNA 
phosphoryltion. Neverthless, the high levels of PCNA Tyr211 phosphorylation detected in 
more than 50% of the colorectal cancer samples were indicative that identifying the 
mechanism of action of PCNA phosphorylation in the MMR pathway is important to 
understanding better the effect of this modification on tumor development, progression, 
and/or invasion. 
 
Supplementation of nuclear extracts derived from the colorectal cancer cell lines by 
incubation with MutLα (Lim2405) and MutSα (DLD-1) failed to completely recover the 
MMR activity to the level observed in the proficient MMR HeLa cell line. This result 
was different from what was observed when HCT116 was supplemented with MutLα, 
which produced MMR activity comparable with HeLa. However, when Lim and DLD-1 
nuclear extracts were incubated in the presence of their respective MMR proteins and 
PCNA WT, a significant stimulation of MMR activity was observed in both cell lines. 
These results indicate that PCNA activity in the MMR pathway was significantly 
decreased in these cell lines when compared with HeLa and also indicate that the high 
levels of PCNA phosphorylation was a good candidate responsible for the decrease 
observed in PCNA activity. This last observation was also supported by the experiments 
in which HeLa nuclear extract was mixed with increasing concentrations of Lim extract 
and MMR inhibition was observed.  
 
Therefore, to test whether that PCNA phosphorylation was the inhibitory factor and 
was responsible for the decrease of PCNA activity in the MMR, different mimetic 
PCNAs were created by site-directed mutagenesis. In vitro MMR assays in the presence 
of phosphorylated mimic PCNAs (Y211D and Y211E) revealed a significant decreased 
in the MMR activity supporting the previous hypothesis of the role of PCNA Tyr211 
phosphorylation in inhibiting the MMR pathway. Neverthless, the in vitro MMR assay 
cannot differentiate at which step the MMR activity in the presence of PCNA 
phosphorylation was inhibited. To differentiate the effect of PCNA phosphorylation in 
the MMR pathway, the different step in where PCNA plays a role were study separated.  
 
Mismatch-provoked excision assays performed in the presence of the 
unphosphorylated and phosphorylated mimic PCNAs revealed that PCNA 
phosphorylation failed to activate initiation of the mismatch removal when compared 
 
 
 
62 
with the unmodified or the unphosphorylated mimic protein. These results suggest that 
some of the protein-protein interactions that are essential for the appropriate MMR 
initiation with 3’ nicked substrates were defective resulting in the inhibition of MMR 
initiation. To explore whether this was the case, far western blot assays were performed 
as a quick and efficient way to study the interaction among PCNA and the MMR 
initiation factors. MutSα and MutSβ interaction with the mimic phosphorylated PCNA 
(Y211D) was significantly decreased while the interaction with the PCNA WT and 
mimic unphosphorylated PCNA was not affected. These results explain the effect of 
PCNA phosphorylation observed in the in vitro MMR and excision assays. However, 
whether the disruption of the MutS and PCNA interactions affects the binding affinity of 
the MutS-homologs or the activation of MutLα endonuclease activity is still not clear. 
Although no differences in the interaction between MutLα and the mimetic PCNAs were 
observed the effect of PCNA phosphorylation cannot be excluded since PCNA and 
MutSα are required for the activation of the latent endonuclease in MutLα.  
 
In vitro DNA synthesis experiments did not show any significant change in DNA 
synthesis activity in gap-filling. Nevertheless, a slightly lower DNA synthesis initiation 
rate was observed in the presence of PCNA Y211D (phosphorylated mimic) and 
Lim2405 (Figure 3.18). These results were indicative that PCNA phosphorylation was 
either disrupting polymerase δ processivity or was recruiting translational polymerase to 
carry out the gap filling procces.  To explore whether the observed delay in DNA 
synthesis was related with translational synthesis that induce mistakes during the gap 
filling process, we performed a mutagenesis assay in the presence of Lim2405 and 
Lim2405 with PCNA WT and PCNA Y211F (unphosphorylated mimic). In HeLa nuclear 
extract the mutation frequency was very low, but with Lim the mutation rate was 8-fold 
higher than with HeLa cells. Interestingly, the addition of PCNA WT or PCNA Y211F 
significantly decreased the mutation rate of Lim to 4- and 6-fold lower, respectively, than 
the rate observed with Lim extract. This result was indicative that PCNA Tyr211 
phosphorylation can function as a regulatory factor of PCNA functions. Phosphorylation 
will increase the affinity of PCNA with certain polymerases and decrease its activity with 
the MMR initiation factors, MutSα and MutSβ.  
 
Based in these findings and the expression of PCNA Tyr211 phosphorylation in CRC 
samples this modification may also used as a cellular marker for CRC because PCNA 
phosphorylation in these cancers correlates with an increase in cell proliferation and, as 
observed in our study, inhibits MMR activity and increases nucleotide incorporation 
mistakes during DNA synthesis. These last two characteristics will increase the mutator 
phenotype in cancer cells increasing the probability of tumor progression and metastasis. 
Therefore, is not surprising that PCNA phosphorylation has been correlated with poor 
prognosis in cancer patients with tumors exhibiting high levels of this modification.    
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FUTURE STUDIES 
Some questions still need to be answered in order to have a complete understanding 
of the role of PCNA phosphorylation in cancer. However, our study brought to light 
important findings that provide a better understanding and significance of this post-
translational modification and provides impetus for additional studies. The regulation of 
PCNA phosphorylation in normal cells is poor understanded. It is known that occurs by 
EGFR, but in a way to keep cell homeostasis the activity of a phosphatase should be 
required to maintain the right levels of PCNA phosphorylation. A combination of 
different analysis can be used for trying to identify the phosphatase involved in 
dephosphorylation of PCNA. One possible experiment can be carry out by increasing the 
levels of PCNA phosphorylation in HeLa cells by using the EGFR ligand, EGF. HeLa 
cells can be treated at different time points with EGF and PCNA Tyr211 phosphorylation 
can be detected. At some points PCNA phosphorylation will increase, followed by 
downregulation of this modification. At these two time points, PCNA interacting partners 
can be identified by co-immunoprecipitation and mass spectrometry. In the other hand, 
peptides corresponding to PCNA WT and PCNA Y211D (mimic phosphorylation) can be 
immobilized and allow interacting with different nuclear extracts. The proteins that 
interact with these two peptides can be separated by using a KCl gradient and identify by 
mass spectrometry. If any phosphatase can be observed to interact with phosphorylated 
PCNA, another set of experiments such as over-expression in cells and detection in 
colorectal cancer samples can be performed in a way to characterize the role in PCNA 
dephophorylation. 
 
One study that also should answer some questions is the determination of the 
functionality of PCNA phosphorylation and MutS-homolog interaction defects that may 
provide a better understanding of MMR activation and the role PCNA plays in this step. 
It is known that PCNA is required differently in 5’ and 3’ nick substrates (92). If PCNA 
phosphorylation disrupts MutSα binding on the mispaired base the MMR initiation in 
both 5’ and 3’ nick substrates should be affected. However, if 3’ nick substrate is only 
inhibited at the MMR initiation is more likely that MutLα endonuclease activation is 
inhibited by PCNA phosphorylation. A more direct evidence of the role of PCNA 
phosphorylation in the MMR initiation can also be assay by performing independent 
experiments in where MutSα binding on mispaired base in the presence of PCNA WT 
and PCNA Y211D or Y211E is determined by using electrophoresis mobility assay 
(EMSA) or the biotinylated G/T DNA immunoprecipitation, and by performing an in 
vitro MutLα endonuclease assay as reported previously (42). 
 
  Also, it may be important to study the interactions of phosphorylated PCNA with the 
different TLS polymerases and the importance of these interactions in cancer. It have 
been documented that PCNA ubiquitylation at Lys164 result in the recruitment of TLS 
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polymerase in stallen replication forks. In addition, it is unclear whether PCNA 
phosphorylation can enhance other PCNA modifications such as ubiquitylation. 
Therefore, a possible experiment to detect PCNA phosphorylation is a better substrate for 
ubiquitylation than the unmodified PCNA will be use the PCNA isoforms and perform 
PCNA ubiquitylation in vitro as previously reported (106).  
 
 How this modification can influence cancer development through genomic instability 
when phosphorylated PCNA is overexpressed in cells proficient in the MMR pathway 
could provide additional important findings for the field of cancer biology. Therefore, 
stable transfected cell lines and transgenic mice expressing PCNA WT and PCNA 
Y211D or Y211E can be created to observe whether PCNA phosphorylation induces MSI 
and/or tumor formation in in vivo studies. 
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CHAPTER FOUR: MUTLα MUTANT FAILS TO INITIATE MISMATCH-
PROVOKED EXCISION/INCISION 
 
INTRODUCTION 
MMR pathway plays an important role in cellular maintenance. When cells are 
exposed to certain exogenous and endogenous factors that produce DNA damage, MMR 
initiation factors are recruited onto the DNA to initiate the repair-signaling cascade 
(29,107,108). The mutation avoidance and genetic stability afforded by the MMR system 
is attributed to its function in the correction of DNA replication errors, the maintenance 
of genetic recombination fidelity, and its role in the apoptotic responses to different DNA 
damaging agents. This system is widely found and has been studied in organisms from 
bacteria up through human cells. A number of proteins involved have been found to be 
essential for proper MMR function. One of these proteins is MutLα, a heterodimeric 
protein composed of two proteins, MLH1 and PMS2, in humans. It is the most highly 
expressed heterodimeric complex among three different MutL homologs found in human 
cells. Around 50% of cancer cells that are found to be MMR deficient show genetic or 
epigenetic modulation of MLH1, indicating the importance of this protein in the 
maintenance of genomic stability. MutL function in this system ranges from protein 
matchmaker by recruiting downstream effector proteins to creating incisions in the newly 
synthesized DNA strand (Table 1.2) (38-40). The MMR pathway has been extensively 
studied in E. coli, and these studies have laid the groundwork for providing a better 
understanding of the MMR mechanism in human cells (37).     
  
In E.coli, when mismatched base pairs and short insertion-deletion loops are 
recognized by the MutS homodimer, the repair system is initiated by recruiting the 
downstream proteins including the MutL homodimer, the strand discrimination factor 
MutH, and DNA helicase II (UvrD) as well as one of the different exonucleases with 
5’→3’ or 3’→5’ directionality (37). In the coordination of this process the MutL 
homodimer plays an essential role. After MutL is recruited onto the DNA by MutS, it 
activates the cryptic endonuclease activity of MutH that nicks the newly synthesized 
strand. MutL then recruits and activates UvrD, which unwinds the DNA exposing the 
nicked strand for exonuclease degradation (109-111). Similar to MutS, whose 
transactions are governed by ATP binding and/or hydrolysis, MutL possesses a weak 
ATPase activity that is also required for proper mismatch repair function. This was 
observed in experiments where mutations around the ATP binding domain of MutL failed 
to complement the MMR activity of a mutL- strain (112). However, unlike MutS, which 
contains a conserved Walker A/B nucleotide binding domain, the MutL N-terminal 
contains four small motifs that have also been found in the histidine kinases, heat-shock 
proteins HSP90, and type II topoisomerases (Figure 4.1). Structural studies identified 
these conserved domains to belong to the superfamily of GHKL (Gyrase, Hsp90, 
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Histidine Kinase, MutL) ATPases (113,114). In human cells, hMLH1 and hPMS2 
(MutL-homologs) also contain the conserved GHKL ATPase domains in the N-terminal 
region (66).  Studies using ADP-PNP show that MutL undergoes a conformational 
change upon binding the nonhydrolyzable ATP analog, changing its elongated structure 
into a more globular form (115). These results indicate that similar to other GHLK 
ATPase members, the ATP binding induces MutL N-terminal dimerization resulting in a 
molecular gate. This ATP-driven conformational change has been shown in type II 
topoisomerases that use this molecular gate to capture the duplex DNA for the creation of 
the dsDNA breaks (116). The crystal structure of MutL with bound ADP-PNP revealed 
the contribution of three distinct amino acid residues in the MutL ATPase function (66). 
The first residue, aspartate 58 (D-58) forms a hydrogen bond with the N6 of the adenine 
base. The second residue, asparagine 33 (N-33) directly binds the Mg
2+
 ion and a water 
molecule that coordinates the ion into the protein. The third residue, glutamate 29 (E-29) 
is involved in the activation of the catalytic water molecule (Figure 4.2). Studies in which 
these residues were mutated revealed that ATP binding rather than ATP hydrolysis is 
required for the recruitment of MutL to the DNA and for the MutL provoked MutH and 
UvrD activation.  
 
In the case of MutL, the heterodimeric composition makes the ATP binding and 
hydrolysis a little bit different from MutL. Mutations in yeast and human MutLof the 
three homologous residues involved in ATPase function in MutL reveal that similar to 
MutS MutLshows an asymmetry in ATP binding where MLH1 binds ATP with a 
higher affinity than PMS2 (66,117,118). However, discrepancies in these studies make 
the understanding of the ATP binding of hMLH1 and hPMS2 confusing. In Tomer et. al 
(117), proteolysis of MutL in the presence of ATP shows a more evident protection of 
MLH1 than PMS2. However, proteolysis in the presence of ADP-PNP showed a better 
protection of PMS2. In Räschle et al. (66), where mutations on the catalytic residue (E) of 
MLH1 (MLH1E34A-PMS2 WT), PMS2 (MLH1WT-PMS2E41A) or both (MLH1E34A-
PMS2 E41A) were analyzed it was observed that although MLH1E34A still binds ATP it 
ATPase activity shows half the hydrolysis than the double mutant (Figure 4.9). On the 
other hand, the ATPase activity of PMS2 E41A was affected at equal levels as the double 
mutant. This last result may indicate that PMS2 ATP hydrolysis can contribute to a 
higher extent to MutLα ATPases more than what was observed in the proteolysis 
analysis. Regardless of which subunit bound ATP with higher affinity, Räschle et al. 
concluded that ATP binding is required to maintain MutLα stability and that its ATP 
hydrolysis may be required after MutSα-MutLα-DNA interaction.  
 
More recently in 2006, MutLα was identified to be a latent endonuclease that is 
activated in a mismatch-, MutSα-, RFC-, PCNA- and ATP -dependent manner (38). The 
putative endonuclease active site was located in PMS2 and was found to be conserved 
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through eukaryotic species but is lacking in the MutL from bacteria that depends on 
d(GATC) adenine methylation for strand discrimination. MutLα endonuclease activity is 
essential in the repair of DNA substrate containing the nick 3’ to the mismatch where 
MutLα incised the DNA produces new sites for Exonuclease I (ExoI) loading and 
subsequent mismatch excision. Although, its endonuclease activity is not required to 
repair DNA substrate containing the nick 5’ to the mismatch, the presence of MutLα is 
required for the initiation of excision in this substrate. Moreover, it induces the 
termination of the mismatch-provoked excision by removing ExoI from the DNA 
avoiding the complete degradation of the nicked DNA (39). 
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Figure 4.1 ATP binding motif of GHLK ATPases  
Alignment of the amino acid sequences of some members of the GHLK ATPase 
superfamily illustrates the conserved motifs that constitute the ATP binding pockets of 
members of this superfamily (red boxes). The red asterisks indicate the residues 
identified to play an essential role in ATP binding and hydrolysis. The black star 
indicates the location of the mutated residue found in an AML patient sample, while the 
highlight residues in yellow indicate the highle conserved residues into the conserved 
ATP binding domains. 
 
©2002 by American Society for Biochemistry and Molecular Biology
Modified from Räschle M et al. J. Biol. Chem. 2002;277:21810-
21820
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Figure 4.2 ATP binding pocket of MutL  
Left, Diagram of the nucleotide-free protein from E. coli illustrating the location of the 
three amino acids (represented in stick form) that are required for ATP binding and 
hydrolysis. The α-helix that contains the asparagines residue (N33) that coordinates 
Mg2+ and the catalytic residue (E29) constitute the ATPase motif I. The two β-sheets 
constitute motifs II and IV, and the aspartate residue (D58) is involved in forming a 
hydrogen bond with the nucleotide. Motif III is represented by the α-helix on top of the 
ATP binding pocket. Middle, Diagram of the MutL with ADPPNP and Mg
2+
 bound.  
Right, the three amino acid residues conserved in the MutL homologs, hMLH1 and 
hPMS2 and their roles are listed. 
 
 MMR-deficiency is the principal cause of the Hereditary Nonpolyposis Colorectal 
Cancer (HNPCC). In more than 50% of the HNPCC cases an alteration in MLH1 is 
found. In addition to HNPCC, MMR-deficiency has been linked to other malignancies 
such as Acute Myeloid Leukemia (AML). Therefore, different DNA samples taken from 
leukemia patients after diagnosis, disease relapse or with persistent disease were screened 
in our lab by Dr. Guogen Mao for MLH1 mutations. Different mutations that result in 
single amino acid changes were found in DNA samples from patients that were newly 
diagnosed or had persistent disease. A change of phenylalanine 99 (F-99) to leucine and 
phenylalanine 571(F-571) to leucine, were identified in a newly diagnosed patient, while 
changes from leucine 509 (L-509) to phenylalanine and tryptophan 712 (W-712) to 
arginine (R) were identified in the DNA from a persistent leukemia patient (Table 4.1). In 
addition, our lab found a three nucleotide deletion in the 3’UTR (untranslated region) of 
MLH1 that result in low expression of MutLα. This 3’UTR deletion was identified in one 
of the leukemia relapse patients that was microsatellite stable (MSS) at the time of 
diagnosis but after the disease relapsed showed microsatellite instability (MSI). This was 
the first time that a group showed a direct correlation between MMR-deficiency and 
leukemia relapse in addition to a new model of MMR regulation (53).  
 
Räschle M et al. J. Biol. Chem. 2002;277:21810-21820
©2002 by American Society for Biochemistry and Molecular Biology
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The different single amino acid substitutions were located at different locations of 
MLH1; in the ATPase domain or MLH1- ExoI and MutS interaction domains (Figure 
4.3). We found that although MLH1- L509F and -F571L shown reduced MMR activity at 
higher concentrations in the in vitro MMR assay, both mutants were still capable of being 
recruited to the DNA and initiating mismatch-provoked excision. However, the MLH1-
F99L, which has weak ATPase activity when compared with MutLα wild-type (WT) 
shows a significantly reduced mismatch provoked excision activity in the MMR assay. 
 
 
 
 
Figure 4.3 Gene locations of the hMLH1mutations identified in AML patients 
F99L is located in motif III of the ATP binding pocket (black). L509F, F571L, and 
W712R are located in domains involved in interaction with ExoI (green) and MutS and 
MutL homologs (light blue). 
 
Gene Case Exon Mutation aa change*
MLH1 Diagnostic E3 TTT→TTA F99L
MLH1 Diagnostic E15 TTT→CTT F571L
MLH1 Persistent E13 CTC→TTC L509F
MLH1 Persistent E19 TGG→AGG W712R
Table 4.1. Genetic alteration of MLH1 gene in AML 
Changed nucleotide are shown in bold .
*aa, amino acid 
F571L
W712R
F99L
L509F
MLH1
n
F571L
Modified from Schmutte, C., Sadoff M.M., et al. (2001) J Biol Chem, 276(35): 33011-33018.
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RATIONALE  
We know that not all single amino acid changes in proteins result in alterations in 
phenotype, in this case in malignancies. Some of these changes may result in a SNP 
(single nucleotide polymorphism) that does not change the protein functionality. 
Therefore, studying how these different alterations identified in MLH1 affect its 
functionality in the MMR pathway can provide a better correlation of the MMR 
deficiency in AML with disease and also may provide more information about the 
mechanism by which MutLα works.  
 
RESULTS 
 
MLH1 ATPase and ExoI interaction domain mutants show different in vitro MMR 
activity 
To investigate the effect of the different single amino acid substitutions identified in 
acute myeloid leukemia samples on MMR activity (Table 4-I), the different mutants were 
re-created in the recombinant human MLH1 gene by using site-directed mutagenesis 
(Material and Methods, section VII). The recombinant mutant proteins were expressed in 
the baculovirus system and purified to ~95% homogeneity (Figure 4.4). MutLα plays a 
different role in MMR depending on the location of the nick relative to the mismatch. 
Therefore, to test the in vitro MMR activity of the different MutLα mutants, two different 
G/T mismatch substrates were used containing the nick either 3’ or 5’ to the mismatch 
(Figure 4.5 & 4.6). MMR activities were measured by adding the recombinant proteins to 
HCT116 nuclear extract (NE), which is deficient in MLH1 and therefore, MutLα activity. 
When the purified MutLα WT (MLH1-WT) protein was added back to the HCT116 NE, 
it was observed that the MMR activity with both substrates was recovered in a 
concentration dependent manner. Interesting, when the mutant L509F was added back to 
the NE, it was observed that at a low protein concentration the MMR activity was 
restored to the same levels as MutLα WT. However, when the protein concentration was 
increased the MMR activity seemed to decrease (Figure 4.5A & 4.6A). The L509F 
mutation is located in the Exo I interaction domain. Therefore, the apparent decrease in 
repair activity with increasing concentrations of the L509F mutant might indicate that 
termination of the mismatch excision was not occuring efficiently generating a bigger 
gap. This larger gap would require a longer time to fill-in resulting in the production of 
less repair product during the time course of the assay. Similar results were obtained with 
the other Exo I/MutS interaction domain mutant, F571L (Figure 4.5 & 6 B). However, 
the decrease in the amount of repair product with the F571L mutant was not as large as 
that observed with L509F.  
 
The MLH1 F99L mutation is located in Motif III of the MLH1 ATPase binding 
pocket (Figure 4.1). When F99L is added to HCT116 nuclear extract the MMR activity is 
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significantly lower than the activity observed using the wild type protein (Figure 4.5C & 
4.6A). This lower activity was observed with both the 5’ and 3’ G/T substrates. These 
results suggest that this mutation may weaken or disrupt the ATP-protein interaction, 
which is indispensable for the proper MutLα function.  
 
 
 
 
 
 
Figure 4.4 Representative gels showing the purified MutLα WT and mutant 
proteins 
Purity of the MutLα proteins was determined using 8% SDS-PAGE and staining the gels 
with coomassie blue. A. Fractions containing purified MutL WT from the final 
purification step. B. The wild type and mutant proteins were well expressed and 
underwent normal dimerization to form MutL.  
 
A.
B.
110 KDa
80 KDa
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Figure 4.5  MLH1 L509F and F99L exhibit reduced MMR activity with the 3’G/T 
heteroduplex substrate 
A-C. MLH1 deficient nuclear extract (75 ug) from HCT116 was incubated with 100 ng 
of 3’G/T heteroduplex substrate and 250, 350, and 450 ng of MutLα WT, L509F (A), 
F571L (B), W712R (B), or F99L (C) at 37
o
C for 15 min. Repair products were digested 
with HindIII and BseRI and resolved on a 1% agarose gel and visualized by ethidium 
bromide staining. 
HCT116
MutLα
C.
--
Repair
3’ G/T
HCT116
MutLα
B.
-- -
Repair
3’ G/T
Figure 4.5 MLH1 L509F and F99L shown lower MMR activity
A-C. H1 deficient nuclear extract, HCT116 (75μg) , was incubated in the presence of
100 ng of 3’G-T heteroduplex and MutLα WT, L509F (A.), F571L (B.), W712R (B.), and
F99L (C.) (250 to 450 ng) at 37ºC for 15 min. Repair products were digested with HindIII
and BseRI. Products were resolved in a 1% agarose gel and visualized by ethidium bromide
staining. MutLα WT, F571L, and W712R were able to restore the in vitro MMR activity,
while the L509F show lower repair product although not as significant as the deficiency
observed in the presence of MLH1-F99L mutant.
 
HCT116
MutLα
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-- -
Repair
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Figure 4.6  MLH1 L509F and F99L exhibit reduced MMR activity with the 5’G-T 
heteroduplex substrate 
MLH1 deficient nuclear extract (75 mg) from HCT116 was incubated with 100 ng of 
5’G-T heteroduplex substrate and MutLa WT, L506F, F99L (A.), F57aL or W712R (B.) 
mutants (250 to 450 ng) at 37
o
C for 15 min. Repair products were digested with HindIII 
and ClaI. Products were resolved by 1% agarose gel electrophoresis and visualized by 
ethidium bromide staining. 
 
 
 
 
 
 
 
 
HCT116
MutLα
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Figure 4.6 MLH1 L509F and F99L shown lower MMR products
A-B. MLH1 deficient nuclear extract, HCT116 (75μg), was incubated in the presence of
100 ng of 5’G-T heteroduplex and MutLα WT, L509F and F99L (A.), and F571L and
W712R (B.) (250 to 450 ng) at 37ºC for 15 min. Repair products were digested with
HindIII and ClaI. Products were resolved in a 1% agarose gel and visualized by ethidium
bromide staining. MutLα WT, F571L, L509F and W712R were able to restore the in vitro
MMR activity, although the L509F and F571L show lower repair products at higher
concentration. The MLH1-F99L mutant could not significant restore the MMR activity in
HCT116.
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Recruitment of MutLα to the DNA is not affected by the MLH1 mutations 
   After MutSα binds to the mispaired bases, MutLα has to be recruited to the DNA to 
activate downstream proteins. Räschle et. al (66) reported that MutSα-ATP binding , but 
not hydrolysis, was required for the formation of the terniary complex between MutSα,  
MutLα, and DNA. To investigate whether the observed change in the MMR activities 
with MutLα L509F and F99L is a result of a defect in the protein-DNA interaction, these 
two proteins were incubated in the presence of the biotinylated G/T substrate with or 
without MutSα and PCNA. As a control we used two different mutants, the MutLα 
double mutant E34A/E41A (EA) and MutLα-PMS2 E705K (EK) mutant, which have 
been well characterized in other studies. (38,66,117). The MutLα EA mutant has residues 
mutated in the ATP catalytic sites of both the MLH1 (E34A) and PMS2 (E41A) subunits 
and can bind but cannot hydrolyze ATP. The MutLα EK contains a mutation in the 
endonuclease domain of PMS2 and lacks MMR activity. Pull-down of the DNA by using 
strepavadin beads shows that the F99L and L509F mutants are able to interact with the 
G/T mismatch (Figure 4.7). This is not unexpected for the L509 mutant since it does 
support MMR activity. It does show that the almost complete loss of MMR activity with 
the F99L mutant is not due to an inability to bind to DNA containing a mismatch.     
 
 
 
 
 
 
 Figure 4.7  MLH1 mutations do not affect binding to DNA  
MutL WT, L509F, F99L, EA or EK proteins (500 ng) were incubated with 80 pmol of 
biotinylated GT substrate in the presence or absence of MutS (500 ng) and PCNA (2 
ug). The DNA was then pulled down using streptavidin beads and products were resolved 
using 12% SDS-PAGE. DNA-protein interactions were visulaized by Western blot using 
MLH1, MSH6 or PCNA antibodies. 
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Figure 4.7 MLH1-DNA binding is not affected in the presence
of MLH1 mutations
MutLα WT, L509F, F99L, EA, and EK (500 ng) were incubated with 80
pmol of biotinylated GT substrate and in the presence or absence of MutSα
(500 ng) and PCNA (2 μg). DNA was pull-down using strepavadin beads
and products were resolved in a 12% SDS-PAGE. DNA protein interaction
were vis alized by using MLH1, MSH6, and PCNA antibodies a
autoradiography.
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MutLα ATPase mutant fails to activate the endonuclease activity required for 
mismatch excision 
In the mismatch repair pathways, after MutLα is bound to the DNA a number of 
downstream proteins are recruited and activated to initiate the mismatch-provoked 
excision. When the nick is located 3’ to the mismatch, not only the same downstream 
proteins as the 5’-nicked substrate activated are required, but unlike when the nick is 
located 5’ to the mismatch, MutLα endonuclease activity is required for repair. Therefore, 
the different MLH1 mutants were assayed for their ability to activate the mismatch-
provoked excision and the endonuclease activity using a 3’-nicked G/T substrate under 
excision conditions (no dNTPs added) where only excision, and not synthesis, will occur. 
When added to HCT116 nuclear extract, MutLα WT, L509F, F571L, and W712R all 
produced the small single stranded products that indicate that these mutants are not 
defective in the activation of the excision step. Moreover, for the L509F and F571L 
mutants that produced decreasing MMR activity when added in increasing 
concentrations, we could not observe any difference in the excision when compared with 
the wild type (Figure 4.8 A & B). However, the reactions containing the ATPase mutant 
F99L showed significantly lower mismatch excision activity than the other proteins. It 
has been reported that MutLα ATPases activity is required for mismatch endonuclease 
activation and for activation of downstream proteins (38). This result suggests that the 
MutLα F99L mutant has a defect in its ATPases activity, affecting the normal protein 
function in the MMR pathway. The same results can also be observed when the same 
excision reactions were performed using the biotinylated 3’G/T gap substrate where 
3’→5’ exonuclease activity (specific or nonspecific) is blocked. With this substrate it is 
more evident that the F99L mutant failed in activates the MutLα endonuclease that is 
required for repair. These results support the previous studies that indicate that MutLα 
endonuclease activity requires both ATP binding and hydrolysis for activation (Figure 
4.8B).  
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Figure 4.8 F99L shows significantly lower mismatch excision activity 
MLH1 deficient nuclear extract from HCT116 cells was incubated with 100 ng of 
3’nicked (A.) or biotinylated 3’ gap (B.) G-T heteroduplex and MutLa WT, L509F, 
F99L, F571L or W712R (300 to 400 ng) in the absence of dNTPs at 37
o
C for 15 min. 
Excision products were digested with PstI and BglI and resolved using a 6% Urea gel and 
visualized by Southern blotting using the V6370 probe.   
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The L509F mutation does not affect the interaction between MutLα and ExoI 
 As mentioned above, the MMR activity of the L509F and F571L mutants are 
comparable to the MutLα WT repair activity at the lower concentration (250 ng) assayed. 
From this we can conclude that both proteins possess normal MMR activity. However, 
the decreases in MMR products produced with higher concentrations of the L509F 
mutant and, to a lesser degree, with the F571L mutant indicate that although these two 
proteins perform normal mismatch removal and repair activity, something is going on in 
the presence of higher protein concentration that reduces MMR activity. Both mutations 
are located at or near the ExoI interaction domain of MLH1 (Figure 4.5). Far-Western 
blotting was used to investigate whether the interaction between ExoI, L509F and F571L 
was different than the interaction with the wild-type MutLα. In Figure 4.9 it can be 
observed that both mutants are able to bind with ExoI at levels higher or comparable to 
the wild type protein. MutLα-ExoI interaction is required for mismatch removal initiation 
and this step is unaffected by the mutations as shown in the excision experiments. This 
MutLα-ExoI interaction is also required for mismatch excision termination. The 
mechanism of how MutLα induces the termination of mismatch excision by releasing 
ExoI from the DNA is still not clear. The termination of the mismatch removal by MutLα 
can be affected and may not be detectable by the Far-Western blotting interaction. If we 
take a closer look at the mismatch repair with the 5’GT substrate that requires ExoI 
loading and activity, it can be observed that with L509F and F571L the total of 
unrepaired products are also diminished in the presence of higher concentrations of the 
mutants (Figure 4.6 A & B). This pattern is the same as what is usually observed in the 
presence of high concentration of ExoI (38). Based on these results we cannot come to a 
clear conclusion about how the L509F and F571L mutants are affecting the MMR 
pathway, but the slightly increased interaction between the mutants and ExoI might lead 
to increased ExoI activity. Nevertheless, more experiments are required to understand the 
behavior of these mutant proteins at the in vitro MMR assay.      
 
 
Figure 4.9 MLH1 mutants at the ExoI 
interaction domain do not exhibit defect in 
the ExoI-MutLα interaction  
Purified MutLα WT, F571L, and L509F were 
incubated in the presence of 600ng of ExoI WT. 
Interactions among these proteins were 
visualized by immunoblotting with ExoI and 
autoradiography.  
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MutLα F99L is slightly defective in ATPase activity  
Both MMR and excision assays indicate that the F99L mutant is defective for ATPase 
activity. To investigate the levels of ATP hydrolysis activity of F99L relative to MutLα 
WT, the proteins were incubated at different time points with γ-
32
P-ATP (Figure 4.10). In 
this assay the F571L mutant was used as a positive control, because mutations at the C-
terminal of MLH1 would not influence the ATPases activity of the protein. The double 
mutant MutLα EA was used as a negative control because its ATP hydrolysis activity is 
close to background levels as observed by Räschle et. al (66). The expression levels of 
the mutant protein observed using the baculovirus system (Figure 4.4B), suggests that 
MLH1 F99L can bind ATP. Because, as reported previously, if MLH1 is defective in 
binding ATP, the protein stability will be affected resulting in the lack of expression of 
MutL heterodimers (66). The F99L mutation is in the hMLH1 subunit while hPMS2 is 
not altered. Therefore, it was not surprising to observe that the ATP hydrolysis of the 
MutL containing the F99L MLH1 mutant shows an ATPase activity somewhere 
between MutLα WT and the double mutant EA (Figure 4.10). This result in comparable 
to the result observed in Räschle et. al (66) where the MLH1EA mutant also shown its 
ATP hydrolysis between the WT and EA/EA. It was surprising, that only this sligh 
reduction in the ATP hydrolysis of F99L can altered the protein function at the point that 
background MMR activity is observed in the presence of this protein (Figure 4.5C and 
4.6A). This result indicates that both MLH1 and PMS2 ATPase activity are required for 
the proper MutLα function in the MMR pathway.   
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Figure 4.10 ATPase activity of hMutLα mutated at the ATP binding motifs 
Purified MutLα WT, F99L, catalytic double mutant EA (Lα 
EA/EA
) or F571L (1 μg) were 
incubated with [γ-
32
P]-ATP for different lengths of time. F99L shows intermediate levels 
of ATP hydrolysis when compared with MutLα WT and EA/EA. ATPase hydrolysis was 
calculated by measuring the free phosphate (Pi) over the total ATP intensity. For WT and 
F99L two replicates (n=2) were used to obtained the ATP activity, while one measure 
was used for EA/EA. ATPase activity was compared with previous observations from 
Räschle et. al (66).  
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MutLα F99L can bind ATP but MLH1 lacks ATPase activity  
If we take a closer look at the location of the F99 residue in MutLα, it can be seen 
that this residue is located in the alpha helix at the top of the ATP binding pocket and is 
part of the Motif III conserved sequence found in the GHLK ATPase superfamily (Figure 
4.11). In the presence of ATP, the amino terminal part of the helix unfolds to form a 
flexible loop that is involved in the binding of the phosphate group of ATP (Figure 4.2) 
(66). Therefore, we wanted to explore the ATP binding characteristics of this mutant and 
compare them with the WT protein. In the presence of [α-
32
P]-ATP, Räschle et. al 
observed that MLH1 binds ATP better than PMS2 in a Mg
2+
-dependent manner (66). 
When we performed a time course of the same experiment using the wild type MutLα we 
obtained similar results where MLH1-ATP crosslinking was observed at a higher extent 
than PMS2 at 5 and 7 min of the UV crosslinking (data not shown). However, we take 
into consideration that this experiment was performed in the presence of Mg
2+ 
meaning 
that ATP hydrolysis can occur which would result in the loss of signal even if 
crosslinking had occurred. However, if we try to perform the crosslinking experiments in 
the absence of Mg
2+
 to prevent hydrolysis, no binding can be detected (Figure 4.12A). 
Therefore, if instead of using [α-
32
P]-ATP we use [γ-
32
P]-ATP, the only products binding 
that can be detected would be ATP binding. In the presence of [γ-
32
P]-ATP it can be 
observed that the wild type MutLα WT shows higher crosslinking of ATP to the PMS2 
subunit than to the MLH1 (Figure 4.12A & B). On the other hand, the double mutant EA 
shows similar ATP crosslinking to both subunits indicating that both are able to equally 
bind ATP. The F99L shows higher binding to both subunits when compared with the WT 
protein. In the case of F99L because the MLH1 subunit fails to efficiently hydrolyze ATP 
we can observe the [γ-
32
P]-ATP-MLH1 interaction was stronger than with the WT 
protein. This result may indicate that MLH1 has a higher affinity for ATP as observed in 
previous studies and as quickly as ATP binds to MLH1 it undergoes to hydrolysis 
showing less crosslinking with the [γ-
32
P]-ATP. While the PMS2 subuntis binds the 
nucleotide and keep it for longer period before hydrolysis occurs and thereby rendering a 
higher ATP-PMS2 crosslinking.  
 
Using [α-
32
P]-ATP we can detect better binding of ATP to the wild type MLH1 WT 
compared with the other MutLα variants because the presence of ATP and ADP bound to 
MLH1.  The experiments shown in Figure 4.12B were carried out at the same time and 
resolved side by side in the same gel. The signal produced with the [γ-
32
P]-ATP was 
stronger than that produced with [α-
32
P]-ATP. The ATP binding observed in the presence 
of the α-nucleotide is not that evident in both ATPase mutants (Figure 4.12B, right 
panel). However, the faint bands (red stars) in the right panel show a similar pattern with 
the F99L mutant as observed with [γ-
32
P]-ATP. Based on these ATP/ADP binding 
experiments it can be proposed that hPMS2 binds ATP but after hydrolysis the ADP 
nucleotide is released, while with hMLH1 after nucleotide hydrolysis ADP remains 
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bound longer than it does to the PMS2 subunit. However, to further test this hypothesis, 
additional experiments will need to be performed.  
 
 
 
 
 
 
 
 
Figure 4.11 Location of F99 in the MLH1 ATP binding pocket 
The three conserved amino acids involved in ATP binding and hydrolysis are shown in 
different colors. The F99 residue is located in the α-helix that makes up motif III of the 
GHLK ATPases. This helix is involved in the binding of the phosphate groups. F99 is 
close to E34 (the Mg
2+
 coordinating residue) and because of its location it is 
understandable that this mutant disrupts MLH1 ATPase activity. The figure was prepared 
using the file 3NA3 from the RCSB Protein Bank and PyMol Software.  
D63
N38
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Figure 4.12 UV-crosslinking of [γ-
32
P]-ATP and [α-
32
P]-ATP to MutLα ATPase 
mutants 
A). Crosslinking of [γ-
32
P]-ATP to MutLα WT, F99L, and Lα
EA/EA
 (1μg) in the presence 
or absence of Mg
2+
 shows that ATP binding is dependent on Mg
2+
 and that PMS2 is more 
efficiently crosslinked than MLH1. B). Purified MutLa (1 μg) incubated with [α-
32
P]-
ATP in the presence eof Mg
2+
 followed by UV-crosslinking shows higher nucleotide 
linking to MLH1. The contrast was adjusted to observe the products in the presence of 
[α-
32
P]-ATP. 
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DISCUSSION 
MutLα is an essential component of the MMR pathway. Mutations in MLH1, the 
main subunit of the different hMutL-homolgs have a high occurrence in MMR-deficient 
cancers. Therefore, it is not surprising that genomic DNA derived from possible MMR 
deficient tumors have been screened for mutations in MLH1 gene. We have previously 
detected several MLH1 mutations in acute myeloid leukemia (AML) patients. One of 
these mutations was located in the GHLK ATPases domain (F99L) (Figure 4.3) and the 
other three mutations (L509F, F571L, and W712R) were located in the C-terminal region 
that is involved in MLH1 interactions with other proteins. In the presence of a high 
concentration of the L509F or F571L mutants the MMR activity of these MLH1 variants 
was reduced. However, when these variants were tested for mismatch-provoked excision 
and endonuclease activity both showed the same activity as the wild-type protein (Figure 
4.8). In addition, their interaction with the ExoI protein was also normal (Figure 4.9). 
These results indicate that higher nuclease activity can be observed in the presence of 
both mutants. However, additional experiments need to be done in order to obtain 
information of the MMR pattern observed in the presence of both variants including 
mismatch-provoked excision in the presence of 5’ GT substrate to corroborate whether 
L509F and F571L can stimulate ExoI activity or are defective in releasing ExoI from the 
DNA (termination of mismatch-provoked excision). In addition, can be taking into 
considerations that MLH1 is not only involved in the MMR pathway but also it plays a 
role in triggering apoptosis in the presence of some chemical agents, such as MNNG. 
Despite the fact that L509F, F571L, and W712R can support the removal of the mispair 
base whether these mutations can disrupt the ability of MLH1 in triggering apoptosis is 
not clear. 
 
The ATPase mutant, F99L, was significantly deficient in complementing the HCT116 
nuclear extract in the presence of both 5’- and 3’-nicked substrates. Its ATPase activity 
showed defects in MLH1 ATPase activity indicating that F99L can bind but cannot 
efficiently hydrolyze the nucleotide. This was also supported by the ATP binding 
experiments where interaction with ATP in both MLH1 and PMS2 subunits were 
observed in F99L, while ADP binding was significantly lower than MutLα WT (Figure 
4.14).  ATP hydrolysis is required to activate MutLα endonuclease activity, and in the 
mismatch excision assay F99L failed to perform the incisions required to remove the 
mispaired base in the nicked strand (Figure 4.8). Therefore, the results also indicate that 
functional ATPases activity of MLH1 and PMS2 are required for the proper function of 
MutLα in the MMR pathway. 
 
Although we could not observed that all the MLH1 mutants are defective in the MMR 
pathway and some of these mutations may arise as single nucleotide polymorphisms, still 
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important to understand the functionality of these mutations in the cells for a better 
diagnosis and treatment of the cancer patients.  
 
FUTURE EXPERIMENTS 
To study the defect in L509F and F571L that lead to lower repair activity in the 
presence of high concentrations of these mutants, a purified system of the mismatch 
excision assay should be performed in the presence of the 5’G/T substrate. This may 
provide helpful information about the L509F and F571L functional interactions with 
ExoI.  
 
As mention above, MSH2 and MLH1 also play an important role in inducing apotosis 
in cells with severe DNA damage. If either of these proteins is absence or non-functional 
the cells will become resistant, tolerating the DNA damage, and subsequently leading 
into a higher mutation frequency. Exist the possibility that mutations such as F571L that 
shows a normal MMR activity can be deficient in MMR-induce apoptosis. Therefore, 
understanding how these mutants affect apoptosis would provide helpful information to 
take into consideration before a chemotherapeutic treatment in a leukemic patient 
containing mutations in MLH1 gene.  
 
To understand better the function of MLH1 F99L in vivo, transgenic mice carrying 
this mutation can be created and monitored for the tumor development, life spam and 
other factor such as fertility. It is known that MLH1 and MLH3 are involved in meiosis 
recombination and absence of these two proteins lead into infertility.  
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CHAPTER FIVE: SUMMARY 
 
PCNA Tyr211 phosphorylation 
There have been few studies of the post-translational modification of MMR proteins. It 
has been reported that the in vitro phosphorylation of MSH2 and MSH6 by protein kinase 
C (PKC) and casein kinase II (CKII) increased the MutSα binding to mismatch substrates 
(119). However, post-translational modifications that may regulate MMR activity have 
not yet been identified.  
 
PCNA phosphorylation by the kinase activity of nuclear EGFR  has been shown to 
occur in vitro and in vivo (72). Increased PCNA phosphorylation has been found to occur 
in regenerating liver and prostate cancer cells (72,120). Because PCNA is required to 
initiate the MMR pathway with 3’-nicked G/T substrates, we explored the effect of this 
modification in MMR pathway both in vitro and in vivo. By screening MSI colorectal 
cancer cell lines, we have identified Lim2405 and DLD-1 cell lines that show elevated 
expression of EGFR (Figure 3.5). Both of these cell lines have also higher levels of 
phosphoryalted PCNA compared to the microsatellite stable (MSS) cell line, HeLa. Both 
of Lim2405 and DLD-1 nuclear extracts showed that the defects in MMR and the defect  
was the result of alterations in PCNA activity rather than the absence of any MMR 
proteins (Figure 3.10 and 3.11). Althoug this study strongly suggests that PCNA 
phosphorylation functions as an MMR inhibitor, it was not clear until we created the 
mimic phosphorylated PCNA (Y211D and Y211E) and unphosphorylated PCNA 
(Y211F).  We demonstrated that the PCNA phosphorylation plays an important role in 
regulating the MMR pathway (Figure 3.14). PCNA Y211D and Y211E have the similar 
inhibitory effect in MMR pathway that was observed in Lim2405 and DLD-1 nuclear 
extracts. Biochemical studies using these mimetic PCNAs revealed that PCNA 
phosphorylation at Tyr211 significantly inhibits the mismatch-provoked excision 
activation (Figure 3.16) possibly by disrupting the interaction between MutSα and PCNA 
(Figure 3.19). However, whether the interaction between PCNA phosphorylation and 
MutSα also affects DNA binding or MutLα endonuclease activity is not clear. To address 
this question, the experiments such as immnoprecipitation or electrophoretic mobility 
shift assays (EMSA) can be used to detect MutSα binding in the absence and presence of 
PCNA WT, Y211D, Y211E, or Y211F. These experiments will help to understand the 
mechanism by which PCNA phosphorylation inhibits the MMR initiation. 
 
In addition to being required for MMR initiation with the 3’ G/T substrate, PCNA is 
required for filling the gap generated after mismatch removal. In vitro resynthesis assays 
revealed that all of mimetic PCNAs were able to perform this activity (Figure 3.17A). 
However, a lower resynthesis rate at the beginning of the gap filling process was 
observed with nuclear extract from Lim2405 cells compared to HeLa (Figure 3.17B),  
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suggesting that the high level of PCNA phosphorylation in Lim2405 cells causes a 
slowdown in the initial resynthesis rate. It was speculated that PCNA phosphorylation 
may induce DNA polymerase switching to translesion polymerases (TLS) and result in 
the slowdown of the resynthesis rate.  To explore this possibility, a mutagenesis assay 
was performed by comparing HeLa to Lim2405 nuclear extract (Figure 3.19). We 
observed that Lim2405 extract produced more mutations in the assay compared to HeLa 
extract. This higher mutation rate with Lim2405 extract was reduced by 4-fold when the 
nuclear extract was incubated with PCNA WT, and the rate was reduced even further (6-
fold less) when the unphosphorylated PCNA mimic Y211F was used (Table 3.2).  
 
Screening of 19 colorectal cancer tissues and comparison with their respective normal 
tissues revealed that 53% of the colorectal cancer patients exhibit higher levels of PCNA 
phosphorylation than their matched normal tissues. This suggests that PCNA 
phosphorylation may function as a regulatory factor of MMR pathway in colorectal 
cancers and can lead to MMR deficiency and then result in a more aggressive cancer 
phenotype due to a higher mutational rate as observed in Lim2405 cells. Based on these 
findings,  we can propose that PCNA phosphorylation inhibits MMR initiation by failing 
to activate the mismatch-provoked excision and increasing the mutation rate during 
resynthesis. The nucleotide misincorporations due to PCNA phosphorylation can result in 
the production of mispaired bases and insertion/deletions.  The mismatches are not 
corrected and generate higher mutations in the colorectal cancer patients with high levels 
of phosphorylated PCNA, which might explain the poor prognosis and low response to 
treatment seen in those patients (Figure 5.1). 
 
Other experiments can be performed to provide additional insights into the role of 
PCNA phosphorylation in the MMR pathway and cancerdevelopment. One possible 
experiment is to use in vivo phosphorylated PCNA to perform similar experiments (in 
vitro MMR, excision, and gap filling assays) as described early. To produce 
phosphorylated PCNA, highly transfectable cells such as 293 or 293T cells can be 
cotransfected with EGFR kinase domain and Flag-PCNA cloned in a mammalian 
expression vector. After transfection, cells can be harvested and Flag-PCNA is isolated 
by using a column containing protein G-agarose linked with a Flag antibody. As control, 
cells transfected with just Flag-PCNA expression vector can be used to produce 
unphosphorylated PCNA. PCNA phosphorylation can be detected by using PCNA and 
tyrosine phosphorylation antibodies.       
 
The cells used in this study, DLD-1 and Lim2405, both are defective in MMR. 
Therefore, we can create a stably transfected cell line with a constitutive expressed EGFR 
and increased PCNA phosphorylation. This cell line can be used for a clonogenic assay to 
detect whether the cell line has developed microsatellite instability with high level of 
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PCNA phosphorylation. Those experiments in combination with the transgenic mice 
overexpressing phosphorylated PCNA mimics can shed light on the role of this 
modification in cancer development, prognosis, and metastasis.  
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Figure 5.1 Role of PCNA Tyr211 phosphorylation in DNA resynthesis and MMR 
pathway 
PCNA phosphorylation can recruit a TLS polymerase to the DNA possibly producing 
nucleotide misincorporations into the DNA resulting in mismatches. (Left) The DNA 
lesion may recruit MutSα onto the DNA but defects in the PCNA-MutSα interaction can 
disrupt MutSα stability on the DNA resulting in less binding to the mismatches. If MutSα 
can bind and recruit MutLα onto the DNA (Right), in the presence of phosphorylated 
PCNA the MutSα, PCNA, and MutLα (heterotrimeric) complex required for 
endonuclease activation may be not be supported resulting in the lack of mismatch-
provoked excision.    
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MutLα ATPase mutation  
Signaling pathways are regulated by a variety of mechanisms, such as genetic 
alterations, epigenetic modifications, miRNAs, post-translational modifications, and 
protein-protein interactions.  MMR pathway is not the exception. Genetic modifications 
(i.e mutations) in two key MMR genes, MLH1 and MSH2, have been identified in the 
majority of MMR deficient cancers. Screening of the DNA from 53 acute myeloid 
leukemia (AML) patients let to the identification of 18 AML samples that exhibited 
mutations in MMR genes or hypermethylation of the MLH1 promoter (50). One of these 
patients possesses a single amino acid change located in the ATPase domain of MLH1. 
This mutation changed the phenylalanine at position 99 to leucine (F99L) and is located 
in motif III, which is one of the four different motifs or domains found in members of the 
GHLK ATPase superfamily. When ATP binds to its binding pocket in MLH1, the N-
terminal of the α-helix that forms motif III unfolds to form a flexible loop that is involved 
in the binding of the phosphate groups in ATP. A closer look to the location of F99L 
(Figure 4.12) shows that this residue is part of this flexible loop. Characterization of the 
MutLα F99L mutant revealed it is deficient in the repair of mismatched DNA with the 
nick located either 5’ or 3’ to the mismatch (Figure 4.5C and 4.6A). However, this 
mutation did not affect the recruitment of MutLα to the DNA (Figure 4.7) indicating that 
the lower MMR activity observed is likely the result of defects in the activation of the 
mismatch-provoked excision and not recruitment of MutL. 
  
In the prokaryote MMR pathway it has been show that ATP hydrolysis is not required 
for recruitment of MutL and UvrD to the DNA, but is required for downstream events 
(121). Therefore, based on the high similarity between MutL and hMutLα we can 
speculate that ATP hydrolysis may be required for recruitment and/or activation of ExoI 
by MutLα in 5’-nicked G/T substrates. To test this hypothesis,  different experiment were 
performed including an excision assay using the 5’ G/T substrate and 
immunoprecipitation to detect ExoI recruitment to the DNA. The incubation of HCT116 
nuclear extract (NE) with the 5’G/T substrate to observe the excision pattern in the 
presence of the purified WT and F99L would tell us whether mismatch-provoked 
excision was activated in the presence of the F99L mutant. If mismatch removal is 
significantly inhibited by F99L, incubation of the HCT116 NE with the 5’G/T substrate, 
followed by immunoprecipitation using antibodies that target MSH2, PCNA or MLH1 
would provide evidence of whether ExoI recruitment or activation is disrupted by the 
F99L mutant. Because if ExoI recruitment can be observed at same levels as the 
immunoprecipitation reaction performed in the presence of the WT MutLα, this would 
indicate that the F99L mutant can recruit ExoI to the DNA but fails to activate the 
exonuclease.  
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Mismatch-provoked excision using a 3’G/T substrate in the presence of F99L fails to 
remove the mismatch compared with the WT and MLH1 C-terminal mutants (Figure 
4.7A). In 2006, when the MutLα latent endonuclease was first detected was also shown 
that this MutLα function was required to produce some incisions 5’ to the nick that 
function as new entry points for ExoI recruitment in support of mismatch removal in the 
3’-nicked substrates. When a biotinylated 3’G/T substrate was used to test MutLα F99L 
endonuclease activity (Figure 4.7B) it was observed that this mutation lacked the intrinsic 
nuclease activity. MutLα endonuclease activation depends on several factors such as 
MutSα, RFC, PCNA, and ATP. If the PCNA, MutSα, and MutLα interaction complex is 
disrupted the endonuclease activity will not be activated. Moreover, ATP hydrolysis 
drives a conformational change in MutLα that activates its endonuclease activity (122). 
MutLα F99L ATPase activity was assayed and compared with MutLα WT and the double 
mutant EA34-41. Although F99L exhibits a moderate reduction in MutLα ATP hydrolysis 
it was not completely defective unlike the double mutant protein which significantly 
lacks ATPase activity (Figure 4.10). ATP/ADP binding experiments corroborate the 
defects in the MLH1 ATPase domain because little signal was observed from the double 
mutant in the presence of [α-
32
P]-ATP when compared with the WT protein. Therefore, it 
can be concluded that both the MLH1 and PMS2 ATPase domains are required to 
activate MutLα endonuclease activity and for maintaining the proper function of MutLα 
in the MMR pathway. However, how this mutation can affect other functions of MLH1 
outside the MMR pathway has not been explored. MLH1 is known to be involved in 
MMR-induce apoptosis by the observations that MLH1-deficient cells are resistant to cell 
death after treatment with cisplatin (123,124). Therefore, we can also study the role of 
this mutation in apoptosis induction in the presence of the DNA damaging agent, 
cisplatin. Transfection of the empty vector, WT and F99L MutLα into HCT116 cells 
followed by treatment with cisplatin and cell death induction (Annexin V or MTT assay) 
can provide certain evidence of how this mutation affects MMR-induce apoptosis.  
 
Although the main molecular events that have to take place to complete the MMR 
pathway are quite understood (recognition, excision, and resynthesis), the details of how 
these events are driven are still not clear. For example, it is known that MutSα binding to 
the DNA recruits MutLα and the formation of the heterotrimeric complex (MutSα-DNA-
MutLα) has to locate the nick to activate the mismatch-provoked excision. However, how 
this communication between the mismatch and the nick takes place is not clear. Three 
different models have been proposed for signaling downstream MMR events following 
mismatch recognition. Two of the models involve binding of MutS to the mismatch 
followed by its sliding along the DNA to search for the nick. In one model, the MutSα 
slides unidirectionally to find the nick in an ATP dependent manner, while in the second, 
movement of MutS is bidirectional. The third model proposes that the MutSα binds to 
the mismatch and remains stationary while protein-protein interactions result in the 
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bending of the DNA bringing the nick and mismatch into close proximity for the 
activation of the mismatch excision (29). Therefore, because the MutLα F99L mutant 
cannot initiate the mismatch-provoked excision different experiments can be designed 
using this protein to gain more insight into which model for the mismatch removal 
activation is most likely correct.  
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APPENDIX 
 
LIST OF ABBREVIATIONS 
 
A: Adenine 
AML: Acute Myeloid Leukemia 
ATP: Adenosine triphosphate 
Beta Mercaptoethanol 
bp: Base pair (s) 
BER: Base Excision Repair 
BSA: Bovine Serum Albumin  
C: Cytosine 
cDNA: complementary DNA 
CV: Column Volume  
ddH2O: double distilled water 
DNA: Deoxyribonucleic acid 
dNTPs: deoxy Nucleotide Triphosphate 
DSB: Double-strand Break 
dsDNA: double strand DNA 
DTT: Dithiothreitol 
EDTA: ethylediamine tetracetic acid 
EGFR: Epidermal Growth Factor Receptor 
EtBr: Ethidium Bromide 
EtOH: Ethanol 
EXOI: Exonuclease I 
EXOV: Exonulcease V 
FBS: Fetal Bovine Serum 
G: Guanine  
GGR: Global Genome Repair 
GHKL: (Gyrase, Hsp90, Histidine Kinase, MutL) 
GST: Gluthathione-S-transferase 
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HNPCC:  Hereditary Nonpolyposis Colorectal Cancer (Lynch Syndrome) 
HR: Homologous Recombination 
hrs: hours 
IPTG: Isopropyl-1-thio-β-D-galactopyranoside 
MDE: Mutation Detection Enhancement  
Min: Minute 
MMR: Mismatch Repair  
MSS: Microsatellite Stable 
MSI: Microsatellite Instability 
MutLα: Complex of MLH1 and PMS2 
MutLβ: Complex of MLH1 and PMS1 
MutLγ: Complex of MLH1 and MLH3 
MutSα: Complex of MSH2 and MSH6 
MutSβ: Complex of MSH2 and MSH3 
nm: nano meter 
nt: nucleotide 
NaOAc: Sodium Acetate 
NER: Nucleotide Excision Repair 
NFDM: Non-Fat Dry Milk 
NHEJ: Non-Homologous Enf Joining 
OD: Optical Density 
O/N: Overnight  
PAGE: Polyacrylamide Gel Electrophoresis 
PCNA: Proliferating Cell Nuclear Antigen 
PCR: Polymerase Chain Reaction  
PBS: Phosphate-buffered saline 
PMSF: Phenylmethylsulfonylfluoride 
PK: Protein Kinase 
RFC: Replication Factor C 
RPA: Replication Protein A 
RT: Room Temperature 
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RPM: Revolutions per Minute 
SNP: Single Nucleotide Polymorphism  
SSB: single-stranded binding  
SSCP: Single-strand Conformation Polymorphism 
ssDNA: Single-stranded DNA 
SUMO: Small Ubiquitin-like Modifier 
SDS: Sodium Dodecyl Sulfate 
T: Thymine  
TBE : Tris/Borate/EDTA 
TBS : Tris-buffered saline 
TCR : Transcription-Coupled Repair 
TE : Tris-EDTA 
TES : Tris-EDTA saline 
TGFRII : Transforming Growth Factor Beta Receptor II 
TLS : Translesion Synthesis 
UV: Ultraviolet 
V: viral strand 
WB: Western Blot 
X-gal: 5-bromo-4-chloro-3-indolyl-βD-galactosidase 
 
 
 
 
 
 
 
 
 
 
 
 
 
96 
 
 
 
 
 
97 
 
REFERENCES 
 
1. Waddington, C. (1940) The genetic control of wing development in 
Drosophila. Journal of Genetics, 41, 75-113. 
2. Issa, J.P. (2000) CpG-island methylation in aging and cancer. Curr Top 
Microbiol Immunol, 249, 101-118. 
3. Holliday, R. and Pugh, J.E. (1975) DNA modification mechanisms and gene 
activity during development. Science, 187, 226-232. 
4. Nguyen, D.X. and Massague, J. (2007) Genetic determinants of cancer 
metastasis. Nat Rev Genet, 8, 341-352. 
5. McCann, J., Choi, E., Yamasaki, E. and Ames, B.N. (1975) Detection of 
carcinogens as mutagens in the Salmonella/microsome test: assay of 300 
chemicals. Proceedings of the National Academy of Sciences of the United 
States of America, 72, 5135-5139. 
6. Weinberg, R.A. (2008), The Molecular Basis of Cancer. Saunder Elsevier, 
Philadelphia, PA, Vol. 3rd Edition, pp. 3-30. 
7. Barrett, J.C. (1993) Mechanisms of multistep carcinogenesis and carcinogen 
risk assessment. Environmental health perspectives, 100, 9-20. 
8. Toyota, M., Ohe-Toyota, M., Ahuja, N. and Issa, J.P. (2000) Distinct genetic 
profiles in colorectal tumors with or without the CpG island methylator 
phenotype. Proceedings of the National Academy of Sciences of the United 
States of America, 97, 710-715. 
9. Knudson, A.G., Jr. (1971) Mutation and cancer: statistical study of 
retinoblastoma. Proceedings of the National Academy of Sciences of the 
United States of America, 68, 820-823. 
10. Sieber, O.M., Tomlinson, S.R. and Tomlinson, I.P.M. (2005) Tissue, cell and 
stage specificity of (epi)mutations in cancers. Nat Rev Cancer, 5, 649-655. 
11. Hahn, S.A., Greenhalf, B., Ellis, I., Sina-Frey, M., Rieder, H., Korte, B., 
Gerdes, B., Kress, R., Ziegler, A., Raeburn, J.A. et al. (2003) BRCA2 
germline mutations in familial pancreatic carcinoma. Journal of the National 
Cancer Institute, 95, 214-221. 
12. Frebourg, T., Kassel, J., Lam, K.T., Gryka, M.A., Barbier, N., Andersen, T.I., 
Borresen, A.L. and Friend, S.H. (1992) Germ-line mutations of the p53 tumor 
suppressor gene in patients with high risk for cancer inactivate the p53 
protein. Proceedings of the National Academy of Sciences of the United States 
of America, 89, 6413-6417. 
13. Todd, R. and Wong, D.T. (1999) Oncogenes. Anticancer research, 19, 4729-
4746. 
 
 
 
98 
14. Bafico A., G.L., Aaronson SA.,. (2008) In Elsevier, S. (ed.), The Molecular 
Basis of Cancer. Saunder Elsevier, Philadelphia, PA, Vol. 3rd Edition, pp. 17-
30. 
15. Faderl, S., Talpaz, M., Estrov, Z. and Kantarjian, H.M. (1999) Chronic 
myelogenous leukemia: biology and therapy. Annals of internal medicine, 
131, 207-219. 
16. Redig, A.J., Vakana, E. and Platanias, L.C. (2011) Regulation of mammalian 
target of rapamycin and mitogen activated protein kinase pathways by BCR-
ABL. Leukemia & lymphoma, 52 Suppl 1, 45-53. 
17. Levine AJ., H.W., Feng Z. (2008) In Elsevier, S. (ed.), The Molecular Basis 
of Cancer. Saunder Elsevier, Philadelphia, PA., Vol. 3rd Edition, pp. 31-38. 
18. Baker, S.J., Markowitz, S., Fearon, E.R., Willson, J.K. and Vogelstein, B. 
(1990) Suppression of human colorectal carcinoma cell growth by wild-type 
p53. Science (New York, N.Y.), 249, 912-915. 
19. Fero, M.L., Randel, E., Gurley, K.E., Roberts, J.M. and Kemp, C.J. (1998) 
The murine gene p27Kip1 is haplo-insufficient for tumour suppression. 
Nature, 396, 177-180. 
20. D'Andrea, D.A. (2008) In Elsevier, S. (ed.), The Molecular Basis of Cancer. 
Saunders Elsevier Philadelphia, PA., Vol. 3rd edition, pp. 39-55. 
21. Shrivastav, M., De Haro, L.P. and Nickoloff, J.A. (2008) Regulation of DNA 
double-strand break repair pathway choice. Cell research, 18, 134-147. 
22. Hang, B. (2006) In Quingyi Wei, L. L., David J. Chen (ed.), DNA Repair, 
Genetic Instability, and Cancer. World Scientific Toh Tuck Link, Singapore, 
pp. 23-64. 
23. Wilson, S.H., Sobol, R.W., Beard, W.A., Horton, J.K., Prasad, R. and Vande 
Berg, B.J. (2000) DNA polymerase beta and mammalian base excision repair. 
Cold Spring Harbor symposia on quantitative biology, 65, 143-155. 
24. Fortini, P. and Dogliotti, E. (2007) Base damage and single-strand break 
repair: mechanisms and functional significance of short- and long-patch repair 
subpathways. DNA repair, 6, 398-409. 
25. Paz-Elizur, T., Krupsky, M., Blumenstein, S., Elinger, D., Schechtman, E. and 
Livneh, Z. (2003) DNA repair activity for oxidative damage and risk of lung 
cancer. Journal of the National Cancer Institute, 95, 1312-1319. 
26. Sampson, J.R., Jones, S., Dolwani, S. and Cheadle, J.P. (2005) MutYH 
(MYH) and colorectal cancer. Biochemical Society transactions, 33, 679-683. 
27. Naryzhny, S.N., Desouza, L.V., Siu, K.W. and Lee, H. (2006) 
Characterization of the human proliferating cell nuclear antigen physico-
chemical properties: aspects of double trimer stability. Biochem Cell Biol, 84, 
669-676. 
 
 
 
99 
28. Yasuda, G., Nishi, R., Watanabe, E., Mori, T., Iwai, S., Orioli, D., Stefanini, 
M., Hanaoka, F. and Sugasawa, K. (2007) In vivo destabilization and 
functional defects of the xeroderma pigmentosum C protein caused by a 
pathogenic missense mutation. Molecular and cellular biology, 27, 6606-
6614. 
29. Li, G.M. (2008) Mechanisms and functions of DNA mismatch repair. Cell 
research, 18, 85-98. 
30. Shah, S.N., Hile, S.E. and Eckert, K.A. (2010) Defective mismatch repair, 
microsatellite mutation bias, and variability in clinical cancer phenotypes. 
Cancer research, 70, 431-435. 
31. Li, G.M. and Modrich, P. (1995) Restoration of mismatch repair to nuclear 
extracts of H6 colorectal tumor cells by a heterodimer of human MutL 
homologs. Proceedings of the National Academy of Sciences of the United 
States of America, 92, 1950-1954. 
32. Drummond, J.T., Li, G.M., Longley, M.J. and Modrich, P. (1995) Isolation of 
an hMSH2-p160 heterodimer that restores DNA mismatch repair to tumor 
cells. Science (New York, N.Y.), 268, 1909-1912. 
33. Watanabe, Y., Haugen-Strano, A., Umar, A., Yamada, K., Hemmi, H., 
Kikuchi, Y., Takano, S., Shibata, Y., Barrett, J.C., Kunkel, T.A.  et al. (2000) 
Complementation of an hMSH2 defect in human colorectal carcinoma cells 
by human chromosome 2 transfer. Molecular carcinogenesis, 29, 37-49. 
34. Koi, M., Umar, A., Chauhan, D.P., Cherian, S.P., Carethers, J.M., Kunkel, 
T.A. and Boland, C.R. (1994) Human chromosome 3 corrects mismatch repair 
deficiency and microsatellite instability and reduces N-methyl-N'-nitro-N-
nitrosoguanidine tolerance in colon tumor cells with homozygous hMLH1 
mutation. Cancer research, 54, 4308-4312. 
35. Tindall, K.R., Glaab, W.E., Umar, A., Risinger, J.I., Koi, M., Barrett, J.C. and 
Kunkel, T.A. (1998) Complementation of mismatch repair gene defects by 
chromosome transfer. Mutation research, 402, 15-22. 
36. Fearon, E.R. and Vogelstein, B. (1990) A genetic model for colorectal 
tumorigenesis. Cell, 61, 759-767. 
37. Lahue, R.S., Au, K.G. and Modrich, P. (1989) DNA mismatch correction in a 
defined system. Science (New York, N.Y.), 245, 160-164. 
38. Kadyrov, F.A., Dzantiev, L., Constantin, N. and Modrich, P. (2006) 
Endonucleolytic function of MutLalpha in human mismatch repair. Cell, 126, 
297-308. 
39. Zhang, Y., Yuan, F., Presnell, S.R., Tian, K., Gao, Y., Tomkinson, A.E., Gu, 
L. and Li, G.M. (2005) Reconstitution of 5'-directed human mismatch repair 
in a purified system. Cell, 122, 693-705. 
 
 
 
100 
40. Constantin, N., Dzantiev, L., Kadyrov, F.A. and Modrich, P. (2005) Human 
mismatch repair: reconstitution of a nick-directed bidirectional reaction. The 
Journal of biological chemistry, 280, 39752-39761. 
41. Wei, K., Clark, A.B., Wong, E., Kane, M.F., Mazur, D.J., Parris, T., Kolas, 
N.K., Russell, R., Hou, H., Jr., Kneitz, B. et al. (2003) Inactivation of 
Exonuclease 1 in mice results in DNA mismatch repair defects, increased 
cancer susceptibility, and male and female sterility. Genes & development, 
17, 603-614. 
42. Pluciennik, A., Dzantiev, L., Iyer, R.R., Constantin, N., Kadyrov, F.A. and 
Modrich, P. (2010) PCNA function in the activation and strand direction of 
MutLalpha endonuclease in mismatch repair. Proceedings of the National 
Academy of Sciences of the United States of America, 107, 16066-16071. 
43. Eshleman, J.R. and Markowitz, S.D. (1995) Microsatellite instabili ty in 
inherited and sporadic neoplasms. Current opinion in oncology, 7, 83-89. 
44. Loukola, A., Eklin, K., Laiho, P., Salovaara, R., Kristo, P., Jarvinen, H., 
Mecklin, J.P., Launonen, V. and Aaltonen, L.A. (2001) Microsatellite marker 
analysis in screening for hereditary nonpolyposis colorectal cancer (HNPCC). 
Cancer research, 61, 4545-4549. 
45. Kohlmann, W. and Gruber, S.B. (1993) In Pagon, R. A., Bird, T. D., Dolan, 
C. R. and Stephens, K. (eds.), GeneReviews. University of Washington, 
Seattle, Seattle WA. 
46. Boland, C.R., Thibodeau, S.N., Hamilton, S.R., Sidransky, D., Eshleman, 
J.R., Burt, R.W., Meltzer, S.J., Rodriguez-Bigas, M.A., Fodde, R., Ranzani, 
G.N. et al. (1998) A National Cancer Institute Workshop on Microsatellite 
Instability for cancer detection and familial predisposition: development of 
international criteria for the determination of microsatellite instability in 
colorectal cancer. Cancer research, 58, 5248-5257. 
47. Francisco, I., Albuquerque, C., Lage, P., Belo, H., Vitoriano, I., Filipe, B., 
Claro, I., Ferreira, S., Rodrigues, P., Chaves, P. et al. (2011) Familial 
colorectal cancer type X syndrome: two distinct molecular entities? Familial 
cancer. 
48. Jass, J.R. (2006) Hereditary Non-Polyposis Colorectal Cancer: the rise and 
fall of a confusing term. World journal of gastroenterology : WJG, 12, 4943-
4950. 
49. Appelbaum, F.R., (2007) The Acute Leukemias. Saunders Elsevier, 
Philadelphia, PA. 
50. Mao, G., Yuan, F., Absher, K., Jennings, C.D., Howard, D.S., Jordan, C.T. 
and Gu, L. (2008) Preferential loss of mismatch repair function in refractory 
and relapsed acute myeloid leukemia: potential contribution to AML 
progression. Cell research, 18, 281-289. 
 
 
 
101 
51. Frohling, S., Scholl, C., Gilliland, D.G. and Levine, R.L. (2005) Genetics of 
myeloid malignancies: pathogenetic and clinical implications. Journal of 
clinical oncology : official journal of the American Society of Clinical 
Oncology, 23, 6285-6295. 
52. Mrozek, K., Marcucci, G., Paschka, P., Whitman, S.P. and Bloomfield, C.D. 
(2007) Clinical relevance of mutations and gene-expression changes in adult 
acute myeloid leukemia with normal cytogenetics: are we ready for a 
prognostically prioritized molecular classification? Blood, 109, 431-448. 
53. Mao, G., Pan, X. and Gu, L. (2008) Evidence that a mutation in the MLH1 3'-
untranslated region confers a mutator phenotype and mismatch repair 
deficiency in patients with relapsed leukemia. The Journal of biological 
chemistry, 283, 3211-3216. 
54. Johnson, P.H. and Grossman, L.I. (1977) Electrophoresis of DNA in agarose 
gels. Optimizing separations of conformational isomers of double- and single-
stranded DNAs. Biochemistry, 16, 4217-4225. 
55. Okajima, T., Tanabe, T. and Yasuda, T. (1993) Nonurea sodium dodecyl 
sulfate-polyacrylamide gel electrophoresis with high-molarity buffers for the 
separation of proteins and peptides. Anal Biochem, 211, 293-300. 
56. Chung, C.T., Niemela, S.L. and Miller, R.H. (1989) One-step preparation of 
competent Escherichia coli: transformation and storage of bacterial cells in 
the same solution. Proceedings of the National Academy of Sciences of the 
United States of America, 86, 2172-2175. 
57. Mandel, M. and Higa, A. (1970) Calcium-dependent bacteriophage DNA 
infection. J Mol Biol, 53, 159-162. 
58. Holmes, J., Jr., Clark, S. and Modrich, P. (1990) Strand-specific mismatch 
correction in nuclear extracts of human and Drosophila melanogaster cell 
lines. Proceedings of the National Academy of Sciences of the United States 
of America, 87, 5837-5841. 
59. Pan, Z.Q., Reardon, J.T., Li, L., Flores-Rozas, H., Legerski, R., Sancar, A. 
and Hurwitz, J. (1995) Inhibition of nucleotide excision repair by the cyclin-
dependent kinase inhibitor p21. The Journal of biological chemistry, 270, 
22008-22016. 
60. Zhang, G., Gibbs, E., Kelman, Z., O'Donnell, M. and Hurwitz, J. (1999) 
Studies on the interactions between human replication factor C and human 
proliferating cell nuclear antigen. Proceedings of the National Academy of 
Sciences of the United States of America, 96, 1869-1874. 
61. Fien, K. and Stillman, B. (1992) Identification of replication factor C from 
Saccharomyces cerevisiae: a component of the leading-strand DNA 
replication complex. Molecular and cellular biology, 12, 155-163. 
 
 
 
102 
62. Chen, J., Jackson, P.K., Kirschner, M.W. and Dutta, A. (1995) Separate 
domains of p21 involved in the inhibition of Cdk kinase and PCNA. Nature, 
374, 386-388. 
63. Su, S.S., Lahue, R.S., Au, K.G. and Modrich, P. (1988) Mispair specificity of 
methyl-directed DNA mismatch correction in vitro. The Journal of biological 
chemistry, 263, 6829-6835. 
64. McCulloch, S.D., Gu, L. and Li, G.M. (2003) Bi-directional processing of 
DNA loops by mismatch repair-dependent and -independent pathways in 
human cells. The Journal of biological chemistry, 278, 3891-3896. 
65. Kunkel, T.A. (1986) Frameshift mutagenesis by eucaryotic DNA polymerases 
in vitro. The Journal of biological chemistry, 261, 13581-13587. 
66. Raschle, M., Dufner, P., Marra, G. and Jiricny, J. (2002) Mutations within the 
hMLH1 and hPMS2 subunits of the human MutLalpha mismatch repair factor 
affect its ATPase activity, but not its ability to interact with hMutSalpha. The 
Journal of biological chemistry, 277, 21810-21820. 
67. Tian, L., Gu, L. and Li, G.M. (2009) Distinct nucleotide binding/hydrolysis 
properties and molar ratio of MutSalpha and MutSbeta determine their 
differential mismatch binding activities. The Journal of biological chemistry, 
284, 11557-11562. 
68. Murata, H., Khattar, N.H., Kang, Y., Gu, L. and Li, G.M. (2002) Genetic and 
epigenetic modification of mismatch repair genes hMSH2 and hMLH1 in 
sporadic breast cancer with microsatellite instability. Oncogene, 21, 5696-
5703. 
69. Towbin, H., Staehelin, T. and Gordon, J. (1979) Electrophoretic transfer of 
proteins from polyacrylamide gels to nitrocellulose sheets: procedure and 
some applications. Proceedings of the National Academy of Sciences of the 
United States of America, 76, 4350-4354. 
70. Renart, J., Reiser, J. and Stark, G.R. (1979) Transfer of proteins from gels to 
diazobenzyloxymethyl-paper and detection with antisera: a method for 
studying antibody specificity and antigen structure. Proceedings of the 
National Academy of Sciences of the United States of America , 76, 3116-
3120. 
71. Edmondson, D.G. and Dent, S.Y. (2001) Identification of protein interactions 
by far western analysis. Curr Protoc Protein Sci, Chapter 19, Unit 19 17. 
72. Wang, S.C., Nakajima, Y., Yu, Y.L., Xia, W., Chen, C.T., Yang, C.C., 
McIntush, E.W., Li, L.Y., Hawke, D.H., Kobayashi, R. et al. (2006) Tyrosine 
phosphorylation controls PCNA function through protein stability. Nat Cell 
Biol, 8, 1359-1368. 
73. Phizicky, E.M. and Fields, S. (1995) Protein-protein interactions: methods for 
detection and analysis. Microbiol Rev, 59, 94-123. 
 
 
 
103 
74. Guo, S., Zhang, Y., Yuan, F., Gao, Y., Gu, L., Wong, I. and Li, G.M. (2006) 
Regulation of replication protein A functions in DNA mismatch repair by 
phosphorylation. The Journal of biological chemistry, 281, 21607-21616. 
75. Gulhati, P., Cai, Q., Li, J., Liu, J., Rychahou, P.G., Qiu, S., Lee, E.Y., Silva, 
S.R., Bowen, K.A., Gao, T. et al. (2009) Targeted inhibition of mammalian 
target of rapamycin signaling inhibits tumorigenesis of colorectal cancer. 
Clinical cancer research : an official journal of the American Association for 
Cancer Research, 15, 7207-7216. 
76. Prelich, G., Tan, C.K., Kostura, M., Mathews, M.B., So, A.G., Downey, K.M. 
and Stillman, B. (1987) Functional identity of proliferating cell nuclear 
antigen and a DNA polymerase-delta auxiliary protein. Nature, 326, 517-520. 
77. Tan, C.K., Castillo, C., So, A.G. and Downey, K.M. (1986) An auxiliary 
protein for DNA polymerase-delta from fetal calf thymus. The Journal of 
biological chemistry, 261, 12310-12316. 
78. Burgers, P.M. (2009) Polymerase dynamics at the eukaryotic DNA replication 
fork. The Journal of biological chemistry, 284, 4041-4045. 
79. Stoimenov I., H.T. (2009) In Trans, B. S. (ed.), DNA damage: from Causes to 
Cures. Portland Press, London, U.K., Vol. 37, pp. 605-613. 
80. Gulbis, J.M., Kelman, Z., Hurwitz, J., O'Donnell, M. and Kuriyan, J. (1996) 
Structure of the C-terminal region of p21(WAF1/CIP1) complexed with 
human PCNA. Cell, 87, 297-306. 
81. Naryzhny, S.N. (2008) Proliferating cell nuclear antigen: a proteomics view. 
Cell Mol Life Sci, 65, 3789-3808. 
82. Moldovan, G.L., Pfander, B. and Jentsch, S. (2007) PCNA, the maestro of the 
replication fork. Cell, 129, 665-679. 
83. Bauer, G.A. and Burgers, P.M. (1988) The yeast analog of mammalian 
cyclin/proliferating-cell nuclear antigen interacts with mammalian DNA 
polymerase delta. Proceedings of the National Academy of Sciences of the 
United States of America, 85, 7506-7510. 
84. Ng, L., Prelich, G., Anderson, C.W., Stillman, B. and Fisher, P.A. (1990) 
Drosophila proliferating cell nuclear antigen. Structural and functional 
homology with its mammalian counterpart. The Journal of biological 
chemistry, 265, 11948-11954. 
85. Xu, H., Zhang, P., Liu, L. and Lee, M.Y. (2001) A novel PCNA-binding motif 
identified by the panning of a random peptide display library. Biochemistry, 
40, 4512-4520. 
86. Naryzhny, S.N., Zhao, H. and Lee, H. (2005) Proliferating cell nuclear 
antigen (PCNA) may function as a double homotrimer complex in the 
mammalian cell. The Journal of biological chemistry, 280, 13888-13894. 
 
 
 
104 
87. Thomson, T.M. and Guerra-Rebollo, M. (2010) Ubiquitin and SUMO 
signalling in DNA repair. Biochemical Society transactions, 38, 116-131. 
88. Chen, J., Bozza, W. and Zhuang, Z. (2011) Ubiquitination of PCNA and its 
essential role in eukaryotic translesion synthesis. Cell Biochem Biophys, 60, 
47-60. 
89. Pfander, B., Moldovan, G.L., Sacher, M., Hoege, C. and Jentsch, S. (2005) 
SUMO-modified PCNA recruits Srs2 to prevent recombination during S 
phase. Nature, 436, 428-433. 
90. Papouli, E., Chen, S., Davies, A.A., Huttner, D., Krejci, L., Sung, P. and 
Ulrich, H.D. (2005) Crosstalk between SUMO and ubiquitin on PCNA is 
mediated by recruitment of the helicase Srs2p. Mol Cell, 19, 123-133. 
91. Umar, A., Buermeyer, A.B., Simon, J.A., Thomas, D.C., Clark, A.B., Liskay, 
R.M. and Kunkel, T.A. (1996) Requirement for PCNA in DNA mismatch 
repair at a step preceding DNA resynthesis. Cell, 87, 65-73. 
92. Guo, S., Presnell, S.R., Yuan, F., Zhang, Y., Gu, L. and Li, G.M. (2004) 
Differential requirement for proliferating cell nuclear antigen in 5' and 3' 
nick-directed excision in human mismatch repair. The Journal of biological 
chemistry, 279, 16912-16917. 
93. Clark, A.B., Valle, F., Drotschmann, K., Gary, R.K. and Kunkel, T.A. (2000) 
Functional interaction of proliferating cell nuclear antigen with MSH2-MSH6 
and MSH2-MSH3 complexes. The Journal of biological chemistry, 275, 
36498-36501. 
94. Flores-Rozas, H., Clark, D. and Kolodner, R.D. (2000) Proliferating cell 
nuclear antigen and Msh2p-Msh6p interact to form an active mispair 
recognition complex. Nat Genet, 26, 375-378. 
95. Yuan, Z., Shin, J., Wilson, A., Goel, S., Ling, Y.H., Ahmed, N., Dopeso, H., 
Jhawer, M., Nasser, S., Montagna, C. et al. (2009) An A13 repeat within the 
3'-untranslated region of epidermal growth factor receptor (EGFR) is 
frequently mutated in microsatellite instability colon cancers and is associated 
with increased EGFR expression. Cancer research, 69, 7811-7818. 
96. Lin, S.Y., Makino, K., Xia, W., Matin, A., Wen, Y., Kwong, K.Y., 
Bourguignon, L. and Hung, M.C. (2001) Nuclear localization of EGF receptor 
and its potential new role as a transcription factor. Nat Cell Biol, 3, 802-808. 
97. Blomqvist, L., Holm, T., Rubio, C. and Hindmarsh, T. (1997) Rectal tumours-
-MR imaging with endorectal and/or phased-array coils, and histopathological 
staging on giant sections. A comparative study. Acta radiologica (Stockholm, 
Sweden : 1987), 38, 437-444. 
98. Bendardaf, R. (2006) Colorectal cancer: from epidemiology to current 
treatment. The Libyan journal of medicine, 1, 42-59. 
 
 
 
105 
99. Spano, J.P., Lagorce, C., Atlan, D., Milano, G., Domont, J., Benamouzig, R., 
Attar, A., Benichou, J., Martin, A., Morere, J.F. et al. (2005) Impact of EGFR 
expression on colorectal cancer patient prognosis and survival. Annals of 
oncology : official journal of the European Society for Medical Oncology / 
ESMO, 16, 102-108. 
100. Whitehead, R.H., Zhang, H.H. and Hayward, I.P. (1992) Retention of tissue-
specific phenotype in a panel of colon carcinoma cell lines: relationship to 
clinical correlates. Immunology and cell biology, 70 ( Pt 4), 227-236. 
101. Ellison, V. and Stillman, B. (2003) Biochemical characterization of DNA 
damage checkpoint complexes: clamp loader and clamp complexes with 
specificity for 5' recessed DNA. PLoS Biol, 1, E33. 
102. Waga, S. and Stillman, B. (1998) The DNA replication fork in eukaryotic 
cells. Annu Rev Biochem, 67, 721-751. 
103. Wang, Z. (2001) Translesion synthesis by the UmuC family of DNA 
polymerases. Mutation research, 486, 59-70. 
104. Lange, S.S., Takata, K. and Wood, R.D. (2011) DNA polymerases and cancer. 
Nat Rev Cancer, 11, 96-110. 
105. Kunkel, T.A. and Alexander, P.S. (1986) The base substitution fidelity of 
eucaryotic DNA polymerases. Mispairing frequencies, site preferences, 
insertion preferences, and base substitution by dislocation. The Journal of 
biological chemistry, 261, 160-166. 
106. Notenboom, V., Hibbert, R.G., van Rossum-Fikkert, S.E., Olsen, J.V., Mann, 
M. and Sixma, T.K. (2007) Functional characterization of Rad18 domains for 
Rad6, ubiquitin, DNA binding and PCNA modification. Nucleic acids 
research, 35, 5819-5830. 
107. Wu, J., Zhu, B.B., Yu, J., Zhu, H., Qiu, L., Kindy, M.S., Gu, L., Seidel, A. 
and Li, G.M. (2003) In vitro and in vivo modulations of 
benzo[c]phenanthrene-DNA adducts by DNA mismatch repair system. 
Nucleic acids research, 31, 6428-6434. 
108. Kaina, B., Ochs, K., Grosch, S., Fritz, G., Lips, J., Tomicic, M., Dunkern, T. 
and Christmann, M. (2001) BER, MGMT, and MMR in defense against 
alkylation-induced genotoxicity and apoptosis. Progress in nucleic acid 
research and molecular biology, 68, 41-54. 
109. Au, K.G., Welsh, K. and Modrich, P. (1992) Initiation of methyl-directed 
mismatch repair. The Journal of biological chemistry, 267, 12142-12148. 
110. Dao, V. and Modrich, P. (1998) Mismatch-, MutS-, MutL-, and helicase II-
dependent unwinding from the single-strand break of an incised heteroduplex. 
The Journal of biological chemistry, 273, 9202-9207. 
 
 
 
106 
111. Yamaguchi, M., Dao, V. and Modrich, P. (1998) MutS and MutL activate 
DNA helicase II in a mismatch-dependent manner. The Journal of biological 
chemistry, 273, 9197-9201. 
112. Aronshtam, A. and Marinus, M.G. (1996) Dominant negative mutator 
mutations in the mutL gene of Escherichia coli. Nucleic acids research, 24, 
2498-2504. 
113. Bergerat, A., de Massy, B., Gadelle, D., Varoutas, P.C., Nicolas, A. and 
Forterre, P. (1997) An atypical topoisomerase II from Archaea with 
implications for meiotic recombination. Nature, 386, 414-417. 
114. Mushegian, A.R., Bassett, D.E., Jr., Boguski, M.S., Bork, P. and Koonin, E.V. 
(1997) Positionally cloned human disease genes: patterns of evolutionary 
conservation and functional motifs. Proceedings of the National Academy of 
Sciences of the United States of America, 94, 5831-5836. 
115. Ban, C. and Yang, W. (1998) Crystal structure and ATPase activity of MutL: 
implications for DNA repair and mutagenesis. Cell, 95, 541-552. 
116. Baird, C.L., Harkins, T.T., Morris, S.K. and Lindsley, J.E. (1999) 
Topoisomerase II drives DNA transport by hydrolyzing one ATP. 
Proceedings of the National Academy of Sciences of the United States of 
America, 96, 13685-13690. 
117. Tomer, G., Buermeyer, A.B., Nguyen, M.M. and Liskay, R.M. (2002) 
Contribution of human mlh1 and pms2 ATPase activities to DNA mismatch 
repair. The Journal of biological chemistry, 277, 21801-21809. 
118. Hall, M.C., Shcherbakova, P.V. and Kunkel, T.A. (2002) Differential ATP 
binding and intrinsic ATP hydrolysis by amino-terminal domains of the yeast 
Mlh1 and Pms1 proteins. The Journal of biological chemistry, 277, 3673-
3679. 
119. Christmann, M., Tomicic, M.T. and Kaina, B. (2002) Phosphorylation of 
mismatch repair proteins MSH2 and MSH6 affecting MutSalpha mismatch-
binding activity. Nucleic acids research, 30, 1959-1966. 
120. Zhao, H., Lo, Y.H., Ma, L., Waltz, S.E., Gray, J.K., Hung, M.C. and Wang, 
S.C. (2011) Targeting tyrosine phosphorylation of PCNA inhibits prostate 
cancer growth. Molecular cancer therapeutics, 10, 29-36. 
121. Robertson, A.B., Pattishall, S.R., Gibbons, E.A. and Matson, S.W. (2006) 
MutL-catalyzed ATP hydrolysis is required at a post-UvrD loading step in 
methyl-directed mismatch repair. The Journal of biological chemistry, 281, 
19949-19959. 
122. Yamamoto, T., Iino, H., Kim, K., Kuramitsu, S. and Fukui, K. (2011) 
Evidence for the ATP-dependent structural rearrangement of the nuclease 
catalytic site in the DNA mismatch repair endonuclease MutL. The Journal of 
biological chemistry. 
 
 
 
107 
123. Drummond, J.T., Anthoney, A., Brown, R. and Modrich, P. (1996) Cisplatin 
and adriamycin resistance are associated with MutLalpha and mismatch repair 
deficiency in an ovarian tumor cell line. The Journal of biological chemistry, 
271, 19645-19648. 
124. Wu, J., Gu, L., Wang, H., Geacintov, N.E. and Li, G.M. (1999) Mismatch 
repair processing of carcinogen-DNA adducts triggers apoptosis. Molecular 
and cellular biology, 19, 8292-8301. 
 
 
 
 
108 
VITAE 
 
Date of Birth:     August 16, 1983 
Place of Birth:    San Juan, Puerto Rico 
 
Education  
2001 – 2006 B.S. in Chemistry  
 Department of Chemistry 
 University of Puerto Rico, Río Piedras 
 San Juan, PR, USA 
Research Experiences   
2007-2012 
 
 
 
 
 
 
 
2004 - 2006 
Graduate Research in Toxicology 
Novel Mechanism Leading to Mismatch Repair 
Deficiency and Mutator Phenotype 
Graduate Center for Toxicology 
University of Kentucky,  
Lexington, KY, USA 
Principal Investigator: Liya Gu                       
 
Undergraduate Research in Biochemistry and 
Molecular Biology 
 Cytotoxicity of New Quinones and 
Polyethylenimine 
 Department of Chemistry 
 University of Puerto Rico, Río Piedras, San Juan, 
PR, USA 
 
 
Principal Investigator: Fernando A. González  
2005 Undergraduate Research in Toxicology 
 Impact of Red Raspberry Extract on AhR & NF-κB 
Pathways 
 Graduate Center for Toxicology University of 
Kentucky 
 Lexington, KY, USA 
 Principal Investigator: Hollie Swanson  
 
Professional Development 
2011 
 
 
 
 
 
 
2010 
 
Platform Presentation:  
2011 DNA Repair Midwest Conference             
PCNA Phosphorylation Inhibits Mismatch Repair 
and Induces Misincorporations During DNA 
Synthesis 
University of Toledo-College of Medicine, Toledo, 
Ohio, USA 
Poster Presentation:  
Markey Cancer Research Day 
 
 
 
109 
 
 
 
2010 
 
 
 
 
2005 
PCNA phosphorylation at tyrosine211  inhibits   
mismatch repair at the initiation step 
University of Kentucky, Lexington, KY, USA 
Poster Presentation:  
Experimental Biology 2010 
PCNA phosphorylation at tyrosine211  inhibits   
mismatch repair at the initiation step 
Anaheim, CA, USA 
Platform Presentation: 
 25
th
 Puerto Rico Interdisciplinary Scientific 
Meeting 
 Cytotoxicity of New Quinones and 
Polyethylenimine 
 University of Puerto Rico- Mayagüez Campus, 
Mayagüez, PR, USA 
  2005 Oral Presentation:  
Summer Internship Meeting 
 Impact of Red Raspberry Extract on AhR & NF-κB 
Pathways 
 University of Kentucky, Lexington, KY, USA 
  
Research Fellowships and Scholarship 
        2007-2011                   NIH supplements Program to promote diversity in 
Health-related research 
        2006-2009                   Lyman T. Johnson Academic Year Fellowship 
2005 Research Initiative Student Enhances Fellow 
(RISE)  
              2004 - 2005 Puerto Rico Louis Stokes Alliance for Minority 
Participation Fellow (PR-LSAMP) 
       2001- 2005 Bristol Myers Scholarship 
 
Scholarly Activities 
2010-present 
 
 
2004 - 2006 
Selection Committee Member for the new Dean for 
College of Medicine 
University of Kentucky, Lexington, KY, USA 
American Chemistry Society (ACS) – Student 
Affiliated Chapter Activity Coordination Board 
Member 
 University of Puerto Rico-Rio Piedras, San Juan, 
PR, USA 
 
Academic Honors and Awards  
2011 
 
 
 
Award 
 
 
 
Platform Presentation  
Second Place, 2011 DNA Repair Midwest 
Conference 
 
 
 
 
110 
2010 
 
2010 
 
 
2006 
2005 
Award 
 
Award 
 
 
Honors 
Award 
2010 ASBMB Annual Meeting Travel 
Award 
Poster Presentation 
Second Place, Markey Cancer Research 
Day 
Magna Cum Laude, BS in Chemistry 
Research Initiative Student Enhances 
(RISE) Fellowship 
2004 - 2005 Award Who’s Who Among Student In American 
Universities And Colleges 
 
Affiliations/Memberships 
    2004 - 2006 ACS – Student Affiliated Chapter 
Member 
    2004 - 2006 Golden Key International Honor Society 
 Publications 
Janice Ortega, Eun Young Lee, Dana L. Napier, Liya Gu, and Guo-Min Li, PCNA 
Phosphorylation Inhibits Mismatch Repair and Induces Misincorporations During 
DNA Synthesis (manuscript) 
 
Guogen Mao, Sanghee Lee, Janice Ortega, Liya Gu, and
 
Guo-Min Li, Modulation 
of microRNA processing by mismatch repair protein MutLα (Cancer Research) 
 
 
